IL144461A - Quinoline and quinazoline derivatives and pharmaceutical compositions containing them - Google Patents

Abstract

An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis. Disclosed are compounds represented by formula (I) and a pharmaceutically acceptable salts and solvates thereof and pharmaceutical compositions comprising said compounds: <CHEM> wherein X and Z each independently represent CH or N; R<1> to R<3> represent H, substituted alkoxy, unsubstituted alkoxy or the like; R<4> represents H; R<5> to R<8> represent H, halogen, alkyl, alkoxy, alkylthio, nitro, or amino, provided that R<5> to R<8> do not simultaneously represent H; R<9> and R<10> represent H, alkyl, or alkylcarbonyl; and R<11> represents alkyl, alkenyl, alkynyl, or aralkyl.

Description

QUINOLEME AND QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BACKGROUND OF THE INVENTION Field of the Invention The present invention relates to quinoline derivatives and quinazoline derivatives having antitumor activity. More particularly, the present invention relates to quinoline derivatives and quinazoline derivatives that are useful for the treatment of diseases such as tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma.

Background Art WO 97/17329 describes quinoline derivatives and quinazoline derivatives having antitumor activity. WO 97/17329, however, discloses neither the effects of these quinoline derivatives and quinazoline derivatives on cytomorphosis nor the compounds according to the present invention.

SUMMARY OF THE INVENTION The present inventors have found that a group of quinoline derivatives and quinazoline derivatives has antitumor activity and, at the same time, has no significant effect on cytomorphosis. The activity of increasing the cell size may be regarded as activity of inducing tissue disorders.

An object of the present invention is to provide compounds which havd antitumor activity and, at the same time, have no significant effect on cytomorphosis.

According to the present invention, there is provided a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X and Z each represent CH or N; R1, R2, and R3, which may be the same or different, represent a hydrogen atom, alkyl, alkoxy, C2_6 alkenyl, C2_6 alkynyl, nitro, or amino, which Cj_6 alkyl, C^g alkoxy, C2_6 alkenyl, and C2_6 alkynyl are optionally substituted by a halogen atom; hydroxyl; C1-4 alkoxy; C1-4 alkoxycarbonyl; amino on which one or two hydrogen atoms are optionally substituted by alkyl optionally substituted by. hydroxy! or alkoxy; group R12R13N- C(=0)-0- wherein R12 and R13, which may be the same or different, represent a hydrogen atom or C1-4 alkyl which alkyl is optionally substituted by hydroxyl or Cj_4 alkoxy; or group R14-(S)m- wherein R14 represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group optionally substituted by alkyl and m is 0 or 1; R4 represents a hydrogen atom; R5, R6, R7, and RB, which may be the same or different, represent a hydrogen atom, a halogen atom, Cj_4 alkyl, alkoxy, Cj_4 alkylthio, nitro, or amino, provided that R5, R6, R7, and RB do not simultaneously represent a hydrogen atom; R9 and R10, which may be the same or different, represent a hydrogen atom, Cx_6 alkyl, or C1-4 alkylcarbonyl , the alkyl portion of which alkyl or Cj. 4 alkylcarbonyl is optionally substituted by a halogen atom; C1-4 alkoxy; amino which is optionally substituted by C]., alkyl optionally substituted by C^, alkoxy; or a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group; and R11 represents C^6 alkyl, C2_6 alkenyl, or C2_6 alkynyl (which alkyl, C2.6 alkenyl, and C2_6 alkynyl each are optionally substituted by a halogen atom or alkoxy), or R15-(CH2)n- wherein n is an integer of 0 to 4 and R1S represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom, alkyl, or C^g alkoxy and is optionally condensed with other saturated or unsaturated three- to seven-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

The compound according to the present invention is useful, for example, for the treatment of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and solid tumor.

DETAILED DESCRIPTION OF THE INVENTION Compound As used herein, the term "C^ alkyl" and "C^ alkoxy" as a group . or a part of a group respectively , . . ·. i mean straight chain or branched chain alkyl and alkoxy having 1 to 6, preferably 1 to 4 carbon atoms.

As used herein, the term "C2.6 alkenyl" and "C2_6 alkynyl" as a group or a part of a group respectively mean straight chain or branched chain alkenyl and alkynyl having 2 to 6, preferably 2 to 4 carbon atoms.

Examples of C^ alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, and n-hexyl.

Examples of C^6 alkoxy include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, and t-butoxy.

Examples of C2_6 alkenyl include allyl, butenyl, pentenyl, and hexenyl.

Examples of C2_6 alkynyl include 2-propynyl, butynyl, pentynyl, and hexynyl.

The term "halogen atom" means a fluorine, chlorine, bromine, or iodine atom.

The saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic ring is preferably five- to seven-membered, more preferably five- or six-membered, saturated or unsaturated carbocyclic or heterocyclic ring.

Examples of saturated or unsaturated three- to seven-membered carbocyclic groups include phenyl, cycloheptyl, cyclohexyl, and cyclopentyl.

The saturated or,j unsaturated three- to seven-membered heterocyclic ring contains at least one hetero-atom selected from oxygen, nitrogen, and sulfur atoms. The term "hetero-atom" used herein means an oxygen, nitrogen, or sulfur atom. Examples of saturated or unsaturated three- to seven-membered heterocyclic groups include pyridyl, piperidino, piperazino, morpholino, imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, pyrrolidinyl, and pyrazolyl.

The saturated or unsaturated heterocyclic group, which may be represented by R15 and R32, may be condensed with other saturated or unsaturated heterocyclic ring to form a bicyclic ring. Such condensed cyclic groups include naphthyl, indanyl, quinolyl, and quinazolinyl.

R1 preferably represents a hydrogen atom.

R2 and R3 preferably represents optionally substituted alkoxy. alkyl, alkoxy, C2_6 alkenyl, and C2_6 alkynyl, which may be represented by R1, R2, and R3, may be substituted by group R14-(S)m-.

The carbocyclic or heterocyclic group, which may be represented by R14 , preferably represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group. The carbocyclic group more preferably represents phenyl. The heterocyclic group more preferably represents a saturated or unsaturated five-membered heterocyclic group containing one to four nitrogen atoms or a ^saturated or unsaturated six-membered heterocyclic group (preferably pyridyl) containing one or two hetero-atoms selected from nitrogen and oxygen atoms. More specifically, the hetero-atom constituting the six-membered heterocyclic group may be one nitrogen atom and one oxygen atom, or one or two nitrogen atoms.

When m is 0 (zero), -(S)m- represents a bond.

The substituted Cj.6 alkoxy group, which may be represented by R1, R2, and R3, preferably represents group R31-(CH2 )p-0- wherein R31 represents a halogen atom, hydroxyl, alkoxy, alkoxycarbonyl , amino on which one or two hydrogen atoms each are optionally substituted by Cr_4 alkyl optionally substituted by hydroxyl or αχ_4 alkoxy, group R12R13N-C ( =0 ) -0- wherein R12 and R13 are as defined in formula (I), or group R14-(S)m-wherein R14 may be as defined in , formula (I); p is an integer of 1 to 6, preferably 1 to 4 , more preferably 1 or 2, particularly preferably 1.

A group of preferred compounds represented by formula (I) include: compounds wherein R1 represents a hydrogen atom and R2 and R3 represent unsubstituted alkoxy, preferably methoxy; compounds wherein R1 represents a hydrogen atom, R2 represents substituted alkoxy, preferably group R31- (CH2)p-0-, and R3 represents unsubstituted alkoxy, preferably methoxy; and compounds wherein R1 represents a hydrogen atom, R2 represents unsubstituted! Cj_4 alkoxy, preferably methoxy, and R3 represents substituted Cj.,, alkoxy, preferably group R31-(CH2)p-0-.

Another group of preferred compounds represented by formula (I) include: compounds wherein at least one of R5, R6, R7, and R8 represents a halogen atom, preferably a chlorine atom or a fluorine atom; compounds wherein at least one of R:', R6, R7, and R8 represents Cj_4 alkyl; compounds wherein two of R5, R6 , R7, and R8 represent methyl and the remaining two represent a hydrogen atom; compounds . wherein pt least, one of R5, R6, R7, and R8 repersents nitro, amino, alkoxy, or Cj_4 alkylthio; compounds wherein Rs, R7, and R8 represent a hydrogen atom and R6 represents a halogen atom, more preferably a chlorine atom or a fluorine atom; compounds wherein R5 and R6 represent C1_i alkyl, more preferably . methyl, and R7 and R8 represent a hydrogen atom; compounds wherein Rs and RB represent a hydrogen atom and R6 and R7 represent C1-4 alkyl, more preferably methyl; and compounds wherein R5, R7, and R8 represent a hydrogen atom and R6 represents Cj_4 alkyl, C1_i alkoxy, alkylthio, nitro, or amino.

In R9 and R10, the saturated or unsaturated three-to seven-membered. carbocyclic or heterocyclic group as the substituent preferably represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group.

R9 and R10 preferably represent a hydrogen atom, methyl, ethyl, propyl, methoxymethyl , formyl, acetyl, benzyl, or phenetyl.

Still another group of preferred compounds represented by formula (I) include: compounds wherein R1, R9, and R10 represent a hydrogen atom; and compounds wherein R1 represents a hydrogen atom and any one of or both R?. and R10 represent a group other than a hydrogen atom.

In groufp R157 (Cji2 ) n-ϊ which may be represented by R11, n is preferably an integer of 0 to 2, more preferably 0 or 1. Preferred examples of R15 include an optionally substituted saturated o unsaturated six-membered carbocyclic group, more preferably phenyl, and an optionally substituted saturated or unsaturated six-membered heterocyclic group, more preferably pyridyl. The hetero-atom(s ) constituting the six-membered heterocyclic group may more specifically consist of one nitrogen atom or one nitrogen atom and one oxygen atom.

A further group of preferred compounds represented by formula (I) include compounds wherein X represents N or CH and Z represents CH.

A stilpL.. further^ group of preferred compounds represented by formula (I) include compounds represented by formula (la): wherein X represents CH or N; R21 and ' R22,' which ' may be the same or different, represent unsubstituted alkoxy or group R31-(CH2)p-0-wherein R31 represents a halogen atom, hydroxyl, alkoxy, alkoxycarbonyl , amino on which one or two hydrogen atoms are optionally substituted by alkyl optionally substituted by hydroxyl or 01-4 alkoxy, group R12R13N-C(=0)-0- wherein R12 and R13, which may be the same or different, represent a hydrogen atom or alkyl which alkyl is optionally substituted by hydroxyl or Cj_4 alkoxy, or group R14-(S)m- wherein R14 represents a s saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group optionally substituted by Cj_4 alkyl and m is 0 or 1; and p is an integer of 1 to 6; R23, R2", R2S, and R26, which may be the same or different, represent a hydrogen atom, a halogen atom, alkyl, Cj_4 alkoxy, alkylthio, nitro, or amino, provided that R23, R24, R25, and R26 do not simultaneously represent a hydrogen atom; R27 and R28, which may be the same or different, represent a hydrogen atom, alkyl, or Cj_4 alkylcarbonyl, the alkyl portion of which alkyl or Cx_ 4 alkylcarbonyl is optionally substituted by a halogen atom; Cj,,, alkoxy; amino which is optionally substituted by alkyl optionally substituted by Cj_4 alkoxy; or a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group; and R29 represents Cx_6 alkyl, C2_6 alkenyl, or C2.6 alkynyl (which alkyl, C2_6 alkenyl, and C2_6 alkynyl each are optionally substituted by a halogen atom or Cj_4 alkoxy), or R32-(CH2)q- wherein q is an integer of 0 to 4 and R32 represents a saturated or unsaturated six-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom, C1-4 alkyl, or C1-4 alkoxy and is optionally condensed with other saturated or unsaturated five- or six-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

R21 and R22 may represent unsubstituted Ci_6 alkoxy, preferably methoxy.

Any one of R21 and R22 may represent unsubstituted alkoxy, preferably raethoxy and the other represents group R31-(CH2 jp-0-.

In group R31-(CH2)p-0-, p is preferably 1 to 4, more preferably 1 or 2, particularly preferably 1.

A group of preferred compounds represented by formula (la) include: compounds wherein at least one of R23, R24, R25, and R26 represents a halogen atom, preferably a chlorine atom or a fluorine atom; compounds wherein at least one of R23, R24, R25, and R26 represents Ci_„ alkyl; compounds wherein two of R23, R24, R25, and R26 represent methyl and the remaining two represent a hydrogen atom; compounds wherein at least one of R23, R24, R2S, and R26 represents nitro, amino, alkoxy, or C1_i alkylthio; compounds wherein R23, R25, and R26 represent a hydrogen atom and R24 represents a halogen atom, more preferably a chlorine atom or a fluorine atom; compounds wherein R23 and R24 represent C1.4 alkyl, more preferably methyl and R2S and R26 represent a hydrogen atom; compounds wherein R23 and R26 represent a hydrogen atom and R24 and R25 represent alkyl, more preferably methyl; and compounds wherein R23, R25, and R26 represent a hydrogen atom and R24 represents alkyl, Ct_4 alkoxy, Cj_4 alkylthio, nitro, or ;amino.

Another group of preferred compounds represented by formula (la) include compounds wherein R27 and R28 represent a hydrogen atom.

Still another group of preferred compounds represented by formula (la) include compounds wherein any one of or both R27 and R28 represent a group other than a hydrogen atom.

In R32-(CH2)q- which may be represented by R29, q is preferably an integer of 0 to 2, more preferably 0 or 1. Examples of preferred R32 include optionally substituted phenyl and an optionally substituted saturated or unsaturated six-membered heterocyclic group, more preferably pyridyl. The hetero-atom( s ) constituting the six-membered heterocyclic group may more specifically consist of one nitrogen atom or one nitrogen atom and one oxygen atom. The saturated or unsaturated six-membered carbocyclic group or heterocyclic group, which may be represented by R32, is preferably condensed with other saturated or unsaturated six-membered carbocyclic ring or heterocyclic ring to form a bicyclxc ring.

A still further group of preferred compounds represented by formula (la) include: compounds wherein X represents , CH or N, R21 and R22 represent unsubstituted Cl_i alkoxy, R23, R25, and R26 represent a hydrogen atom, R24 represents a halogen atom, Cx_4 alkyl, C1_i alkoxy, or nitro, , ' R27 and R28 represent a hydrogen atom, and R29 represents C1_6 alkyl, C2.6 alkenyl, or C2_6 alkynyl (which alkyl, C2_6 alkenyl, and C2.6 alkynyl each are optionally substituted by a halogen atom or alkoxy), or -(CH2)q-R32 wherein q is an integer of 0 or 1 and R32 represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C1-4 alkyl, or C1-4 alkoxy; compounds wherein X represents CH or N, R21 and R22 represent unsubstituted alkoxy, R23, R25, and R26 represent a hydrogen atom, R24 represents a halogen atom, alkyl, C1-4 alkoxy, or nitro, , . : any one of or both R27 and R28 represent a group other than a hydrogen atom, and R29 represents alkyl, C2.6 alkenyl, or C2_6 alkynyl (which Cx_6 alkyl, C2.6 alkenyl, and C2.6 alkynyl each are optionally substituted by a halogen atom or C!_4 alkoxy), or -(CH2)q-R32 wherein q is an integer of 0 or 1 and R32 represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C1-4 alkyl, or Cw alkoxy; compounds wherein X represents CH or N, R21 and R22 represent unsubstituted C^,, alkoxy, R23, R2S and R26 represent a hydrogen atom, R24 represents a halogen atom, C1_4 alkyl, Cx_t alkoxy, or nitro, R27 represents a hydrogen atom, R2B represents a group other than a hydrogen atom, and R29 represents alkyl, C2_6 alkenyl, or C2.6 alkynyl (which C_6 alkyl, C2_6 alkenyl, and C2_6 alkynyl each are optionally substituted by a halogen atom or C^ alkoxy), or -(CH2)q-R32 wherein q is an integer of 0 or 1 and R32 represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, alkyl, or Cx_4 alkoxy; compounds . wherein X represents CH or N, any one of R21 and R22 represents unsubstituted C1-4 alkoxy and the other represents group R31-(CH2)p-0-, preferably R21 represents unsubstituted alkoxy and R22 represents group R31-(CH2)p-0-, R23, R25, and R26 represent a hydrogen atom, R24 represents a halogen atom, Cx_4 alkyl, C1-4 alkoxy, or nitro, R27 and R28 represent a hydrogen atom, and R29 represents C1_6 alkyl, C2_6 alkenyl, or C2.6 alkynyl (which alkyl, C2_6 alkenyl, and C2_6 alkynyl each are optionally substituted by a halogen atom or alkoxy), or -(CH2)q-R32 wherein q is an integer of 0 or 1 and R32 represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_4 al'kyl, or C1_ll alkoxy; compounds wherein · X represents CH or N, any one of R21 and R22 represents unsubstituted alkoxy and the other represents group R31-(CH2)p-0-, preferably R21 represents unsubstituted Cj_4 alkoxy and R22 represents group R31-(CH2)p-0-, R23, R25, and. R2.6 represent a hydrogen atom, R24 represents a halogen atom, Cj_4 alkyl, C1_t alkoxy, or nitro, any one of or both R27 and R28 represent a group other than a hydrogen atom, and R29 represents. Cj_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl (which ' Cj_6 'alkyl, C2.6 alkenyl, and C2_6 alkynyl each are optionally substituted by a halogen atom or alkoxy), or -(CH2)q-R32 wherein q is an integer of 0 or 1 and R32 represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, alkyl, or Cj_4 alkoxy; compounds wherein X represents CH or N, any one of R21 and R22 represents unsubstituted C alkoxy and the other represents group R31-(CH2)p-0-, preferably R21 represents unsubstituted alkoxy and R22 represents group R31-(CH2 )p-0-, R23, R25, and R26 represent a hydrogen atom, R24 represents a halogen atom, alkyl, alkoxy, or nitro, R27 represents a hydrogen atom, R28 represents a group other than a hydrogen atom, and R29 represents alkyl, C2.6 alkenyl, or C2_6 alkynyl (which alkyl, C2.6 alkenyl, and C2.6 alkynyl each are optionally substituted by a halogen atom or C1-4 alkoxy), or -(CH2)q-R32 wherein q is an integer of 0 or 1 and R32 represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, Cj_4 alkyl, or C1_i alkoxy; and compounds wherein X represents CH or N, any one of R21 and R22 represents unsubstituted alkoxy and the other represents group R31- (CH2 )p-0- , preferably R21' represents unsubstituted alkoxy and R22 represents group R31-(CH2)p-0-, R23 and R26 represent a hydrogen atom, R24 and R25 represent a halogen atom, alkyl, Cj.4 alkoxy, or nitro, R27 and R28 represent a hydrogen atom, and R29 represents alkyl, C2_6 alkenyl, or C2_6 alkynyl (which alkyl, C2_6 alkenyl, or C2_6 alkynyl each are optionally substituted by a halogen atom or Cx_4 alkoxy), or -(CH2)q-R32 wherein q is an integer of 0 or 1 and R32 represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, alkyl, or Cx_4 alkoxy.

Examples of preferred compounds according to the present invention include compounds described in Examples 1 to 186.

Another examples of preferred compounds according to the present invention include the following compounds : N-{2-chloro-4-[ ( 6 , 7-dimethyl-4-quinazolinyl )oxy]-phenyl}-N'-isobutylurea; N- ( 4- { [ 7- (benzyloxy )-6-methoxy-4-quinazolinyl] oxy}-2-chlorophenyl ) -N ' -propylurea ; N- ( 4-{ [ 6- (benzyloxy)-7-methoxy-4-quinazolinyl ]oxy}-2-chlorophenyl ) - ' -propylurea ; N- ( 2-chloro-4-{ [ 7-niethoxy-6-( 3-morpholinopropoxy ) - 4-quinazoliny1 ] oxy}phenyl ) - ' -propylurea; N- [ 2-chloro~4-;( {6-methoxy-7-[ 2- ( lH-l-imidazolyl ) -ethoxy ] -4-quinazolinyl}oxy ) phenyl ] -N ' -ethylurea ; N- [ 2-chloro-4- ( {6-methoxy-7- [ 2- ( lH-1 , 2 , 3-triazol-l-yl ) ethoxy ] -4-quinazolinyl}oxy ) henyl ] - ' -ethylurea ; N- [ 2-chloro-4- ( { 6-methoxy-7-[ 3- ( lH-1 , 2 , 3-triazol-l-yl ) propoxy ] -4-quinazolinyl }oxy ) phenyl ] -N ' -ethylurea ; N- [ 2-chloro-4- ( {6-methoxy-7-[ 2- ( 4-methyl-piperazino ) ethoxy ] -4-quinazolinyl }oxy ) phenyl ] - ' -ethylurea; N- ( 2-chloro-4-{ [ 6-methoxy-7- ( 2-morpholinoethoxy ) -4-quinazolinyl ] oxy} henyl ) - ' -ethylurea ; N- ( 2-chloro-4-{ [ 6-methoxy-7-( 3-morpholinopropoxy ) - 4-quinazolinyl ].oxy}pheny!l ) -N ' -ethylurea; N- [ 2-chloro-4- ( {6-methoxy-7-[ 2- ( dimethylamino ) - ethoxy] -4-quinazolinyl}oxy)phenyl ] - ' -ethylurea; N-t 2-chloro-4-( {6-methoxy-7-[ 2- ( lH-l-imidazolyl) - ethoxy] -4-quinazolinyl}oxy )phenyl ]-N ' -propylurea; N- [ 2-chloro-4- ( { 6-methoxy-7-[ 2- ( lH-1 , 2 , 3-triazol-l yl ) ethoxy] -4-quinazolinyl}oxy)phenyl ] - ' -propylurea ; N- [ 2-chloro-4r- ( {6-methoxy-7-[ 3-( lH-1 , 2 , 3-triazol-l yl ) propoxy] -4-quinazolinyl}oxy) phenyl ] -N' -propylurea; N- ( 2-chloro-4-{ [ 6-methoxy-7- ( 3-morpholinopropoxy ) -4-quinazolinyl ]oxy}phenyl ) -N' -propylurea; N- [ 2-chlorp-4- ( 6-methoxy-7- [ 2- (dimethylamino ) -ethoxy] -4-quinazolinyl}oxy )phenyl ]- ' -propylurea; N- [ 2-chloro-4- ( {,6-methoxy-7- [ 2- ( 1H-1-imidazolyl ) -et oxy] -4-quina'zoliriy1}o-ky)phenyl ]- ' -butylurea ; N- [ 2-chloro'-4- ( {6-methoxy-7- [ 2- ( lH-1 , 2 , 3-triazol-l yl ) ethoxy] -4-quihazolinyl}oxy) phenyl ] -N ' -butylurea; N- [ 2-chloro-4- ( {6-methoxy-7- [ 3- ( lH-1 , 2 , 3-triazol-l yl ) propoxy] -4-quinazolinyl}ox )phenyl ] - ' -butylurea ; N- [ 2-chloro-4- ( { 6-methoxy-7- [ 2- ( 4-methyl-piperazino) ethoxy ] -4-quinazolinyl}oxy) phenyl ] -N ' -butylurea; N- ( 2-chloro-4-{ [ 6-methoxy-7- ( 2-morpholinoethoxy) -4 quinazolinyl]oxy> henyl ) -N' -butylurea; N- ( 2-chloro-4-{ [ 6-methoxy-7- ( 3-morpholinopropoxy ) -4-quinazolinyl ]oxy}phenyl ) -N ' -butylurea; N- [ 2-chloro-4- ({6-methoxy-7- [ 2- (dimethylamino ) -ethoxy] -4-quinazolinyl}oxy)phenyl ]-N' -butylurea; and N- [ 2-chloro-4- ( {6rmethoxy-7- [ 2- ( dimethylamino ) -ethoxy] -4-quinolyl}oxy ) nenyl ] - ' -propylurea .

Examples of particularly preferred compounds according to the present invention include: ( 13 ) N-{2-chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl )oxy]■ phenyl}-N' -propylurea; (51) N-(2-chloro-4-{[6-methoxy-7-( 2-morpholinoethoxy) -4-quinolyl ]oxy}phenyl ) - ' - ( 2 , 4-difluorophenyl ) urea; ( 62 ) N-{2-chloro-4-[ ( 6, 7-dimethoxy-4-quinazolinyl) oxy] henyl}- ' -propylurea ; ( 76 ) N-{2-chloro-4-[ ( 6, 7-dimethoxy-4-quinazolinyl) 5 oxy ] henyl}-N' -ethylurea; (117) N-{2-chloro-4-[ ( 6 , 7-dxmethoxy-4-quinazo- linyl ) oxy ] phenyl}- ' -methylurea ; (119) N- ( 2-chloro-4-{ [ 6-methoxy-7- ( 3-morpholino- propoxy ) -4-quinazo inyl ]oxy}phenyl ) -N' -propylurea ; (135) N-(2-chloro-4-{ [ 6-methoxy-7- ( 3-piperidino- propoxy) -4-quinazolinyl ] oxy}phenyl ) -N' -propylurea; ( 142 ) N- ( 2-chloro-4-{ [ 6-methoxy-7- ( 3-pyridyl- . methoxy ) -4-quinolyl ] oxy}phenyl ) - ' -propylurea ; (143) N-(2-chloro-4-{ [ 6-methoxy-7- ( 4-pyridyl-15 methoxy ) -4-quinolyl ] oxy}pheny1 ) -N ' -propylurea; · ·- · (144 ): N- ( 2-chloro-4-{ [ 6-methoxy-7- ( 2-morpholino-- ·.·. ■ethoxy ) -4-quinolyl]oxy} henyl )-N' -propylurea; (145) N-[2-chloro-4-({6-methoxy-7-[2-(lH-l,2/3- triazol-l-yl ) ethoxy ] -4-quinolyl}oxy ) henyl ]-N' - 20 propylurea; ( 146 ) · N- [ 2-chloro-4- ( {7- [ 2- ( lH-l-imidazolyl ) - ethoxy ] -6-methoxy^4-quinolyl}oxy ) phenyl ] - ' -propylurea ; ( 148 ) N- [ 2-chloro-4- ( { 6-methoxy-7- [ 2- ( 4-methy1- piperazino ) ethoxy ] -4-quxnolyl}oxy ) phenyl ] - ' -propylurea ; 25 (149) N-(2-chloro-4-{[7-(2-hydroxyethoxy)-6- methoxy-4-quxnolyl ]oxy}phenyl ) -N ' -propylurea ; ( 151 ) N- ( 2-chloro-4-{ [ 6-methoxy-7- ( 3-morpholino- propoxy) -4-quinolyl ] oxy}phenyl ) -N' -propylurea; (152) N-[2-chloro-4-(6-methoxy-7-{[3-(4-methyl-30 pxperazino ) propoxy ] - -quxnolyl}oxy ) phenyl ] - ' - propylurea; ( 153 ) N- [ 2-chloro-4- ( 6-methoxy-7-{ [ 3- ( lH-1 ,2,3- triazol-1-yl ) ropoxy ] -4-quinolyl}oxy ) phenyl ] -N ' - propylurea; (157) N-{2-chloro-4-[ (7-{3-[ ( 2-hydroxyethyl ) - (methyl ) amino ] ropoxy}-6-methoxy-4-quxnolyl ) oxy ] - phenyl}-N ' -propylurea ; (159) N- { 2-chloro-4- [ ( 6-methoxy- 7 - { [ 5 - ( 1H- 1,2,3-triazol-l-yl )pentyl ]oxy} -4-quinolyl ) oxy ] phenyl }-N' -propylurea ; ( 160 ) N- [ 2-chloro-4- ( { 7- [ 4- ( lH-l-imidazolyl ) -butoxy ] -6-methoxy-4-quinolyl}oxy ) phenyl ] -N ' -propylurea ; ( 162 ) N- ( 2-chloro-4-{ [ 6-methoxy-7- ( 2-morpholino-ethoxy ) -4-quinazolinyl ] oxy}phenyl ) -N ' - ( 2 , 4-difluoro-phenyl )urea; ( 163 ) N- (2-chloro-4-{ [ 6-methoxy-7- ( 3-morpholino-propoxy ) -4-quinazolinyl ] oxy}phenyl ) -N' - (2 , 4-difluoro-phenyl)urea; (164) N-[2-chloro-4-( {6-methoxy-7- [ 3- ( 4-methyl-piperaz.ino ) propoxy ] -4-quinazolinyl}oxy ) phenyl ] -N ' - ( 2 , 4-difluorophenyl ) urea ; (165) N-{2-chloro-4-[ (7-{3r-[ ( 2-hydroxyethyl ) - •"(methyl) amino ] propoxy }-6-methoxy-4-quinazolinyl ) oxy ] -phenyl}-N '-( 2 , 4-difluorophenyl )urea :- . ( 16.8) N.-(2-chloro-4-{ [ 6-methoxy-7- ( 3-morpholino-propoxy) -4-quinolyl] oxy}phenyl)-N'- (2, 4-difluorophenyl )-urea; ( 169 ) N-(2-chloro-4-{ [ 6-methoxy-7- ( 3-pyridyl-methoxy ) -^4-quinolyl ] oxy}phenyl ) -N ' - ( 2 , 4-difluorophenyl ) -urea; (170) N-[2-chloro-4-({6-methoxy-7-[2-(ltf-l,2,3-triazol-1-yl ) ethoxy ] -4-quinoly 1}oxy )phenyl ] -N' - (2,4-difluorophenyl )urea ; (184) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy ) -4-quinazolinyl ] oxy}phenyl ) -N ' -methylurea ; (185 ) N-(2-chloro-4-{ [ 6-methoxy-7- ( 3-piperidino-propoxy) -4-quinazolinyl]oxy}phenyl)-N'-ethylurea; and ( 186) N-(2-chloro-4-{ [ 6-methoxy-7-( 4-pyridyl-methoxy ) -4-quinolyl ] oxy}phenyl ) - ' - ( 2 , 4-difluorophenyl ) -urea.

Examples of more preferred compounds according to the present invention include the following compounds: ( 62 ) N-{2-chloro-4- [ ( 6 , 7-dimethoxy-4-quinazolinyl ) -oxy ] henyl }-N ' -propylurea ; (142) N-(2-chlord-4-{ [ 6-methoxy-7- ( 3-pyridyl-methoxy ) -4-quinolyl ]oxy> henyl ) -N ' -propylurea ; and ( 169 ) N-( 2-chioro-4-{ [ 6-methoxy-7- ( 3-pyridyl-methoxy) -4-quinolyl ]oxy}phenyl ) -N ' - ( 2 , 4-difluorophenyl ) -urea.

The compounds according to the present invention may form pharmaceutically acceptable salts thereof. Preferred examples of such salts include: alkali metal or alkaline earth metal salts such as sodium salts, potassium salts or calcium salts; hydrohalogenic acid salts such as hydrofluoride salts, hydrochloride salts, hydrobromide salts, or hydroiodide salts; inorganic acid salts such as nitric acid salts, perchloric acid salts, sulfuric acid salts, or phosphoric acid salts; lower alkylsulfonic acid salts such as methanesulfonic acid salts, trifluoromethanesulfonic acid salts, or ethanesulfonic -acid' sal s; arylsulfonic acid salts such as benzenesulfonic acid salts or p-toluenesulfonic acid salts; organic acid salts such as fumaric acid salts, succinic acid salts, citric acid salts, tartaric acid salts, oxalic acid salts, maleic acid salts, acetic acid salts, malic acid salts, lactic acid salts, or ascorbic acid salts; and amino acid salts such as glycine salts, phenylalanine salts, glutamic acid salts, or aspartic acid salts.

Further, the compounds according to the present invention may form solvates (for example, hydrates).

Production of compounds The compounds according to the present invention may be produced, for example, according to scheme 1 and scheme 2.

Scheme 1 Starting compounds necessary for the synthesis of the compounds according to the present invention may be commercially available, or alternatively may be produced according to a conventional process. For example, a 4-chloroquinoline derivative may be synthesized by a conventional process as described in Org. Synth. Col. Vol. 3, 272 (1955), Acta Chim. Hung., 112, 241 (1983) or WO 98/47873. A 4-chloroquinazoline derivative may be synthesized by a conventional process as described in J. Am. Chem. Soc . , fi>. 1299 ( 1946) or J. Am. Chem. Soc, , 1305 (1946).

Alternatively, the 4-chloroquinazoline derivative may be produced by a process which comprises the steps of: (1) first reacting a benzoic ester with formamide to prepare a quinazolone derivative (see Production Example 34) and (2) then heating the 4-quinazolone derivative using toluene or sulfolane as a solvent in the presence of phosphorus oxychloride (see Production Examples 35 and 36). The quinazolone derivative is generally synthesized in the presence of a benzoic ester, sodium methoxide, formamide, and a solvent such as DMF or methanol. In the step (1), the reaction proceeds in a system where only the benzoic ester and formaldehyde are present. This is advantageous in that the synthesis can be carried out using a small number of starting compounds. The 4-quinazolone derivative is generally halogenated by heating the quinazolone derivative and phosphorus oxychloride. In this case, in many cases, due to high reactivity of the quinazoline derivative, the influence of the solvent has caused the quinazoline derivative to be returned to the starting compound and consequently made it impossible to complete the reaction. In the step (2), the reaction is completed in the presence of toluene or sulfolane, and, thus, this is advantageous from the viewpoint of an increase in yield.

Next, 4-chloroquinoline derivative or a corresponding quinazoline derivative is allowed to act on nitrophenol in the presence of a suitable solvent or in the absence of a solvent to synthesize a 4- (nitrophenox )quinoline . derivative or a corresponding quinazoline derivative which is then stirred in a suitable solvent, for example, Ν,Ν-dimethylformamide, in the presence of a catalyst, for example, palladium hydroxide-carbon or palladium-carbon, in a hydrogen atmosphere to give a 4-(aminophenoxy )quinoline derivative or a corresponding quinazoline derivative. Alternatively, a 4-chloroquinoline derivative or a corresponding quinazoline derivative may be allowed to act on aminophenol in the presence of a base, for example, sodium hydride, to give a 4- ( aminophenoxy )quinoline derivative or a corresponding quinazoline derivative.

Alternatively, the 4- ( aminophenoxy)quinoline derivative or the , corresponding quinazoline derivative may also be1' produced by dissolving aminophenol in an aqueous sodium hydroxide solution and then subjecting the solution to a two-phase reaction with a solution of a 4-chloroquinazoline derivative or a corresponding quinazoline derivative in an organic solvent in the presence of a phase transfer catalyst or in the absence of a catalyst (see Production Examples 37 and 38). In this reaction, for example, phenol remaining unreacted and a decomposition product of 4-chloroquinazoline are left in the aqueous . layer, while the target product is present in the organic layer. That is, the organic layer contains only the target product. Therefore, the post-treatment is advantageously simple. Further, the production of N-alkylaminophenoxy-quinazoline as a byproduct can be advantageously suppressed.

The 4- ( aminophenoxy)quinoline derivative or the corresponding quinazoline derivative thus obtained may be reacted with an acid chloride or an acid anhydride in the presence of a base, followed by reduction, for example, with lithium aluminum hydride to introduce a substituent into R9 (step 1A) .

Alternatively, the 4-(aminophenoxy )quinoline derivative or the corresponding quinazoline derivative may be reacted with an aldehyde or a ketone to produce an imine, followed by reduction, for example, with sodiumboroncyanohydride to introduce a substituent into R9 (step IB).

The derivative with a substituent introduced into R9 is allowed, to act on >an isocyanate derivative (0=C=N-R11) by a conventional method (step 2), and a suitable alkylating agent (R10Hal) is allowed to act in the presence of a base, for example, sodium hydride (step 3) to produce the compound of formula ( I ) .

Alternatively, R9 and R10 may also be introduced by allowing a suitable alkylating agent (R9Hal, R10Hal) to act on a urea derivative, wherein R9 and/or R10 represent a hydrogen atom, in the presence of a base, for example, sodium hydride (steps 5 and 7).

The urea derivative, wherein R9 and/or R10 represent a hydrogen atom, may be produced by allowing an isocyanate derivative to act on the 4-(aminophenoxy )quinoline derivative or the corresponding quinazoline derivative, produced in scheme 1, according to a conventional method, or by adding a triphosgene to the 4- ( aminophenoxy )quinoline derivative or the corresponding quinazoline derivative in the presence of a base, for example, triethylamine, and then reacting the mixture with a suitable alkylamine (R NH2, R10R NH) ( steps 4 and 6 ) .

The derivative having a specific substituent at the 7-position of the quinoline ring may be produced, for example, according to scheme 3.

Scheme 3 A suitable substituent (for example, benzyl) may be allowed to act on a commercially available 4'-hydroxyacetophenone derivative to protect the hydroxyl group, followed by action of a nitrating agent (for example, nitric acid-acetic acid) to introduce a nitro group. '. . , t .

The nitro group may be then reduced to an amino group which is then reacted with a formic ester in the presence of a base to form a quinolone ring, followed by action of a chlorinating agent, for example, phosphorus oxychloride, to produce a 4-chloroquinoline derivative.

The 4-chloroquinoline derivative thus obtained may be allowed to act on aminophenol in the presence of a base, for example, sodium hydride, to produce a 4- ( aminophenoxy ) quinoline derivative.

The urea portion may be synthesized by allowing an isocyanate derivative (0=C=N-R29) to act on the derivative thus obtained according to a conventional method, or by treating the derivative with triphosgene and then allowing an aromatic amine or alkylamine (R29NH2) to act on the treated derivative.

Next, the protective group (PG) for the hydroxyl group at the 7-position of the quinoline ring may be removed, followed by action of an alkyl halide (R22Hal wherein R22 represents an alkyl portion when R22 represents alkoxy). in the presence of a base, or by action of an alcohol derivative (R2 OH) according to a conventional method, for example, Mitsunobu reaction, to produce a compound, according to the present invention, having an alkoxy grou at the 7-position of the quinoline ring.

The alkyl halide used in the substitution reaction may be commercially: available or produced according to a process described, for example, in J. Am. Chem. Soc, 1945, 67, 736.

The alcohol derivative used in the substitution reaction may be commercially available or produced according to a process described, for example, in J. Antibiot. (1993), 46(1), 177 and Ann. Pharm. Fr. 1977, 35, 503.

The derivative having a specific substituent at the 6-position of the quinoline ring may be produced using 3 ' -hydroxyacetophenone derivative as the starting compound according to scheme 3.

The derivative having a specific substituent at the 7-position of the quinazoline ring may be produced according to scheme 4.

Scheme 4 Oxidation Depro- tection ί6 The 2-amino-benzoic ester derivative may be produced by esterifying a 2-nitro-benzoic acid derivative synthesized according to a method described, for example, in J. Med. Chem. 1977, 20, 146, for example, with dimethylsulfuric acid in the presence of a base, for example, potassium .carbonate and then reducing the nitro group, for example, with iron/acetic acid.

Next, the compound thus obtained may be allowed to act on formamide in the presence of a base to form a 4-quinazolone ring, followed by action of a chlorinating agent, for example, phosphorus oxychloride, to produce a 4-chloroquinazoline derivative.

The 4-chloroquinazoline derivative thus obtained may be allowed to act on an aminophenol derivative in the presence of a base, for example, sodium hydride, to produce a 4- (aminophenoxy) quinazoline derivative.

The urea portion may be synthesized by allowing an isocyanate derivative (0=C=N-R29) to act on the derivative thus obtained according to a conventional method, or by treating the derivative with triphosgene and then allowing an aromatic amine or alkylamine (R29NH2) to act on the treated derivative.

Next, the protective group (PG) for the hydroxyl group at the 7-position of the quinazoline ring may be removed, followed by action of an alkyl halide (R22Hal wherein R22' represents an alkyl portion when R22 represents alkoxy) in the presence of a base, or by action of an alcohol derivative (R22 OH) according to a conventional method, for example, Mitsunobu reaction, to produce a compound, according to the present invention, having an alkoxy group at the 7-position of the quinazoline ring.

The alkyl halide and the alcohol derivative used in the substitution reaction may be commercially available or produced according to a process described in the literature referred to in the description of scheme 3.

The derivative having a specific substituent at the 6-position of the. quinazoline ring may be produced using 3-hydroxybenzaldehyde derivative as the starting compound according to scheme 4.

Use of compounds/pharmaceutical composition The compounds., according to the present invention have inhibitory activity against tumor proliferation in vivo (see Pharmacological Test Example 4).

Further, the compounds according to the present invention inhibit . in vitro the activation of MAPK (mitogen-activated protein kinase) caused by stimulation of vascular endothelial cells with VEGF (vascular endothelial growth factor) (see Pharmacological Test Examples 1 and 2). Upon the stimulation of vascular endothelial cells with VEGF, MAPK is activated by a signal transmission system downstream of the receptor, and, consequently, an increase in phosphorylated MAPK is recognized (Abedi, H. and Zachary, I., J. Biol. Chem. , 272, 15442-15451 (1997)). The activation of MAPK is known to play an important role in the growth of vascular endothelial cells in angiogenesis (Merenmies, J. et al., Cell Growth & Differ., 83-10 (1997); and Ferrara, N. and Davis-Smyth, T., Endocr. Rev., 18, 4-25 (1997)). Therefore, the compounds according to the present invention have angiogeneisis inhibitory activity.

Angiogenesis at pathologic sites is deeply involved mainly in diseases, such as tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma, and metastasis of solid tumors (Forkman, J. Nature Med. 1: 27-31 (1995); Bicknell, R., Harris, A. L. Curr. Opin. Oncol. 8: 60-65 (1996)). Therefore, the compounds according to the present invention can be used in the treatment of diseases, such as tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma, and metastasis of solid tumors.

The compounds according to the present invention have no significant influence on cytomorphosis (see Pharmacological Test Example 3). Therefore, the compounds according to the present invention can be administered to living bodies with very excellent safety. According to the present invention, there is provided a pharmaceutical composition comprising the compound according to the present invention. The pharmaceutical composition according to the present invention may be used in the treatment of diseases, such as tumor, diabetic retinopathy, chronic , rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma, and metastasis of solid tumors.

Further, according to the present invention, there is provided a .method for treating a disease selected from the consisting of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma, comprising the step of administering the compound according to the present invention, together with a pharmaceutically acceptable carrier, to mammals .

The compounds according to the present invention can be administered to human and non-human animals orally or parenterally by administration routes, for example, intravenous administration, intramuscular administration, subcutaneous administration, rectal administration, or percutaneous administration. Therefore, the pharmaceutical composition comprising as an active ingredient the compound according to the present invention is formulated into suitable dosage forms according to the administration routes.

Specifically, oral preparations include tablets, capsules, powders, granules, and syrups, and parental preparations include injections, suppositories, tapes, and ointments .

These various preparations may be prepared by conventional methods, for example, with commonly used component, such as excipients, disintegrants , binders, lubricants, colorants, and diluents.

Excipients include, for example, lactose, glucose, corn, starch, sorbit, and crystalline cellulose. Disintegrants include, for example, starch, sodium alginate, gelatin powder, calcium carbonate, calcium citrate, and dextrin. Binders include, for example, dimethylcellulose, polyvinyl alcohol, polyvinyl ether, methylcellulose, ethylcellulose, gum arabic, gelatin, hydroxypropylcellulose, and polyvinyl pyrrolidone. Lubricants include, for example, talc, magnesium stearate, polyethylene glycol, and hydrogenated vegetable oils .

In preparing .injections, if necessary, for example, buffers, pH adjustors, stabilizers, tonicity agents, and preservatives may be added.

The content of the compound according to the present invention in the pharmaceutical composition according to the present invention may vary according to the dosage form. , In general, however, the content is 0.5 to 50% by weight, preferably 1 to 20% by weight, based on the whole composition.

The dose may be appropriately determined in consideration of, for example, the age, weight, sex, difference in diseases, and severity of condition of patients, and the preparation may be administered, for example, in an amount of 0.1 to 100 mg/kg, preferably 1 to 50 mg/kg. This dose is administered at a time daily or divided doses of several times daily.

The compound according to the present invention may be administered in combination with other medicament( s ) . In this case, the compound according to the present invention may be administered simultaneously with or after or . - before . the administration of other medicament ( s )'. For example, when the object disease is malignant tumor, the compound according to the present invention can be allowed to act on target vascular endothelial cells to allow the tumor to regress, followed by the administration of a carcinostatic agent to effectively eliminate the tumor. The type, administration intervals and the like of the carcinostatic agent may be determined depending upon, for example, the type of cancer and the condition of patients. This treatment method is true of diseases other than the malignant tumor.

Furthermore, according to the present invention, there is provided a:' method for inhibiting the angiogenesis of target blood vessels, comprising the step of making the compound according to the present invention in contact with vascular endothelial cells of target blood vessels. Target blood vessels include blood vessels involved in feedings to tissues causative of diseases (for example, tumor tissues, retinopathy tissues, or rheumatism tissues). The compound according to the present invention may be brought into contact with the vascular endothelial cells, for example, by general administration (for example, intravenous administration or oral administration), local administration (for example, percutaneous administration or intraarticular administration), or drug targeting using a carrier (f6r example, liposome, lipid microsphere, or polymeric forms of drugs).

EXAMPLES The present invention will be described with reference to the following examples , though it is not limited to these examples only.

Production Example L. 2-Chloro-4- [ ( 6 f 7-dimethoxy-4-quinolyl ) oxy ] aniline Sodium hydride (60 wt%, 0.72 g) was added to dimethyl sulfoxide (10 ml). The mixture was stirred at 50°C for 30 min and was then cooled to room temperature. 4-Amino-3-chlorophenol hydrochloride (1.61 g) was added to the cooled mixture, and the mixture was stirred at room temperature for ;10 min. Next, 4-chloro-6, 7-dimethoxyquinpline. ( 1.00: g) was added thereto, and the mixture was stirred at 100°C overnight. Water was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was then washed with a saturated aqueous sodium hydrogencarbonate solution and was dried over .anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure, and methanol was added to the residue. The precipitated crystal was collected by suction filtration to give 0.89 g (yield 60%) of the title compound.

^H-NMR . (CpCl3, ,400 MHz): δ 4.05 (s, 3H), 4.05 (s, 3H), 4.08 (s, 2H) , .6.44 ■ (d, ; J = 5.4 Hz, 1H), 6.85 (d, J = 8.5 Hz,., 1H);, 6.93 i - 6Ϊ96 (m, 1H),. 7.15 (d, J = 2.7 Hz, 1H), 7.41 (s, 1H), .7.54 (s, 1H), 8.48 (d, J = 5.1 Hz, Production Example 2: 4- [ ( 6 f 7-Dimethoxy-4-quinolyl ) oxy ] - 2 r 3-dimethylaniline Sodium hydride (60 wt%, 0.72 g) was added to dimethyl sulfoxide (10 ml). The mixture was stirred at 50°C for 30 min and was then cooled to room temperature. 4-Amino-2 , 3-dimethylphenol hydrochloride (1.55 g) was added to the cooled mixture, and the mixture was stirred at room temperature for 10 min. Next, 4-chloro-6 , 7-dimethoxyquinoline (1.00 g) was added thereto, and the mixture was stirred at 100°C overnight. Water was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was then washed with a saturated aqueous sodium hydrogencarbonate solution and was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure, and methanol was added to the residue. The precipitated crystal was collected by suction filtration to give 0.94 g (yield 65%) of the title compound. 1H-NMR (CDCI3, 400 MHz): δ 2.07 (s, 3H), 2.15 (s, 3H), 3.62 (s, 2H), 4.05 (s, 3H), 4.07 (s, 3H), 6.25 (d, J = 5.4 Hz, 1H), 6.64 (d, J = 8.5 Hz, 1H), 6.83 (d, J = 8.5 Hz, 1H), 7.42 (s, 1H), 7.64 (s, 1H), 8.42 (d, J = 5.4 Hz, 1H) Production Example :3 : --[ ( , 7-Dimgthoxy-4-quinQlyl )oxy] - 2 f 5-dimethylaniline Sodium hydride (60 wt%, 0.36 g) was added to dimethyl sulfoxide (10 ml), and the mixture was stirred at 50°C for 30 min and was then cooled to room temperature. 4-Amino-2,5-dimethylphenol (1.23 g) was added to the cooled mixture, and the mixture was stirred at room temperature for 10 min. Next, 4-chloro-6, 7-dimethoxyquinoline (1.00 g) was added thereto, and the mixture was stirred at 100°C overnight. Water was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was then washed with a saturated aqueous sodium hydrogencarbonate solution and was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure, and the residue was purified by chromatography on silica gel by development with chloroform/acetone (1/1) to give the title compound.

Production Example ii 3 , 5-Dichloro-4- [ ( 6 , 7-dimethoxy-4-quinolypoxy] aniline Sodium hydride (60 wt%, 0.36 g) was added to dimethyl sulfoxide (10 ml), and the mixture was stirred at 50°C for 30 min and was then cooled to room temperature. 4-Amino-2 , 6-dichlorophenol (1.59 g) was added to the cooled mixture, and the mixture was stirred at room temperature for 10 min. Next, 4-chloro-6, 7-dimethoxyquinoline (1.00 g) was added thereto, and the mixture was stirred at 100°C overnight. Water was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was then washed with a saturated aqueous sodium hydrogencarbonate solution and was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure, and the residue was purified by chromatography on silica gel by development with chloroform/acetone (1/1) to give 0.35 g (yield 22%) of the title compound.

'H-NMR ( CDClj, 400 MHz): 3.84 (s, 2H), 4.05 (s, 3H), 4.08 (s, 3H), 6.28 (d, J = 5.4 Hz, 1H), 6.74 (s, 2H), 7.43 (s, 1H), 7.64 (s, 1H), 8.48 (d, J = 5.4 Hz, 1H) Production Example 5; 4-[ ( 6.7-Dimethoxy-4-quinolyl )oxy]-2-nitroaniline · Sodium hydride {60 wt%, 0.54 g) was added to dimethyl sulfoxide (15 ml), and the mixture was stirred at 70°C for 30 min and was then cooled to room temperature. 4-Amino-3-nitrophenol (2.07 g) was added to the cooled mixture,, and the mixture was stirred at room temperature for 10 min. Next, 4-chloro-6, 7-dimethoxyquinoline (1.50 g) was added thereto, and the mixture was stirred at 100°C for 4 hr. Water was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was then washed with a saturated aqueous sodium hydrogencarbonate solution and was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure, and the residue, was purified by chromatography on silica gel by development with chloroform/acetone (1/1) to give 0.53 g (yield 23%) of the title compound.

Production Example 6j 1- [ 2-Amino-4- (benzyloxy) -5-methoxyphenylj-l-ethanone 1- ( 4-Hydroxy-3-methoxypheny1 ) -1-ethanone (20 g) , potassium carbonate (18.3 g), tetra-n-butylammonium iodide (4.45 g), and benzyl bromide (17.3 ml) were dissolved in N,N-dimethylformamide (300 ml), and a reaction was allowed to proceed at 100°C for one hr. The solvent was removed by distillation under the reduced pressure, and water was added to the residue, followed by extraction with ethyl acetate. The ethyl acetate layer was dried over sodium sulfate. Next, the solvent was removed by distillation under the reduced pressure. The residue .' nd, fuming nitric acid (12.47 ml) were dissolved in acetic acid (120 ml), and a reaction was allowed to proceed at room temperature for 2 hr. The reaction solution was neutralized at 0°C by the addition of an aqueous 1 sodium hydroxide solution, followed by extraction with chloroform. The chloroform layer was then dried over sodium sulfate. Next, the solvent was removed by distillation under the reduced pressure. The residue was dissolved in ethanol (1160 ml) and water (120 ml) with heating. Ammonium chloride (19.2 g) and zinc (101.7 g) were added thereto. The mixture was heated under ~reflux for ) 3 hr. The react ion solution was filtered through Celite, followed by washing with chloroform/methanol (3/1). The solvent was removed by distillation under the reduced pressure, and the residue was made alkaline with an aqueous sodium hydroxide solution, and the alkaline solution was extracted with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure, and the residue was purified by chromatography on silica gel by development with chloroform/ethyl acetate (10/1) to give 24.95 g (yield 77%) of the title compound (3 steps).

'H-NMR (CDCI3, 400 MHz): δ 2.51 (s, 3H), 3.84 (s, 3H), 5.14 (s, 2H), 6.12 (s, 2H), 7.15 - 7.62 (m, 7H) Production Example 7_i 7- (Benzyloxy ) -6-methoxy-l , 4-dihydro-4-quinolinone ! 1- [ 2-Amino-4- ( benzyloxy ) -5-methoxyphenyl ] -1-ethanone (24.95 g) was dissolved in tetrahydrofuran (450 ml), and sodium methoxide (24.87 g) was added to the solution. The mixture was stirred at room temperature for one hr. Ethyl formate (37.07 ml) was then added thereto, and the mixture was stirred at room temperature for 2 hr. Water (150 ml) was then added thereto, and the mixture was stirred overnight. The reaction solution was adjusted to pH 4 by the addition of concentrated sulfuric acid at 0°C. Water was added thereto, and the mixture was extracted with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by / chromatography on silica gel by development with chloroform/methanol (10/1) to give 17.16 g (yield 66%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 3.84 (s, 3H), 5.19 (s, 2H), 5.97 (d, J = 7.1 Hz, 1H), 7.09 (s, 1H), 7.28 - 7.51 (m, 6H), 7.78 (d, J = 7.3 Hz, 1H), 11.50 - 11.75 (br, in) · ; Production Example SJE 7- (Benzyloxy) -4-chloro-6-metho yguinQline Phosphorus oxychloride (14.19 ml) was added to 7- (benzyloxy ) -6-methoxy-l , 4-dihydro-4-quinolinone (17.16 g), and the mixture was heated under reflux for one nr. The solvent was removed by distillation under the reduced pressure. > The residue was dissolved in chloroform, and the solution was made alkaline by the addition of an aqueous sodium hydroxide solution, followed by extraction with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure, and the residue was purified by chromatography on silica gel by development witli chloroform/acetone (10/1) to give 3.82 g (yield 21%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 4.06 (s, 3H), 5.32 (s, 2H), 7.30 - 7.55 (m, 8H), 8.56 (d, J = 4.9 Hz, 1H) Production Example 9_j 4-{ [ 7- (Benzyloxy ) -6-methoxy-4-quinolyl]oxy>-2.5-dimethylaniline Sodium hydride (60 wt%, 1.17 g) was added to dimethyl sulfoxide (25 ml), and the mixture was stirred at 60°C for 30; min and was then cooled to room temperature. Next, 4-amino-2 , 5-dimethylphenol (4.00 g) was added thereto, and the mixture was stirred at room temperature for 10 min. 7-(Benzyloxy)-4-chloro-6-methoxyquinoline (4.36 g) was then added thereto. The mixture was stirred for 22 hr before water was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was then washed with a saturated aqueous . sodium hydrogencarbonate solution and was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure, and methanol was added to the residue to prepare a suspension. '. The,, precipitated crystal was collected by suction filtration to - give 3.04 g (yield 52%) of the title compound.

^H-NMR ( CDClj , 400 MHz): δ 2.05 (s, 3H), 2.16 (s, 3H), 3.58 (s, 2H), 4.06 (s, 3H), 5.32 (s, 2H), 6.28 (d, J = 5.1 Hz, 1H), 6.61 (s, 1H), 6.81 (s, 1H), 7.28 - 7.42 (m, 3H), 7.44 (s, 1H), 7.49 - 7.54 (m, 2H), 7.63 (s, 1H) , 8.39 (d, J = 5.1 Hz,. 1H) Mass analysis,, found (ESI-MS, m/z): 401 (M++l) Production Example' 10: N- ( 4-{ [ 7- ( Benzyloxy ) -6-methoxy-4 -quinolyl]oxy}-2 ,5-dimethylphenyl)-N,-(2 ,4-difluorophenyl ) urea 4-{ [ 7- (Benzyloxy ) -6-methoxy-4-quinolyl ]oxy}-2 , 5-dimethylaniline (300 mg) was dissolved in chloroform (5 ml). 2 , 4-Di-fluorophenyO. isocyanate (200 μΐ) was then added to the solution, and the mixture was stirred at 70°C overnight. The reaction solution was purified by chromatography on silica gel by development with chloroform/acetone (75/25) to give 368 mg (yield 88%) of the title compound.

'H-NMR (CDC13, 400 MHz): δ 2.17 (S, 3H), 2.26 (s, 3H), 4.06 (s, 3H), 5.33 (s, 2H), 6.29 (d, J = 5.1 Hz, 1H), 6.42 (s, 1H), 6.76 - 6.93 (m, 3H), 6.70 (s, 3H), 7.30 - 7.54 (ra, 7H.) , 7.60 (s, 1H), 8.04 - 8.12 (m, 1H), 8.44 (d, J = 5.4 Hz, 1H) Production Example 11: N- ( 4-{ [ 7- ( Benzyloxy ) -6-methoxy-4-quinolyl ] oxy}-2.5-dimethylphenyl ) - ' - ( 2-methoxyphenyl ) -urea 4-{ [ 7-(Benzyloxy ) -6-methoxy-4-quinolyl ]oxy}-2 ,5-dimethylaniiine. (300 mgi) was dissolved in chloroform (5 ml). 2-Methoxyphenyl isocyanate (0.24 ml) was then added to the solution, and the mixture was stirred at 70°C overnight. The reaction solution was purified by chromatography on silica gel by development with chloroform/acetone (75/25) to give 365 mg (yield 89%) of the title compound. 1H-NMR (CPC13, 400 MHz): δ 2.17 (s, 3H), 2.28 (s, 3H), 3.83 (s, 3H), 4.07 (s, 3H), 5.33 (s, 2H), 6.26 (s, 3H), 6.29 (d, J =: 5.4 Hz, 1H), 6.86 - 7.06 (m, 4H), 7.12 (s, 1H), 7.30 - 7.41 (m, 3H), 7.46 (s, 1H), 7.50 - 7.56 (m, 3H), 7.61 (s, 1H), 8.11 - 8.16 (m, 1H), 8.43 (d, J = 5.4 Hz, 1H) -.',.'· . '■■ I Production Example 12. 4-{ [ 7- (Benzyloxy ) -6-methoxy-4-quinolyl ]oxy}-2-chloroaniline Sodium hydride (60 wt%, 320 mg) was added to dimethyl sulfoxide (3.6 ml), and the mixture was stirred at 60°C for 30 min and was then cooled to room temperature. Next, 4-amino-3-chlorophenol hydrochloride (720 mg) was added thereto, and the mixture was stirred at room temperature for 10 min. 7- (Benzyloxy ) -4-chloro-6-methoxyquinoline . ( 600 mg) was then added thereto, and the mixture was stirred at 105°C for 22 hr. Water was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was then washed with a saturated aqueous sodium hydrogencarbonate solution and was dried over anhydrous sodium sulfate. The solvent 1 was removed by distillation under the reduced pressure, and methanol was added to the residue to prepare a suspension. The precipitated crystal was collected by suction filtration to give 533 mg (yield 66%) of the title compound. 1H-NMR (CDCI3, 400 MHz): δ 4.05 (s, 3H), 4.08 (s, 2H), 5.32 (s, 2H), 6.42 (d, J = 5.1 Hz, 1H), 6.84 (d, J = 8.5 Hz, 1H), 6.93 (dd, J = 2.4 Hz, 8.1 Hz, 1H), 7.14 (d, J = 2.4 Hz, 1H), 7.29 - 7.42 (m, 3H), 7.44 (s, 1H), 7.49 - 7.53 (m, 2H), 7.55 (s, 1H), 8.45 (d, J = 5.3 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 497 (M++l) Production Example 13; N- ( 4-{ [ 7- (Benzyloxy ) -6-methoxy-4-quinolyl 1oxyV -2-^chlorophenyl -N ' - ( 2 , 4-difluorophenyΊ ) -urea ! 4- { [ 7- ( Benz loxy ) - 6-methoxy-4 -quinoly1 ] oxy } -2- chloroaniline (260 mg) was dissolved in chloroform (10 ml). 2 , 4-Difluorophenyl isocyanate (198 mg) was then added to the solution, and the mixture was stirred at room temperature for. 2 hr. The reaction solution was purified by chromatography on silica gel by development with chloroform/acetone (10/1) to give 337 mg (yield 94%) of the title compound.

^-NMR (CDC13, 400 MHz): δ 4.04 (s, 3H), 5.32 (s, 2H), 6.49 (d, J = 5.1 Hz, 1H), 6.86 - 6.96 (m, 3H), 7.10 - 7.17 (m, 2H), 7.22 - 7.28 (m, 1H), 7.28 - 7.41 (m, 3H), 7.45 - 7.53 (m, 4H), 7,96 - 8.04 (m, 1H), 8.27 (d, J = 9.0 Hz, 1H), 8.49 (d, J ~ 5.4 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 562, 564 (M++l) Production Example H N-{2-Chloro-4- [ ( 7-hydroxy-6-methoxy-4-quinoly1 ) oxy ] henyl>-N ' - ( 2.4-difluorophenyl ) -urea N- ( 4-{ [ 7- (Benzyloxy) -6-methoxy-4-quinolyl ] oxy}-2-chlorophenyl ) - '— ( 2 , 4-difluorophenyl )urea (215 mg) was dissolved in dimethylformamide (11 ml). Palladium-carbon (215 mg) was added, to the solution, and the mixture was stirred in a hydrogen atmosphere at room temperature overnight. Ethyl acetate (30 ml) was added to the reaction solution, and the mixture was then filtered through Celite. The solvent was removed by distillation under the reduced pressure to give 174 mg (yield 96%) of the title compound. < 1 i ■ ■ 1H-NMR (DMSO-d6, 400 MHz): δ 3.94 (s, 3H), 6.47 (d, J = 5.1 Hz, 1H), 7.01 - 7.11 (m, lH), 7.18 - 7.36 (m, 3H), 7.44 - 7.52 (m, 2H), 7.95 (s, 1H), 7.98 - 8.13 (m, 1H), 8.23 (d, J = 9.5 Hz, 1H), 6.50 (d, J = 5.1 Hz, 1H), 8.81 (s, 1H), 9.31 (s, 1H) Mass analysis, found (ESI-MS, m/z): 472 (M++l) Production Example L5_j 4-{ [7- (Benzyloxy )-6-methoxy-4-quinolyl ]oxy}-2 r 3-dimethylaniline Sodium hydride (60 wt%, 0.32 g) was added to dimethyl sulfoxide (6 ml), and the mixture was stirred at room temperature for 30 min. 4-7Amino-2 , 3- dimethylphenol -(1.10/g) was then added thereto, and ■■ '.: ■'..· i · ■ i ■ the mixture was stirred, at room temperature for 10 min. Next, 7-(benzyloxy ) -4-chloro-6-methoxyquinoline (1.20 g) was added thereto, and the mixture was stirred at 110°C for 6 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was dried over anhydrous magnesium ■ sulfate. The solvent was removed by distillation under the reduced pressure, and the residue was purified by chromatography on silica gel by development -.with chloroform/acetone (6/1) to give 0.78 g (yield 49%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 1.87 (s, 3H), 1.96 (S, 3H), 3.97 (s, 3H), 4.78 (s, 2H), 5.23 (s, 2H), 6.12 (d, J = 5.3. Hz, 1H), 6.54 (d, J = 8.4. Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 7.2'7 -< 7.51 (m, 7H), 8.31 (d, J = 5.3 Hz, 1H) Production Example 16: N- ( 4-{ [ 7- (Benzyloxy ) -6-methoxy-4-quinolyl ]oxy}-2 , 3-dimethylphenyl ) -N ' - ( 2 f 4-difluoro-phenyl) urea 4-{ [ 7- (Benzyloxy )-6-methoxy-4-quinolyl]oxy}-2 , 3-dimethylaniline (260 mg) was dissolved in N,N-dimethyiformamide (5 ml). 2 , 4-Difluorophenyl isocyanate (121 mg) was then added to the solution, and a reaction was allowed to proceed at room temperature overnight. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was washed with methanol and was collected by filtration to give 219 mg (yield 61%) of the title compound. ■ ; ^-NMR (DMS0-d6, 400 MHz): δ 1.99 (s, 3H), 2.17 (s, 3H), 3.90 (s, 3H), 5.24 (s, 2H), 6.18 (d, J = 5.1 Hz, 1H), 6.95 - 6.98 (m, 2H), 7.25 - 7.63 (m, 9H), 8.05 -8.08 (m, 1H), 8.34 - 8.36 (m, 211), 8.79 (s, III) Production Example Hi 7- (Benzyloxy )-4-( 3-fluoro-4-nitrophenoxy ) -6-methoxyquinoline 7- (Benzyloxy) -4-chloro-6-methoxyquinoline (300 mg) and 3-fluoro-4-nitrophenol (785 mg) were dissolved in chlorobenzene (3 ml), and the solution was stirred at 130°C for 5 hr. Chloroform and an aqueous sodium hydroxide solution were added to the reaction solution, and the mixture was stirred for one hr. The reaction solution was extracted with chloroform, and the chloroform layer was dried over anhydrous magnesium sulfate. The solvent was removed by distillation, under the reduced pressure. The residue was purified by thin- layer chromatography on silica gel by development with hexane/ethyl acetate (1/1) to give 197 mg (yield 47%) of the title compound.

^- MR (DMSO-d6, 400 MHz): δ 3.83 (s, 3H), 5.25 (s, 2H), 6.91 (d, J = 5.1 Hz, 1H), 7.29 - 7.50 (m, 9H), 8.18 - 8.23 (m, 1H), 8.56 (d, J = 5.1 Hz, 1H) Production Example 18: 4- ( 4-Amino-3-fluorophenoxy ) -6-methoxy-7-quinolinol 7- ( Benzyloxy) -4- ( 3-fluoro-4-nitrophenoxy ) -6-methoxyquinoline (190 mg) was dissolved in N,N-dimethylformamide (5 ml) and triethylamine (1 ml). Palladium hydroxide (40 mg) was added to the solution, and the mixture was stirred in a hydrogen atmosphere at room temperature overnight. The solvent was removed by distillation under the reduced pressure. The residue was purified by thin-layer chromatography on silica gel by development with chloroform/methanol (20/1) to give 75 mg (yield 56%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 3.87 (s, 3H), 5.11 (s, 2H), 6.29 (d, J = 5.1 Hz, 1H), 6.77 - 6.80 (m, 2H), 6.93 - 6.99 (m, 1H), 7.19 (s, 1H), 7.40 (s, 1H), 8.31 (d, J = 5.1 Hz, 1H) , 10.03 (s, 1H) Production Example 19: N- ( P 4-Di luorophenyl ) -N' -{2-fluoro-4-[ r7-hydroxy-6-methoxy-4-quinolyH oxy] henyl}-urea 4- ( 4-Amino-3-fluorophenoxy ) -6-methoxy-7-quinolinol (70 mg) was dissolved in chloroform (1.5 ml) and N,N-dimethylformamide (1 ml). 2 , 4-Difluorophenyl isocyanate (43 mg) was then added to the solution, and a reaction was allowed to ; proceed at room temperature for 3 hr. Methanol was added to the reaction solution. The solvent was removed by distillation under the reduced pressure. The residue was purified' by thin-layer chromatography on silica gel by development with chloroform/methanol (20/1) to quantitatively give the title compound.

^-NMR (DMSO-d6, 400 MHz): δ 3.94 (s, 3H), 6.47 (d, J = 5.1 Hz, 1H):, 7.04 - 7.10 (m, 2H), 7.28 - 7.34 (m, 2H), 7.47 (s, 1H),;: 8.05 - 8.15 (m, 2H), 8.30 (s, 1H), 8.43 (d, J = 5. If Hz", 1H), 8.97 - 9.03 (m, 2H), 10.10 (s, 1H) ; Production Example 20; 4-Chloro-6-methoxy-7-quinolinol 7- (Benzyloxy )-4-chloro-6-methoxyquinoline (100 mg), thioanisole (300 μΐ), and methanesulfonic acid (25 μΐ) were dissolved in trifluoromethanesulfonic acid (1 ml). The solution was stirred at room temperature for 30 min. The solvent was removed by distillation under the reduced pressure. The residue was made neutral by the addition of an 'aqueous sodium hydroxide solution, and hexane was added thereto to prepare a suspension. The crystal was collected by suction filtration to give 53 mg (yield 75%) of the title compound.

^-NMR (DMS0-d6, 400 MHz): δ 3.98 (s, 3H), 7.33 (s, 1H), 7.36 (s, 1H), ;7.47 (d, J = 4.9 Hz, 1H), 8.54 (d, J = 4.9 Hz, 1H), 10.37 (br, 1H) .

Production Example : 21 : 4-Chloro-6-methoxy-7-(2-methoxyethoxy ) quinoline 4-Chloro-6-methoxy-7-quinolinol (50 mg), potassium carbonate (40 mg) , , tetra-n-butylammonium iodide (9 mg), and 2-bromoethyl methyl ether (40 mg) were dissolved in N,N-dimethylformamide (10 ml). The solution was stirred at 70°C overnight. ( The solvent was removed by distillation under the 'reduced pressure. A saturated aqueous sodium hydrogencarbonate solution was added to the residue, followed. by extraction with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed ,by distillation under the reduced pressure. The residue was pμrified by chromatography on silica gel by development with hexane/acetone/dichloromethane (6/2/1) to give 47 mg (yield 74%) of tshe 'title, compound. 1H-NMR, (CDC13, - 40.0 MHz) : 6 3.49 (s, 3H), 3.88 - 3.90 (m, 2H), 4.04 (s, 3H), 4.32 ^ 4.35 (m, 2H), 7.35 (d, J = 4.9 Hz, lH), .7.40 (s, 1H) , 7.43 (s, 1H), 8.57 (d, J = 4.9 Hz, 1H) , ' } . 4 Production Example' 22'; 2-ΟΙ.1ΟΓΟ-4-·( [ ( 6-met OXy-7-( 2-methoxyethoxy ) -4-quinblyi ] oxy}aniline Sodium hydride (60 wt%, 153 mg) was added to dimethyl sulfoxide (2 ml). The mixture was stirred at 60°C for 30 min and was then cooled to room temperature. 4-Amino-3-chlprophenol hydrochloride (343 mg) was added thereto, and the mixture was stirred at room temperature for 10 min. Next, a solution of 4-chloro-6-methoxy-7- ( 2-methoxyethoxy )quinolirie (254 mg) in dimethyl sulfoxide (2 ml) was added to the reaction solution, and the mixture was stirred at 110°C overnight. Water was added to the reactio solution, followed by extraction with chloroform. The chloroform layer was then washed with a saturated aqueous sodium hydrogencarbonate solution and was dried over anhydrous- sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (7/3) to give the title compound. ' ^-NMR (CDC13, 400 MHz): δ 3.49 (s, 3H), 3.89 - 3.91 (m, 2H), 4.02 (s, 3H), 4.09 (s, 2H), 4.33 - 4.35 (m, 2H), 6.43 (d, J .= 5.4 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 6.93 - 6.96 (m, 1H) , 7.15 (d, J = 2.7 Hz, 1H), 7.41 (s, 1H), 7.52 (s, 1H), 8.47 (d, J = 5.1 Hz, 1H) Production Example 23; 2-Chloro-4- [ I 6.7-dimethoxy-4-quinazolinyl) oxy] aniline Sodium hydride (60 wt%, 5.80 g) was added to dimethyl sulfoxide (40 ml);. The mixture was stirred at 60°C for 30 min and was then cooled to room temperature. Next, 4-amino-3-chlorophenol hydrochloride (13.05 g) was added thereto. The mixture was stirred at room temperature fo 10 min. 4-Chloro-6 , 7-dimethoxyquinazoline (8.14 g), which is a chloroquinazoline derivative synthesized by a conventional method as described, for example, in J. Am. Chem. Soc, , 1299 (1946) or J. Am. Chem. Soc, 6fi, 1305 (1946), was then added thereto. The mixture was stirred at 110°C- for 30 min. Water was then added to the reaction solution, followed by extraction with chloroform. The chloroform layer was then washed with a saturated aqueous sodium hydrogencarbonate solution and was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure, and methanol was added to the residue to prepare a suspension. The precipitated crystal was collected by suction filtration to give 9.13 g (yield 76%) of the title compound. 1H-NMR (CDC13, 400 MHz): δ 4.05 - 4.08 (m, 8H), 6.85 (d, J = 8.5 Hz, 1H), 7.00 (dd, J = 2.7 Hz, 8.8 Hz, 1H), 7.21 (d, J = 2.7 Hz, 1H), 7.32 (s, 1H), 7.52 (s, 1H), 8.64 (s, 1H) Mass analysis, found (ESI-MS, m/z): 332 (M++l) Production Example 24; N-Benzyi-N-(2 f 4-difluorophenyl ) amine Magnesium sulfate (5.59 g) and a minor amount of acetic acid were added to a solution of 2,4-difluoroaniline (2.37 ml) and benzaldehyde (2.36 ml) in methanol (46 ml). ; The mixture was stirred at room temperature for 45 min. Sodium boron hydride (2.64 g) was added thereto under ice cooling, and the mixture was stirred at room temperature for one hr. The solvent was removed by distillation under the reduced pressure. Water and ethyl acetate were added to the residue. The mixture was stirred. and was filtered through Celite. The organic layer was extracted with ethyl acetate and was dried over anhydrous sodium sulfate. The solvent was removed by distillation ; under the reduced pressure. The residue was purified byj chromatography on silica gel by development with hexane/acetone (30/1) to give 3.04 g (yield 60%) of the title compound.

'H-NMR (CDCIJ, 400 MHz): δ 4.34 (s, 2H), 6.56 - 6.82 (m, 3H), 7.25 - 7.38 (m, 5H) Production Example 25: Methyl 4- (benzyloxy) -5-methoxy-2-nitrobenzoate- Commercially available methyl vanillate (50 g) and potassium carbonate (76 · g) were dissolved in N,N-dimethylformamide (200 ml). Benzyl bromide (33 ml) was added dropwise to the solution over a period of 10 min. The mixture was stirred at room temperature overnight. Water (200 ml) was . added thereto , followed by extraction with ethyl acetate. Saturated brine was then added to the organic layer, and j the mixture was extracted with ethyl acetate. Sodium sulfate was added to the organic layer to dry the organic layer. Next, the organic layer was filtered, and the solvent was then removed by distillation under the reduced pressure. The residue was dried through a vacuum pump to give 68 g of a white solid. Subsequently, 100 ml of acetic acid and 200 ml of nitric acid were added under ice cooling. The mixture was stirred for 8 hr, and water was then added thereto. The resultant solid was then collected by filtration, was thoroughly washed with water, and was dried through a vacuum pump to give 74 g (yield 93%) of the title compound . 1H-NMR (CDCIj, 400 MHz): δ 3.90 (s, 3H), 3.98 (s, 3H), 5.21 (s, 2H), 7.08 (s, 1H), 7.31 - 7.45 (m, 5H), 7.51 (s, 1H) · . · j Production Example ,26; 7- I Benzyl oxy ) -6-methoxy-3 f 4-dihydro-4-quinazol inone Methyl 4- (benzyloxy) -5-methoxy-2-nitrobenzoate (15.0 g) was dissolved in acetic acid (200 ml) at room temperature. Iron (powder) (13.2 g) was then added to the solution. The temperature of the mixture was raised to 90qC, and the mixture was then stirred for one hr. The resultant gray solid was filtered through Celite, followed by washing^ with acetic acid. Concentrated hydrochloric acid was added to the mother liquor. The solvent was then removed by distillation under the reduced pressure. This ^resulted in the precipitation of a solid. The solid: was collected by filtration, was washed with ethyl acetate and ether, and was dried through a vacuum pump. Subsequently, chloroform and methanol were added to the solid to prepare a suspension, and a 10% aqueous sodium hydroxide solution was then added to dissolve the solid, followed by extraction with chloroform. After washing with water, the organic layer was dried over sodium sulfate. Next, the organic layer was filtered, and the solvent was then removed by distillation under .the reduced pressure. The residue was dried through a vacuum pump to give 9.5 g (yield 70%) of a crude product of methyl 2-amino-4- (benzyloxy)-5-methoxybenzoate.

Methyl 2-amino-4-(benzyloxy)-5-methoxybenzoate (650 mg) was dissolved in N, N-dimethylformamide (15 ml) and methanol (3 ml). Formamide (0.46 ml) and sodium methoxide (373 mg) were added to the solution. The mixture was heated to 100°C and was stirred overnight. The reaction solution was cooled to room temperature, and 10 ml of water was then added to the cooled reaction solution. The reaction solution was neutralized with a 1 M aqueous hydrochloric acid solution to' precipitate a solid. The solid was collected by filtration, was washed with water and ether, and was then dried through a vacuum pump to give 566 mg (yield 87%) of the title compound. aH-NMR (DMSO-d6, 400 MHz): δ 3.88 (s, 3H), 5.25 (s, 2H), 7.23 (s, 1H), 7.33 - 7.49 (m, 6H), 7.97 (s, 1H), ( 12.06 (br, 1H) ! Production Exampl 27: 7-( Benzyloxy ) -4-chloro-6- methoxyquinazoline .

Phosphorus,' oxychlpride (515 ml) was added to 7- (benzyloxy ) -6-me:thoxy-3 , 4-dihydro-4-quinazolinone (400 mg) and diisoprppyiethylamine (0.3 ml), and the mixture was refluxed for 20 min. The reaction solution was cooled to room temperature. A 10% aqueous sodium hydroxide .solution was then . added to the reaction solution, followed by extraction, with chloroform. The organic layer was dried over sodium sulfate. The organic layer . was filtered, and; the solvent was then removed by distillation under the reduced pressure. The residue was dried through a' vacuum pump to give 420 mg (yield 99%) of the title compound.

^- MR ( CDClj, 400 MHz): δ 4.08 (s, 3H), 5.34 (s, 2H), 7.35 - 7.51 (m, 7H), 8.86 (s, 1H) Production Example 28 ; Methyl 5- (benzyloxy) -4-methoxy-2-nitrobenzoate Commercially ·... available methyl 3-hydroxy-4-methoxybenzoate (10 g) and potassium carbonate (23 g) were dissolved in N,N-dimethylformamide (50 ml). Benzyl bromide (6.5 ml) ,was added dropwise to the solution over a period of 10 min. The mixture was stirred at room temperature overnight. Water (200 ml) was added thereto, and the mixture was extracted with ethyl acetate. Saturated brine -was then added to the organic layer, followed by extraction with ethyl acetate. Sodium sulfate was added to the organic layer to dry the organic layer. Next, the organic layer was filtered, and the solvent was then removed by distillation under the reduced pressure. The residue was dried through a vacuum pump to give 8.4 g of a white solid. Subsequently, 7.0 g of the solid was placed in a flask, and 100 ml of acetic acid and 200 ml of > nitric acid were added thereto under ice cooling. The mixture was stirred for 8 hr, and water was then added! thereto. The resultant solid was collected by filtration, was thoroughly washed with water, and was dried through a vacuum pump to give 7.9 g (yield 96%) of the title compound.

^- MR (CDC13, 400 MHz): δ 3.89 (s, 3H), 3.96 (s, 3H), 5.21 (s, 2H), 7.15 (s, 1H), 7.34 - 7.45 (m, 6H) Production Example 2_9_j 6- (Benzyloxy ) -7-methoxy-3 , 4-dihydro-4-quinazolinone Methyl 5- (benzyloxy) -4-methoxy-2-nitrobenzoate (15.8 g) was dissolved in acetic acid (200 ml) at room temperature. Iron (powder) (13.9 g) was then added to the solution. The mixture was heated to 90°C and was stirred for one hr. The resultant gray solid was filtered through Celite and was washed with acetic acid. Concentrated hydrochloric acid was added to the mother liquor, and the solvent was then removed by distillation under the reduced pressure to precipitate a solid. The solid was collected by filtration, was washed with ethyl acetate and ether, and was dried through a vacuum pump. Subsequently, chloroform and methanol were added to the solid to prepare a > suspension, and a 10% aqueous sodium hydroxide solution was then added to the suspension to dissolve the solid, followed by extraction with chloroform. The extract was washed with water, and the organic layer was then dried over sodium sulfate. Next, the organic layer was filtered, and the solvent was then removed by distillation under the reduced pressure. The residue was dried through a vacuum pump to give 10.4 g (yield 73%) of a crude product of methyl 2-amino-5-(benzyloxy ) -4-methoxybenzoate .

Methyl 2-amino-5- (benzyloxy ) -4-methoxybenzoate (5.0 g) was dissolved in N,N~dimethylformamide (150 ml) and methanol (30 ml). Formamide (3.5 ml) and sodium methoxide (2.8 g) were added to the solution. The mixture was heated to 100°C and was then stirred overnight. The reaction solution was then cooled to room temperature, and 10 ml of water was then added. The reaction solution was neutralized with a 1 M aqueous hydrochloric acid solution to precipitate a solid. The solid was collected by filtration, was washed with water and ether, and was. then dried through a vacuum pump to give 3.7 g (yield 76%) of the title compound.

'H-NMR (DMSO-dfi, 40Q MHz): δ 3.92 (s, 3H), 5.21 (s, 2H), 7.16 (s> 1H) , 7.33 - 7.49 (m, 5H), 7.55 (s, 1H), 7.99 (s, 1H), 12.06 (br, 1H) Production Example 30: 6- ( Benzyloxy ) -4-chloro-7-methoxyquinazoline Phosphorus oxychloride (3.1 ml) was added to 6- ( benzyloxy ) -7-methoxy-3 , 4-dihydro-4-quinazolinone (3.5 g) and diisopropylethylamine (11.5 ml). The mixture was refluxed for 20 min. The reaction solution was cooled to room temperature, and a 10% aqueous sodium hydroxide solution was then added to the cooled reaction solution, followed by extraction with chloroform. The organic layer was dried over sodium sulfate. The organic layer was filtered, and; the solvent was then removed by distillation under the reduced pressure. The residue was dried through- a vacuum pump to give 2.9 g (yield 72%) of the title compound. 1H-NMR (CDC13, 400 MHz): δ 4.07 (s, 3H), 5.32 (S, 2H), 7.35 - 7.53 (m, 7H), 8.86 (s, 1H) Production Example 31 : 4-{ [ 7- (Benzylox ) -6-methoxy-4-quinazolinyl]oxy}-2-chloroaniline 7- ( Benzyloxy ) -4-chloro-6-methoxyquinazoline (30.0 g) and tetrabutylamitionium chloride (13.9 g) were dissolved in acetone (400 ml), and the solution was stirred at room temperature. A solution of 4-amino-3-chlorophenol hydrochloride (36.0 g) in a 20% aqueous sodium hydroxide solution (64 ml) was added thereto. The mixture was then heated under reflux for 3 hr. The reaction solution was cooled to room temperature, and chloroform and water wete added to the cooled reaction solution, followed by extraction with chloroform. The extract was washed with a saturated aqueous sodium hydrogencarbonate solution and saturated brine and was then dried over anhydrous sodium sulfate. Next, sodium sulfate was removed, and the solvent was then removed by distillation. The .residue was washed with methanol, and the washed solid was .subjected to evaporation to dryness in vacuo through a vacuum pump to give 36.6 g (yield 90%) of the title compound.

XH-NMR (DMSO-dg, 400 MHz): δ 3.96 (s, 3H), 5.34 (s, 2H), 6.86 (d, Jr;= 8.8. Hz, 1H), 7.00 (dd, J = 2.7 Hz, 8.8 Hz, 1H), 7.22 (d, J;-=. 2 /.7 Hz, 1H) , 7.35 - 7.54 (m, 7H), 8.53 (s, 1H) . ; Production Example 32: N- ( 4- { [ 7- ( Benzyloxy ) -6-methoxy-4-quinazo] inyl ]oxy>-2-chlorophenyl ) -N' -propylurea 4-{ [ 7- (Benzyloxy ) -6-methoxy-4-quinazolinyl ]oxy}-2-chloroaniline .(12.2 g) was dissolved in anhydrous chloroform. Triethylamine ( 8.4 ml) was then added to the solution, and the mixture was stirred at room temperature. . Separately, triphosgene (4.5 g) was dissolved in anhydrous chloroform (12 ml), and the solution was added dropwise to the mixed solution. The mixture was stirred at room temperature for 20 min, and n-propylamine (4.9 ml) was then added thereto, followed by stirring at room temperature for additional one hr to precipitate a white solid. This solid was collected by filtration and was ithen^ washed with chloroform to give 9.4 g (yield 63%) of the title compound.

'H-NMR (DMSO-d6, 400 MHz): δ 0.91 (t, J = 7.3 Hz, 3H), 1.44 - 1.50 (m, 2H), 3.06 - 3.09 (m, 2H), 3.98 (s, 3H), 5.35 (s, 2H), 6.97 - 7.01 (m, 1H), 7.23 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.37 - 7.57 (m, 9H ) , 8.20 (d, J = 9.3 Hz, 1H), 8.55 (s, 1H) Production Example 33: N-{?-Ch1oro-4-[ ( 7-hydroxy-6-methoxy-4-quinazolinyl ) oxy] henyl } - ' -propylurea N- ( 4-{ [ Ί - ( Benzyloxy ) -6-methoxy-4-quinazolinyl ] oxy} -2-chlorophenyl)- ' -propylurea (42.2 g) was dissolved in trifluoroacetic acid (200 ml). Methanesulfonic acid (11.1 ml) was then added to the solution, and the mixture was stirred at 100°C for 4 hr. The reaction solution was cooled { to ' room temperature, and trifluoroacetic acid was removed by distillation under the reduced pressure. Chloroform and methanol were added to the mixture as the residue, followed by extraction with a 10% aqueous sodium hydroxide solution three times. The aqueous layer was neutralized with concentrated hydrochloric acid to precipitate a solid. The solid was washed with water, methanol, and ether in that order, and was then dried in vacuo through a vacuum pump to give 20.7 g (yield 60%) of the title compound.

^-NMR . (DMSO-de, 400 MHz): δ 0.91 (t, J = 7.3 Hz, 3H), 1.42 - 1.49 (m, 2H), 3.06 - 3.17 (m, 2H), 3.84 (s, 3H), 6.65 (s, IH), ?-:'03 (m, , 1H) , 7.14 (dd, J = 2.7 Hz, 9.0 Hz, lH) , ; 7.20 (s, IH), 7.35 (d, J = 2.7 Hz, 1H), 8.05 (s, IH), 8.14 (dd, J = 2.7 Hz, 8.8 Hz, 1H), 8.19 (s, 1H) Production Example 34; 6 , 7-Dimethoxy-4-quinazolone Formamide (150 ml) was added to methyl 2-amino-3,4-dimethoxybenzoate (;20.0 g, 94.8 mmol). The mixture was heated at 160°C for 8.5 hr. The reaction solution was cooled and was then filtered. The collected precipitate was washed with water (100 ml χ 2 times), and the washed precipitate was dried in vacuo to give 17.85 g (yield 91.5%) of the target compound.

'H-NMR (DMS0-d6, 400 MHz): δ 4.01 (s, 3H), 4.02 (s, 3H), 7.14 (s, IH), '7.34 (s, IH), 7.61 (s, 1H), 7.97 (s, 1H) Production Example 35: 4--Chloro-6 , 7-dimethoxyquinazoline Sulfolane (250 ml ).·' and phosphorus oxychloride (250 ml = 412.5 g, 2.69 mol) were added to 6 , 7-dimethoxy-4-quinazolone (50.1 g, 0^24 mol), and the mixture was stirred at 120°C for one hr. The reaction mixture was cooled to room temperature, and the excess phosphorus oxychloride was then removed by distillation under the reduced pressure. The residue was poured into ice water (1000 ml), and chloroform (1000 ml) was added thereto. The aqueous layer was adjusted to pH 6.5 by the addition of a 20% sodium hydroxide solution, followed by the separation of the organic layer from the aqueous layer.

The separated organic layer was washed with water (1000 ml * six times), was dried over sodium sulfate, and was then concentrated under the reduced pressure. Tetrahydrofuran (470 ml) was added to the residue, and the mixture was refluxed. The reaction solution was cooled to -5°C to -10°C and was filtered and dried to give 38.5 g (yield 71.4%) of the target product. 1H-NMR (DMS0-d6, 400 MHz): δ 4.09 (s, 3H), 4.09 (s, 3H), 7.14 (s, 1H), 7.34 (s, 1H), 7.61 (s, 1H), 7.97 (s, 1H) Production Example 36: 4-Chloro-6.7-dimethoxyquinazoline Toluene (100 ml) and phosphorus oxychloride (7.4 g, 48.6 mmol) were added to 6 , 7-dimethoxy-4-quinazolone (10.0 g, 48.5 mmol), and the mixture was stirred at 120°C for 6.5 hr. The reaction solution was cooled to room temperature, was then filtered, was washed with toluene (100 ml, 50 ml), and was dried to give 11.5 g (yield 91%) of the target product.

Production Exampl 37; 4- ( 4 ' -Amino-3 · -chloro ) -phenoxy- 6 r 7-dimethoxyquinazoline Sodium hydroxide (8.5 g, 0.21 mol ) and water (90 ml) were added to and dissolved in 4-amino-3-chlorophenol hydrochloride (14.6 g, 81 mmol). 4-Chloro-6 , 7-dimethoxyquinazoline (12 g, 53 mmol) and methyl ethyl ketone (225 ml) were added to the solution, and the mixture was refluxed for 2 hr. The reaction solution was cooled to about 50°C, and chloroform (500 ml) and water (500 ml) were then added to the cooled reaction solution. The mixture was stirred for 10 min, and the I organic layer was then separated from the aqueous layer. Chloroform (250 ml) was added to the aqueous layer, and the mixture was stirred for 10 min, followed by layer separation. The organic layer was concentrated under the reduced pressure. Methanol (50 ml) was added to the residue, and the mixture was stirred for 30 min. The reaction solution was then filtered and was dried to give 15.6 g (yield 85%) of the target product. 1H-NMR (DMSO-d6, 400 MHz): δ 3.95 (s, 3H), 3.97 (s, 3H), 5.33 (s, 2H) , 6.85 (d, J = 8.8 Hz, 1H), 6.98 (dd, J = 2.8 Hz, J = 8.8 Hz, 1H), 7.20 (d, J = 2.8 Hz, 1H), 7.36 (s, 1H), 7.51 (s, 1H), 8.53 (s, 1H) Production Example ■ 38;v 4- ( 4 ' -Amino-3 ' -chloro ) -phenoxy- 6 , 7-dimethoxyquinazoline ·; A 20% aqueous sodium hydroxide solution (3.5 ml) and water (2 ml) were added to and dissolved in 4-amino- 3-chlorophenol hydrochloride (1.3 g, 7.2 mmol). 4-Chloro-6 , 7-dimethoxyquinazoline (0.8 g, 3.6 mmol), chloroform (6 ml), and tetrabutylammonium bromide (0.58 g, 1.8 mmol) were added to the solution, and the mixture was refluxed for 2 hr. The reaction solution was cooled. Chloroform (10 ml) and water (10 ml) were then added to the cooled reaction solution, and the mixture was stirred for 10 min, followed by the separation of the organic layer from the aqueous layer. Chloroform (10 ml) was added to the separated aqueous layer, and the mixture was - stirred for 10 min, followed by layer separation. The organic layer was concentrated under the reduced pressure. Methanol (2 ml) was added to the residue, and the mixture was stirred for 30 min. The reaction solution was then filtered and was dried to give 1.0 g (yield 83%) of the target product.

Example V; N- ( 2.4-Di orobenzyl ^ -N ' -{4- [ ( 6.7-dimethoxy- 4-quinolyl)o y]-2-fluorophenyl}urea 4-[ ( 6 , 7-Dimethoxy-4-quinolyl)oxy]-2-fluoroaniline (100 mg) was dissolved in toluene (5.0 ml) and triethylamine (1.0 ml) with heating. A solution of triphosgene (103 mg) in dichloromethane (1.0 ml) was then added to the solution, and the mixture was heated under reflux for 3 min. Next, 2 , 4-difluorobenzylamine (54 mg) was added thereto, and the mixture was heated under reflux for additional 5 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was dried over anhydrous sodiuni sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 123 mg (yield 80%) of the title compound. 1H-NMR (CDCljV- 4Ό0 MHz): δ 4.02 (s, 3H), 4.03 (s, 3H), 4.47 (d, J .'=' 5.9 Hz, 2H), 5.78 - 5.90 (m, 1H), 6.46 (d, J - 5.4 Hz, 1H), 6.74 - 6.99 (m, 4H), 7.03 - 7.14 (m, 1H), 7.35 -7.44. (m, 2H , 7.50 (s, 1H), 8.16 (t, J = 9.0 Hz, 1H),. 8.47 (d, J = 5.1 Hz, 1H) Mass analysis, found (FD-MS, m/z): 483 (M+) Example 2 ; N-{4-[ ( 6.7-Dimethoxy-4-quinolyl)oxyj-2- fluorophenyl}-N'-(2-fluoroethyl ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy ] -2-fluoroaniline (100 mg) was . dissolved in toluene (10 ml) and triethylamine (0.5 ml) with heating. A solution of triphosgene (47 mg) in dichloromethane (1.0 ml) was then added to the solution, and the mixture was heated under reflux for 5 min. Next, 2-fluoroethylamine hydrochloride (42 mg) was added thereto, and the mixture was heated under reflux for additional 8 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, followed by extraction with ethyl acetate.! The ethyl acetate layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 93 mg (yield 72%) of the title compound. 1H-NMR (DMS0-d6, 400 MHz): δ 3.40 (m, 1H), 3.47 (m, 1H), 3.93 (s, 3H), 3.95 (s, 3H), 4.42 (t, J = 4.9 Hz, 1H), 4.54 (t, J = 4.9 Hz, 1H), 6.51 (d, J = 5.4 Hz, 1H), 6.88 (m, 1H), 7.05 (m, 1H), 7.28 (dd, J = 2.7 Hz, J = 11.7 Hz, 1H), 7.40 (s, 1H), 7.49 (s, 1H), 8.21 (m, 1H), 8.47 (br, 1H), 8.48 (d, J = 5.4 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 404 (M++l) Example 3_j : N--f 4-r r6,7-Dimethoxy-4-guinolyl)oxy]-2- fluorophenyl}-N'-( 2-pyridylmethyl )urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl)oxy ]-2-fluoroaniline (100 mg) was! dissolved in toluene (5 ml) and triethylaraine (1 ml). A solution of triphosgene (104 mg) in dichloromethan.e:' was then added to the solution, and the mixture was refluxed for 5 min. Next, 2- ( aminomethyl ) pyridine (40 μ1·) was added thereto, and the mixture was heated under reflux for 2 hr. A saturated aqueous sodium hydrogencarbonate solution (1 ml) and chloroform (2 ml) were added to the reaction solution. The mixture was . supported on diatomaceous earth, followed by extraction with chloroform. The solvent was removed by distillation ^under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (8/1) to give 126 mg (yield 88%) of the title compound.

'H-NMR (CDCI3, - 400 MHz) : δ 4.07 (s, 3H), 4.09 (s, 3H), 4.61 (d, J = 5.4 Hz, 2H), 6.40 - 6.50 (br, 1H), 6.61 (d, J = 5.9 Hz, 1H), 6.92 - 7.01 (m, 2H), 7.21 -7.25 (m, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.56 (s, 1H), 7.68 - 7.78 (m, 2H), 7.75 (s, 1H), 8.27 - 8.34 (m, 1H), 8.49 (d, J = 6.1 Hz, 1H), 8.55 (d, J = 4.1 Hz, 1H) Mass analysis, found (FD-MS, m/z): 448 (M+) Example £j N-Allyl-N'-{4-[ (6.7-dimethoxy-4-quinoly1 )-oxy]-2-fluorophenyl}urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl )oxy ] -2-fluoroaniline (100 mg) was, dissolved in toluene (5 ml) and triethylamine (1 ml), and a solution of triphosgene (104 mg) in dichloromethane was then added to the solution. The mixture was heated under reflux for 5 min. Next, allylamine (22 mg) was added to the reaction solution, and the mixture was heated under reflux for additional 4 hr. A saturated aqueous sodium hydrogencarbonate solution (1 ml) and chloroform (2 ml) were added to the reaction solution, and the mixture was supported on diatomaceous earth, followed by extraction with chloroform. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone ,(2/1) to give 125 mg (yield 98%) of the title compound.

JH-NMR (CDC13, 400 MHz): δ 3.91 - 3.96 (m, 2H), 4.06 (s, 3H), 4.09 (s, 3H), 5.14 - 5.20 (m, 1H), 5.26 - 5.33 (m, 1H), 5.58 - 5.66 (br, 1H), 5.86 - 5.98 (m, 1H), 6.56 (d, J = 5.9 Hz, 1H), 6.88 - 7.01 (m, 2H), 7.23 (s, 1H), 7.55 (s, 1H), 7.66 (s, 1H), 8.26 - 8.33 (m, 1H), 8.47 (d, J = 5.9 Hz, 1H) Mass analysis, found (FD-MS, m/z): 397 (M+) Example 5 ; : N-{4- [ ( 6 , 7-Dime oxy- - uinoly1 )Q y3-2- fluorophenyl} -N' -propylurea 4-t ( 6 , 7-Dimethoxy-4-quinolyl)oxy]-2-fluoroaniline (100 mg) was dissolved in toluene (10 ml) and triethylamine (2 ml), and a solution of triphosgene (104 mg) in dichloromethane was then added to the solution. The mixture was heated '.under reflux for 5 min. Next, propylamine (29 mg) was added, and the mixture was heated under reflux for 40 min. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was then dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by thin-layer chromatography on silica gel by development with chloroform/methanol (10/1) to give 89 mg (yield 71%) of the title compound.

^-NMR (CDCI3, 400 MHz): δ 0.97 (t, J = 7.6 Hz, 3H), 1.55 - 1.64 (m, 2H) , 3.24 - 3.29 (m, 2H), 4.05 (s, 3H), 4.06 (s, 3H), 5.11 (t, J = 5.4 Hz, 1H), 6.51 (d, J = 5.4 Hz, 1H), 6.74 - 6.76 (m, 1H), 6.91 - 6.99 (m, 2H), 7.48 (s, 1H), 7.52 (s, 'lH), 8.18 - 8.23 (m, 1H), 8.49 (d, J = 5.6 Hz, 1H) Mass analysis, found (FD-MS, m/z): 399 (M+) Example 6: N-{4-[ ( 6.7- imethoxy-4-quinolyl )oxy ] -2-fluorophenyl}-N,-(4-fluorobutyl)urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy] -2-fluoroanxline (100 mg) was dissolved in toluene (6 ml) and triethylamine (1.0 ml) with heating, and a solution of triphosgene (104 mg) in dichloromethane (1.0 ml) was then added to the solution. The mixture was heated under reflux for 5 min. Next, 4-fluorobutylamine hydrochloride (55 mg) was added to the reaction solution, and the mixture was. heated under reflux for additional 2 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 80 mg (yield 55%) of the title compound. 1H-NMR (CDC13, 400 MHz): δ 1.66 - 1.87 (m, 4H), 3.33 - 3.40 (m, 2H), 4.04 (s, 3H), 4.05 (s, 3H), 4.44 (t, J = 5.6 Hz, 1H), 4.56 (t, J = 5.7 Hz, 1H), 4.90 (t, J = 5.7 Hz, 1H), 6.48 - 6.52 (m, 2H), 6.93 - 7.02 (m, 2H), 7.42 (s, 1H), 7.51 (s, 1H), 8.15 (t, J = 8.9 Hz, 1H), 8.50 (d, J = 5.1 Hz, 1H) ! Mass analysis, found (FD-MS, m/z): 431 (M+) Example ll N-{4-[ ( 6 , 7-Dimethoxy-4-quinolyl)oxy]-2-fΊ uorophenyl}-N ' - ( 2-propyny1 )urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy] -2-fluoroanxline (150 mg) was dissolved in chloroform (10 ml) and triethylamine (2 ml), and a solution of triphosgene (156 mg) in dichloromethane was added to the solution. The mixture was heated under reflux for 10 min. Next, propargylamine (53 mg) was added, and the mixture was heated under reflux for additional 30 min. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate.. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development yith chloroform/acetone (2/1) to give 164 mg (yield 87%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 2.49 - 2.51 (m, 1H), 3.90 - 3.95 (m, 8H),: 6.52 (d, J = 5.1 Hz, 1H), 6.89 -6.92 (m, 1H), 7.04 - 7.06 (m, 1H) 7.26 - 7.29 (m, 1H), 7.39 (s, 1H), 7.49. (s, 1H), 8.16 - 8.20 (m, 1H), 8.46 -8.49 (m, 2H) Example 8: N-{4- [ ( 6 , 7-Dimethoxy-4-quinolyl )oxy ] -2-f uorophenyl }-N'-ethylurea 4-[ ( 6 , 7-Dimethoxy-4-quinolyl)oxy] -2-fluoroaniline (100 mg) was dissolved in toluene (8 ml) and triethylamine (1.0 ml) with heating, and a solution of triphosgene (47 mg) in toluene (1.0 ml) was then added to the solution. The mixture was heated under reflux for 5 min. Next, ethylamine hydrochloride (60 mg) was added to the reaction solution, and the mixture was heated under reflux for additional 5 hr. A saturated aqueous sodium hydrogencarbonate solution was added to , the reaction solution, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 70 mg (yield 53%) of the title compound. / ^-NMR (CDCljV 400 MHz): δ 1.21 (t, J = 7.3 Hz, 3H), 3.34 (m, 2H), 4.06 (s, 3H), 4.08 (s, 3H), 5.64 (br, 1H), 6.55 (d, J = 5.6 Hz, 1H), 6.89 (dd, J = 2.7 Hz, J = 11.2 Hz, 1H), 6.97 (m, 1H), 7.26 (br, 1H), 7.54 (s, 1H), 7.62 (s, 1H), 8.28 (t, J = 9.0 Hz, 1H), 8.47 (d, J = 5.6 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 386 (M++l) Example : 2J ; : N-Butyl-N' -{4- [ ( 6.7-dimethoxy-4-quinolyl)oxy ]-2-fluorophenyl}urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy] -2-fluoroaniline (100 mg) was dissolved in toluene (8 ml) and triethylamine (1.0 ml) with . heating, and a solution of triphosgene (47 mg): in, toluene (1.0 ml) was then added to the solution. The mixture was heated under reflux for 5 min. Next, butylamine (80 mg) was added to the reaction solution, and the mixture was heated under reflux for additional 5 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 117 mg (yield 81%) of the title compound, ^H-NMR (CDC13, 400 MHz): δ 0.94 (t, J = 7.3 Hz, 3H), 1.40 (m, 2H)^ 1.55 ; (m, .2H), 3.29 (dd, J = 7.1 Hz, J = 12.9 Hz, 2H), 4.06 (s, 3H), 4.09 (s, 3H), 5.72 (br, 1H), 6.56 (d, J = 5.9 Hz, 1H), 6.88 (dd, J = 2.7 Hz, J = 11.2 Hz, 1H), 6.97 (d, J = 9.0 Hz, 1H), 7.33 (s, 1H), 7.55 (s, 1H), 7.65 (s, lH),.-8.*30 (t, J = 9.0 Hz, 1H), 8.46 (d, J = 5.9 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 414 (M++l) Example iO: Ν-ί sec-Butyl )-N'-{4- [ ( 6 r 7-dimethoxy-4-quinolyl ) oxy] -2-fluorophenyl}urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy] -2~fluoroaniline (100 mg) was dissolved in chloroform (5 ml) and triethylamine (1, ml),, and a solution of triphosgene (104 mg) in dichloromethane was then added to the solution. The mixture was heated under reflux for 5 min. Next, sec-butylamine (48 μΐ) was added to the reaction solution. The mixture was heated under reflux for 10 min. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (8/2) to give 117 mg (yield 89%) of the title compound. 1H-NMR (C Clj, 400 MHz): δ 0.95 (t, J = 7.6 Hz, 3H), 1.18 (d, J = 6.6 Hz, 3H), 1.47 - 1.55 (m, 2H), 3.79 - 3.89 (m, 1H), 4.04 (s, 6H), 5.28 (d, J = 8.1 Hz, 1H), 6.48 (d, J = 5.4 Hz,. 1H), 6.89 - 6.98 (m, 2H), 7.08 (d, J = 2.7 Hz, 1H), 7.42 (s, 1H), 7.51 (s, 1H), 8.20 - 8.24 (m, J = 9.0 Hz, 1H), 8.48 (d, J = 5.4 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 414 (M++l) Example LL N-{4-[ ( 6.7-Dimethoxy-4-quinolyl )oxy]-2- fluorophenyl}-N'-isobutylurea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl )oxy] -2-fluoroaniline (100 mg) was dissolved in chloroform (5 ml) and triethylamine (1 ml), and a solution of triphosgene (104 mg) in dichloromethane was then added to the solution. The mixture was heated under reflux for 5 min. Next, isobutylamine (50 μΐ) was added to the reaction solution, and the mixture was heated under reflux for 10 min. The reaction solution was purified by chromatography on silica gel by development with chloroform/acetone (4/1). Thus, the title compound was quantitatively obtained.

'H-NMR (CDCI3, 400 MHz): δ 0.94 (d, J = 6.6 Hz, 6H), 1.77 - 1.84 (m, 1H), 3.10 - 3.13 (m, 2H), 4.03 (s, 3H), 4.03 (s, 3H), 5.58 (t, J = 5.4 Hz, 1H), 6.47 (d, J = 5.4 Hz, H), 6.88 - 6.97 (m, 2H), 7.18 (s, 1H), 7.41 (s, 1H), 7.50 (s, 1H), 8.18 - 8.23 (m, 1H), 8.48 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 414 (M++l) Example 12l N-{4-[ I 6.7-Dimethoxy-4-quinolyl)oxy3-2- luorophenyl}- ' - ( 1.2-dimethylpropy1 ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy] -2-fluoroaniline (100 mg) was dissolved in chloroform (5 ml) and triethylamine (1 ml), and a solution of triphosgene (47 mg) in dichloromethane was then added to the solution.

The mixture was stirred at room temperature for 30 min.

Next, 1 , 2-dimethylpropylamine (55 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature for 10 min:. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 89 mg (yield 65%) of the title, compound. 1H-NMR (CDC13, 400 MHz): δ 0.93 (d, J = 2.2 Hz, 3H), 0.95 (d, J = 2.4 Hz, 3H), 1.14 (d, J = 6.8 Hz, 3H), 1.72 - 1.80 (m, 1H), 3.76 - 3.84 (m, 1H), 4.04 (s, 3H), 4.05 (s, 3H), 4.91 (d, J = 8.5 Hz, 1H), 6.48 (d, J = 5.4 Hz, 1H), 6.74 (d, J = 2.9 Hz, 1H), 6.91 - 6.98 (m, 2H), 7.42 (s, lH), 7.51 (s, 1H), 8.18 - 8.23 (m, 1H), 8.49 (d, J = 5.4 Hz, 1H) Mass analysis, foufid (ESI-MS, m/z): 428 (M++l) Example 13_i N-{2-Chloro-4- [ ( 6 , 7-dimet oxy-4- n i no! yΊ ) oxy ] phenyl }-N' -propylurea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl )oxy ] aniline (100 mg) was dissolved in chloroform (7.5 ml) and triethylamine (1 ml), and a solution of triphosgene (99 mg) in chloroform was then added to the solution. The mixture was heated under reflux for 5 min. Next, n-propylamine (21 mg) was added to the reaction solution, and the mixture was heated under reflux for additional 2 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was supported on diatomaceous earth, followed by extraction with chloroform. The solvent was removed by distillation under the reduced pressure. The residue was purified by Chromatography on silica gel by development with chloroform/methanol (8/1). Thus, the title compound was quantitatively obtained.

^- MR (CDC13, 400 MHz): δ 0.99 (t, J = 7.3 Hz, 3H), 1.58 - 1.65 (m, 2H), 3.24 - 3.31 (m, 2H), 4.04 (s, 3H), 4.05 (s, 3H), 4.94 (t, J = 5.9 Hz, 1H), 6.48 (d, J = 5.1 Hz, 1H), 6.77 (s, 1H), 7.11 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.21 (d, J = 2.7 Hz, lH), 7.43 (s, 1H), 7.52 (s, 1H), 8.27 (d, J = 9.0 Hz, 1H), 8.50 (d, J = 5.1 Hz, 1H) Mass analysis, found (FD-MS, m/z): 415, 417 (M+) Example - 14;, , N-{2-Chloro-4- [ 16 r 7-dimethoxy-4-quinolyl )oxy ] phenyl}-N'- ( 4-fluoro-2-methylphenyl ) urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl ) oxy] aniline ,· . ', ; (122 mg) was dissolved, in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 4-fluoro-2-methylaniline (126 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature for 2 hr. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 142 mg (yield 79%) of the title compound. 1H-NMR (CDC13, 400 MHz): δ 2.37 (s, 3H), 4.04 (s, 3H), 4.04 (s 3H-), 6.31-1 (s, 1H), 6.47 (d, J = 5.1 Hz, 1H), 6.97 - 7.06 (m, 3H), 7.11 - 7.14 (m, 1H), 7.19 (d, J = 2.7 Hz, lH), 7.41 - 7.44 (m, 2H), 7.50 (s, 1H), 8.35 (d, J = 9.0 Hz, 1H), 8.50 (d, J = 5.4 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 482, 484 (M++l) Example 15; N-( 5-Bromo-6-methyl-2-pyridyl )-N,-{2-chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl)oxy]phenyl}urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl )oxy]aniline (122 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 6-amino-3-bromo-2-methylpyridine (208 mg) was added to the reaction solution, and the mixture was stirred at room' temperature for 2 hr. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 155 mg (yield 77%) of the title compound. rH-NMR ( CDCI3 , 400 MHz); δ 2.69 (s, 3H), 4.06 (s, 6H), 6.53 (d, J = 5.4 Hz, 1H), 6.56 (d, J = 8.5 Hz, 1H), 7.14 - 7.17 (m, 1H), 7.30 (d, J = 2.7 Hz, 1H), 7.44 (s, 1H), 7.53 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.93 (s, 1H), 8.49 (d, J = 9.0 Hz, 1H), 8.52 (d, J = 5.4 Hz, 1H), 11.92 (s, 1H) Mass analysis, found (ESI—MS, m/z): 543, 545, 547 (M++l ) ' !'. . ■ y , [ Example 16: Nr-{2-Chloro-4-[ ( 6 r 7-dimethoxy-4- quinolyl ) oxy ]phenyl.}-N '-( 5-chloro-2-pyridyl ) urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl ) oxy ] aniline (122 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at rooiti temperature for 30 min. Next, 2-amino-5-chloropyridine (143 mg) was added to the reaction solution, "■' and the mixture was stirred at room temperature for 2 hr. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acet ne (2/1)·" to give 148 mg (yield 82%) of the title compound.

^- MR (CDClj, 400 MHz): δ 4.06 (s, 3H), 4.06 (s, 3H), 6.53 (d, J = 5.1 Hz, 1H), 6.95 (d, J = 8.8 Hz, 1H), 7.14 - 7.17 (m, lH), 7.31 (d, J = 2.7 Hz, 1H), 7.44 (s, 1H), 7.53 (s, lH), 7.64 - 7.67 (m, 1H), 8.28 (d, J = 2.7 Hz, 1H), 8.50 - 8.53 (m, 2H), 8.92 (s, 1H), 12.11 (brs, 1H) Mass analysis, found (ESI-MS, m/z): 485, 487, 489 (M++l) Example III N- 5-Bromo-2-pyridyl ) -N' -{2-chloro-4- [ ( 6 r 7-d imethoxy-4-quinolyl ) oxy ]phenyl >urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl ) oxy ] aniline (122 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichiorpmethane was then added to the solution. The mixture was stirred ;at room temperature for 30 min. Next, 2-amino-5-bromopyridine (192 mg) was added to the reaction solution, and the mixture was stirred at room temperature for 2 hr. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone · (.2/1 ) to give 108 mg (yield 55%) of the title compound.

XH-NMR (CDC13, 400 MHz): δ 4.06 (s, 3H), 4.06 (s, 3H), 6.53 (d, J = 5.1 Hz, 1H), 6.80 (d, J = 8.8 Hz, 1H), 7.14 - 7.18 (m, 1H), 7.30 (d, J = 2.7 Hz, 1H), 7.45 (s, 1H), 7.53 (s 1H)., .7.77· - 7.80 (m, 1H), 8.15 (s, 1H), 8.39 (d, J = 2.4 Hz, 1Η)·, 8.50 (d, J = 9.0 Hz, 1H), 8.52 (d, J = 5.4 Hz, 1Ή), 12.09 (brs, 1H) Mass analysis, found (ESI-MS, m/z): 529, 531, 533 (M++l) Example L8j_ N-< 2-Chloro-4- [ ( 6.7-dimethoxy-4-quinolyl )oxy ] phenyl }-N' - ( 2-methoxyphenyl ) urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl )oxy ] aniline (100 mg) was dissolved in chloroform( 10 ml), and 2-methoxyphenyl isocyanate (54 mg) was added to the solution. The mixture was stirred at 60°C overnight. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (6/4) to give 111 mg (yield 77%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 3.85 (s, 3H), 4.04 (S, 3H), 4.05 (s, 3H), 6.50 (d, J = 5.1 Hz, lH), 6.89 - 6.93 (m, 1H), 6.98 - 7.03 (m, 1H), 7.05 - 7.10 (m, 1H), 7.14 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.23 (d, J = 2.7 Hz, 1H), 7.35 (s, 1H), 7.36 (s, 1H), 7.44 (s, 1H), 7.52 (s, 1H), 8.05 - 8.07 (m, 1H), 8.34 (d, J = 9.0 Hz, 1H), 8.52 (d, J = 5.4 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 480, 482 (M++l) Example I i . N--f 2-Chloro-4-[ ( 6.7-dimethoxy-4-quinoly1 ) oxy ] henyl }~N ' - 12-methylpheny1 ) urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl ) oxy ] aniline (122 mg) was dissolved in chloroform (10 ml), and o-toluyl isocyanate (59 mg); was- added to the solution. The mixture was stirred at room temperature overnight. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of chloroform, and a large amount of ether was added to the solution to precipitate a crystal. The crystal was collected by filtration to give 59 mg (yield 34%) of the title compound. 1H-NMR (CDClj, 400 MHz): δ 2.38 (s, 3H) , 4.04 (s, 3H), 4.05 (s, 3H), 6.22 (s, 1H), 6.47 (d, J = 5.1 Hz, 1H), 7.01 (s, 1H), 7.11 - 7.14 (m, 1H), 7.18 (d, J = 2.7 Hz, 1H), 7.25 - 7.35 (m, 3H), 7.42 (s, 1H), 7.46 (d, J = 6.8 Hz, lH),. 7.50 (s, 1H) , 8.37 (d, J = 8.8 Hz, 1H), 8.50 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 464, 466 (M++l) Example 20; ' N-{2-Chloro-4-[ I 6 , 7-dimethoxy-4-quinolyl ) oxy ] phenyl}- ' - ( 5-methyl-2-pyridyl ) urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl ) oxy] aniline (122 mg) was dissolved in chloroform (10 ml) and triethylamine ( 1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 2-amino-5-picoline (120 mg) was added to the reaction solution, and the mixture was' stirred at room temperature for 2 hr. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 119 mg (yield 69%) of the title compound. 1H-NMR ( CDClj , 400 MHz): δ 2.31 (s, 3H), 4.06 (s, 6H), 6.53 (d, J = 5.4 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 7.13 - 7.16 (m, lH), 7.29 (d, J = 2.7 Hz, 1H), 7.43 (s, 1H), 7.49 - 7.52 (m, 1H), 7.54 (s, HI), 8.00 (s, 1H), 8.14 (s, 1H), 8.52 (d, J = 5.1 Hz, 1H), 8.55 (d, J = 9.0 Hz, 1H), 12.57 (brs, 1H) Mass analysis, found (ESI-MS, m/z): 465, 467 (M++l) Example _ 21A , N-{2-Chloro-4-[ ( 6 , 7-dimethpxy-4-quinolyl ) o yIptienyl'}- * -;( 6-methy1-2-pyridyl ) urea 2-?Chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl )oxy ]aniline (122 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 6-amino-2-picoline (120 mg) was added to the reaction solution, and the mixture was stirred at room temperature for 2 :hr. Methanol was added to the reaction solution, and the: solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 73 mg (yield 42%) of the title compound.

^H-NMR. (CPC13, 400. MHz): δ 2.57 (s, 3H), 4.06 (s, 6H), 6.54 (d, J; =e 5.4 Hz', 1H), 6.66 (d, J = 8.1 Hz, 1H), 6.83 (d, J = 7.6 Hz, 1H), 7.15 - 7.18 (m, 1H), 7.30 (d, J = 2.7 Hz, 1H), 7.44 (s, 1H), 7.54 - 7.59 (m, 2H), 8.36 (s, 1H), 8.52 (d, J = 5.1 Hz, 1H), 8.57 (d, J = 9.0 Hz, 1H), 12.45 (s, 1H) Mass analysis, found (ESI-MS, m/z): 465, 467 (M++l) Example 22; N-{2-Ch1 oro-4- [ ( 6.7-dimethoxy-4- uinolyl ) oxy ]phenyl>- ' - ( 4-methoxypheny1 lurea hydro-chloride 2-Chloro-4-[ ( 6 , 7-dimethoxy-4-quinolyl )oxy] aniline (100 mg) was dissolved in chloroform (4 ml), and 4-methoxyphenyl isocyanate (60 μΐ) was then added to the solution. A reaction was then allowed to proceed at room temperature overnight. The solvent was removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of chloroform, and a large amount of ether was added thereto. The resultant precipitate was collected by suction filtration to give 90 mg (yield 67%) of N-2-chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl )oxy ]pheny1- ' - ( 4-methoxy-phenyl )urea . This product was suspended in 4 ml of methanol, and a hydrochloric acid-methanol solution was added to the suspension. The. mixture was stirred at room temperature for 4 hr, and. the solvent was then removed by distillation to. give the title compound.

^-NMR (DMSO-d6, 400 MHz): δ 3.73 (s, 3H), 4.03 (s, 3H), 4.05 (s, 3H ) , .6 i 9.0 ( d , J = 9.3 Hz, 2H), 6.97 (d, J = 6.6 Hz, 1Ή) 7.37 r- 1.41 (m, 3H), 7.62 (s, 1H), 7.67 (d, J = 2.7 Hz, IE), 8.39 (d, j = 9.0 Hz, 1H), 8.49 (s, lH), 8.82 (d, J = 6.6 Hz, 1H), 9.49 (s, 1H) Example 23: . N-{2-Chloro-4- [ ( 6.7-dimethoxy-4- uinoly1 ) oxy] henyl■}- ' - ( 1-naphthyl )urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl ) oxy ] aniline (122 mg) was dissolved in chloroform (10 ml), and 1- naphthyl isocyanate ( 75 mg) was added to the solution. The mixture was stirred at room temperature overnight. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of chloroform, and a large amount of ether was added to the solution to precipitate a crystal. The crystal was collected by, filtration, to give 105 mg (yield 57%) of the title compound. ' 'H-NMR (CDCI3, 400 MHz): δ 4.03 (s, 3H), 4.04 (S, 3H), 6.44 (d, J = 5.4 Hz, 1H), 6.72 (s, 1H), 7.10 - 7.13 (m, 3H), 7.41 (s, 1H), 7.48 (s, 1H), 7.55 - 7.69 (m, 4H), 7.88 - 7.96 (m, 2H), 8.15 (d, J = 7.6 Hz, 1H), 8.38 -8.40 (m, 1H), 8.48 (d,' J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 500, 502 (M++l) Example 2JL.L N-(2.4-Difluorophenyll-N'-{4-[ (6.Ί-dimethoxy-4-quinolyl \ oxy ] -2.3-dimethy phenyl }urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy ] -2 , 3-dimethyl-aniline (710 mg) was dissolved in chloroform (7 ml), and 2 , 4-difluorophenyl isocyanate (310 μΐ) was then added to the solution. The mixture was heated under reflux for one hr, and a large amount of ether was added to the reaction solution; ! The resultant precipitate was collected by suction filtration to give 735 mg (yield 70%) of the title compound.

'H-NMR (CDC13, 400 MHz): δ 2.14 (s, 3H), 2.27 (s, 3H), 4.04 (s, 3H.) , 4.06 (s, 3H), 6.27 (d, J = 5.4 Hz, 1H), 6.78 - 6.89 (m, 2H), 6.95 (s, 1H), 7.03 (d, J = 8.5 Hz, 1H), 7.10 (s, 1H), 7.40 - 7.45 (m, 2H), 7.61 (s, 1H), 8.03 - 8.12 (m, 1H), 8.46 (d, J = 5.4 Hz, 1H) Mass analysis, found (FAB-MS, m/z): 480 (M++l) Example 25: N-{4- [ / 6 f 7-Dimethoxy-4-qu nolyl ^ oxyj -2.3-dimethylphenyl}-N' - ( 4-fluoro-2-methylphenyl urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy] -2 , 3-dimethyl-aniline (120lmg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 4-fluoro-2-methylaniline (126 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature for 2 hr. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (91/9) to give 160 mg (yield 91%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 2.12 (S, 3H), 2.22 (s, 3H), 2.25 (s, 3H), 4.05 (s, 3H), 4.06 (s, 3H), 6.24 (d, J = 5.1 Hz, 1H), 6.33 (s,, lH), 6.42 (s, 1H), 6.94 - 7.03 (m, 3H), 7.43 (s, lH), 7!i46 - 7.55 (m, 2H), 7.60 (s, 1H), 8.43 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 476 (M++l) Example 26j N-{4-[ ( 6.7-Dimethoxy-4-guinoly1 )oxy]-2f 3-dimethylphenyl>-N;-(3-fluoro-2-methoxyphenyl)urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl )oxy] -2 , 3-dimethylaniline (120 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 3-fluoro-o-anisidine (132 μΐ) was added to the reaction solution, and the mixture was stirred at .roomi temperature for 2 nr. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (91/9) to give 23 mg (yield 13%) of the title compound. 1H-NMR (CpClj, 400 MHz): δ 2.15 (s, 3H), 2.32 (s, 3H), 3.84 (d, J - 1.7 Hz, 3Ή):, 4.05 (s, 3H), 4.08 (s, 3H), 6.28 (d, J = 5.4 Hz, 1H), 6.72 - 6.77 (m, 1H), 6.96 - 7.09 (m, 3H), 7.43 (d, J = 8.5 Hz, 1H), 7.46 (s, 1H), 7.60 (s, 1H), 7.62 (s, 1H), 8.02 - 8.05 (m, 1H), 8.46 (d, J = 5.4 Hz, 1H) .. ; Mass analysis, found (ESI-MS, m/z): 492 (M++l) examp e 27: N— ( 5-Bromo-6-methy1- -pyridyl)-N'-{4-[(6f7-dimethoxy-4-quinolyl)oxy -2 , 3-dimethylphenyl}urea 4- [ ( 6 , 7-Dimethoxy~4-quinolyl ) oxy] -2 , 3-dimethyl-aniline (120 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 6-amino-3-bromo-2-methylpyridine (208 mg) was added to the reaction solution, · and the mixture was stirred at room temperature for 2 hr. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (91/9) to give 103 mg (yield 52%) of the title compound.

^-NMR (CDC13, 400. MHz): δ 2.16 (s, 3H), 2.42 (s, 3H), 2.65 (s,' 3H) , 4.06 f,(s, 3H),. 4.08 (s, 3H), 6.32 (d, J = 5.1 Hz, 1H), 6.64 (d, J = 8.8 Hz, 1H), 7.04 (d, J = 8.8 Hz, 1H), 7.44 (s, 1H), 7.64 (s, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 8.29 (s, 1H), 8.45 (d, J = 5.4 Hz, 1H), 11.30 (brs, lH) Mass analysis, found (ESI-MS, m/z): 537, 539 (M++l) Example 28; N-(5-Chloro-2-pyridyl -N'-{4-[ (6 r7-dimethoxy-4-quinbly1 )oxy] -2 , 3-dimethylpheny1>urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy] -2 , 3-dimethyl- aniline (3.00 g) was dissolved in chloroform (150 ml) and triethylamine (6. ml), and a solution of triphosgene (2.74 g) in dichloromethane was then added to the solution. The :mixture , - s stirred at room temperature for 30 min. Next, 2-amino-5-chloropyridine (2.38 g) was added to the reaction solution, and the mixture was then stirred at room temperature for additional 2 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure, and the residue was purified by chromatography on silica gel by development with chloroform/methanol (20/1) to give 3.4 g (yield 77%) of the title compound. 1H-NMR ( C Clj, 400 MHz): δ 2.16 (s, 3H), 2.38 (s, 3H), 4.06 (s, 3H), 4,;08 (s, 3H), 6.31 (d, J = 5.4 Hz, 1H), 6.89 (d, J .= 8.8 Hz;, 1H), 7.04 (d, J = 8.8 Hz, 1H), 7.44 (s, 1H), 7.62 - 7.68 (m, 2H), 7.90 (d, J = 8.8 Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H), 8.45 (d, J = 5.4 Hz, 1H), 8.50 (s, lH), 11.23 (brs, 1H) Mass analysis,, found (ESI-MS, m/z): 479, 481 (M++l) Example 29: N- ( 5-Bromo-2-pyridyl )-N'-{4-[ ( 6.7-dimethoxy-4-quinolyl ;ioxy]-2.3-dimethylphenyl}urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl )oxy ] -2 , 3-dimethyl-aniline (120 mg)'was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 2-amino-5-bromopyridine (192 mg) was added to the reaction solution, and the mixture was stirred at room temperature for .2 nr. Methanol was added to the reaction solution, and' the1 solvent was remqyed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (91/9). The solvent was removed by distillation,·.·.. aheL a crystal was precipitated from a minor amount of methanol and a large amount of ether. The crystal was collected by filtration to give 80 mg (yield 41%) of the; title compound. 1H-NMR (CDCI3, .400 MHz) : δ 2.16 ( s , 3H), 2.38 (s, 3H), 4.06 (s, 3H), 4.08 (s, 3H), 6.31 (d, J = 5.1 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 7.03 (d, J = 8.8 Hz, 1H) , 7.45 (S, 1H), 7.64 (s, 1H), 7.75 - 7.77 (m, 1H), 7.89 (d, J = 8.8 Hz, 1H), 8.31 (d, . J = 2.4 Hz, 1H), 8.45 (d, J = 5.4 Hz, IH), 8.8Ϊ: (s, 1H)., 11.17 (brs, 1H) Mass analysis, found (ESI-MS, m/z): 523, 525 (M++l) Example 30: N-{4-[ ( 6 f 7-Dimethoxy-4-quinolyl )oxy]-2 f 3-dimethylphenyiy-N'-^-methoxyphenyi^urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl )oxy] -2 , 3-dimethyl-aniline (120 mg.) was dissolved in chloroform (10 ml), and 2-methoxyphenyi isocyanate (60 μΐ) was added to the solution. The mixture was stirred at room temperature overnight. Methanol was, added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of chloroform, and a large amount of ether was added thereto to precipitate a crystal which was then collected by filtration, to give 131 mg (yield 75%) of the title compound. ! ^ 1H-NMR (CDCI3, 400 MHz): δ 2.16 (s, 3H), 2.32 (s, 3H), 3.81 (s, 3H), 4.06 (s, 3H), 4.08 (s, 3H), 6.25 (s, 1H), 6.26 (d, J = 5.4 Hz, 1H), 6.85 - 6.87 (m, 1H), 6.97 - 7.07 (m, 4H), 7.41 (d, J = 8.5 Hz, 1H), 7.44 (s, 1H), 7.62 (s, 1H), 8.15 - 8.17 (m, 1H), 8.45 (d, J = 5.4 Hz, 1H) Mass analysis; found (ESI-MS, m/z): 474 (M++l) Exam le 31 : W-{4-[ (6,7-Dimethoxy-4-quinoly ^oxy]-2f 3-dimethylphenyl}-N' - ( 2-methylpheny1 ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy] -2 , 3-dimethyl-aniline (120 mg) was dissolved in chloroform (10 ml), and o-toluyl isocyanate (55 μΐ) was added to the solution. The mixture was stirred at room temperature overnight. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of chloroform, and a large amount of ether was added to the solution to precipitate a crystal which was then collected by filtration to give 130 mg (yield 70%) of the title compound.

'H-NMR ( CDClj, 400 MHz): δ 2.12 (s, 3H), 2.22 (s, 3H), 2.26 (s, .3H), 4.05 (s, 3H), 4.07 (s, 3H), 6.23 -6.28 (m, 3H), 7.02 (d, J = 8.5 Hz, 1H), 7.14 - 7.17 (m, 1H), 7.24 - 7.29 (m, 2H), 7.43 (s, 1H), 7.49 (d, J = 8.5 Hz, 1H), 7.60 (s, 1H), 7.63 (d, J = 7.3 Hz, lH), 8.43 (d, J = 5.4 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 458 (M++l) Example 3_2J N— ( 4-Chl oro—2-methylphenyl ^ -N' -{4- [ ( 6 r 7-dimethoxy-4-quinolyl ) oxy ] -2 , 3-dimethylphenyl }urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy ] -2 , 3-dimethyl-aniline (120 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 4-chloro-2-methylaniline (130 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature for 2 hr. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (91/9) to give 136 mg (yield 75%) of the title compound.

^-NMR (CDC13, 400 MHz): δ 2.14 (s, 3H), 2.18 (s, 3H), 2.27 (s, 3H), 4.05 (s, 3H), 4.07 (s, 3H), 6.24 (d, J = 5.4 Hz, 1H), 6.33 (s, 1H), 6.40 (s, 1H), 7.03 (d, J = 8.5 Hz, 1H), 7.19 - 7.21 (m, 2H), 7.42 - 7.44 (m, 2H), 7.60 (3, 1H), 7.65 (d, J = 9.0 Hz, 1H), 8.44 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 492, 494 (M++l) Example 33j N-{4-[ I 6.7-Dimethoxy-4-quino1y1 ^oxy]-2r - dimethylpheny1}- - ( 2-pyridy1 ) urea 4-[ (6 , 7-Dimethoxy-4-quinolyl)oxy ]-2 , 3-dimethyl-aniline (120 ;mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred , at room temperature for 30 min. Next, 2-aminopyridine. (104 mg) was added to the reaction solution, and the mixture was heated under reflux overnight. Methanol' was added to the reaction solution, and the solvent was . removed by distillation under the reduced pressure. The residue was purified by chromatography ort , silica gel by development with chloroform/methanol (91/9) to give 72 mg (yield 44%) of the title compound.

'H-NMR (CDCI3, 4.00 MHz): δ 2.16 (s, 3H), 2.41 (S, 3H), 4.06 (s, 3H), 4.08 . (s, 3H), 6.32 (d, J = 5.4 Hz, 1H), 6.92 - 6.98 (m, 2H) , 7.04 (d, J = 8.8 Hz, 1H), 7.44 (s, lH), 7.65) (s , 1H) , 7.„67 - 7.69 (m, 1H), 7.97 (d, J = 8.8 Hz, 1H), 8.25 - 8.27 (m, 1H), 8.45 (d, J = 5.1 Hz, 1H), 8.72 (s, 1H), 11.77 (br, 1H) Mass analysis, found (ESI-MS, m/z): 445 (M++l) Example 3_4J N- 4-[ ( 6.7-Dimethoxy-4-qui nolyl \oxy] -2. -dimethylphenyl} -N ' - ( -methyl-2-pyridyl ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinoly1 )oxy ] -2 , 3-dimethyl-aniline (120 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 2-amino-5-picoline (120 mg) was added to the reaction solution, and the mixture was stirred at room temperature for 2 hr. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced · pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (91/9) to give 122 mg (yield 72%) of the title compound.

XH-NMR (CDCI3, 400 MHz): δ 2.15 (s, 3H), 2.28 (s, 3H), 2.39 (s, 3H), 4.04 (s, 3H), 4.07 (s, 3H), 6.32 (d, J = 5.4 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 7.43 (s, 1H), 7.45 - 7.48 (m, 1H), 7.64 (s, 1H), 7.99 (d, J = 8.8 Hz, 1H), 8.06 (d, J = 1.5 Hz, 1H), 8.44 (d, J = 5.4 Hz, 1H), 9.23 (s, 1H), 11.77 (br, 1H) Mass analysis, found (FD-MS, m/z): 458 (M+) Example 3_5_j N-{4- [ ( , 7-Dimet Qxy-4-quinolyl )oxy] -2 ,3-riimethylphenyl}-N'-(6-methyl-2-pyridyl^urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy ] -2 , 3-dimethyl-aniline (120 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (110 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 6-amino-2-picoline (120 mg) was added to the reaction solution, and the mixture was heated under reflux overnight. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by- development with chloroform/acetone (40/60) to give 64 mg (yield 38%) of the title compound. 1H-NMR (CDC13, 400 MHz): δ 2.16 (s, 3H), 2.44 (s, 3H), 2.54 (s, 3H), 4.06 (s, 3H), 4.08 (s, 3H), 6.32 (d, J = 5.4 Hz, 1H), 6.61 (d, J = 8.3 Hz, 1H), 6.82 (d, J = 7.6 Hz, 1H), 7.04 (d, J = 8.8 Hz, 1H), 7.44 (s, 1H), 7.53 - 7.57 (m, 1H), 7.65 (s, 1H), 7.79 (s, 1H), 7.99 (d, J = 8.8 Hz, 1H), 8.44 (d, J = 5.1 Hz, 1H), 11.76 (br, 1H) Mass analysis, found (FD-MS, m/z): 458 (M+) Example 36: N-{4- [ I 6.7-Dimethoxy-4-qninoly ) oxy ] -2.3-dimethylphenyl> -N ' - ( 4-met oxyphenyl )urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy ] -2 , 3-dimethyl-aniline (100 mg) was dissolved in chloroform (4 ml), and 4-methoxyphenyl isocyanate (60 μΐ) was then added to the solution. The mixture was allowed to react at room temperature overnight, and the solvent was removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of chloroform, and a large amount of ether was added to the solution. The resultant precipitate was then collected by suction filtration to give 115 mg (yield 78%) of the title compound.

^-N R (CDC13, 400 MHz): δ 2.02 (s, 3H), 2.30 (s, 3H), 3.76 (s, 3H), 4.06 (s, 3H), 4.12 (s, 3H), 6.46 (d, J = 6.3 Hz, 1H), 6.78 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 8.8 Hz, 1H), 7.39 (d, J = 9.0 Hz, 2H), 7.67 (s, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.92 (s, 1H), 8.20 - 8.23 (m, 1H) Mass analysis, found (ESI-MS, m/z): 474 (M++l) Example 3_ZJ N- < 2.4-Difluorophenyl ) -N' -{4- [ ( 6.7-dimethoxy-4-quinolyl)oxy]-2.5-dimethylphenyl >urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy ] -2 , 5-dimethyl-aniline (200 mg) was dissolved in chloroform (15 ml), and 2 , 4-difluorophenyl isocyanate (88 μΐ) was then added to the solution. The mixture was heated under reflux for one hr. The reaction solution was purified by chromatography on silica gel by development with chloroform/acetone (4/1) to give 287 mg (yield 97%) of the title compound. 1H-NMR (CDC13„ 400 MHz): δ 2.17 (s, 3H) 2.26 (s, 3H), 4.05 (s, 3H), 4.06 (s, 3H), 6.31 (d, J = 5.4 Hz, 1H), 6.57 (s, 1H), 6.81 - 6.95 (m, 3H), 7.00 (s, 1H), 7.43 (s, 1H), 7.55 (s, 1H), 7.59 (s, 1H), 8.05 - 8.13 (m, 1H), 8.47 (d, J = 5.4 Hz, 1H) Mass analysis, found (FD-MS, m/z): 479 (M+) Example 38: N- 4-f ( 6.7-Dimethoxy-4-qu inolyl ) oxy ] -2.5-dimethylpheny1 >-N ' -propylurea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy ] -2 , 5-dimethyl-aniline (150 mg) was dissolved in chloroform (13 ml) and triethylamine (1.5 ml), and a solution of triphosgene (151 mg) in chloroform was then added to the solution. The mixture was heated under reflux for 5 min. Next, n-propylamine (33 mg) was added to the reaction solution, and the mixture was heated under reflux for additional 2 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was supported on diatomaceous earth, followed by extraction with chloroform. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (4/1) to give 178 mg (yield 95%) of the title compound. 1H-NMR (CDC13 400 MHz): δ 0.94 (t, J = 7.3 Hz, 3H), 1.51 - 1.65 (m, 2H), 2.15 (s, 3H), 2.26 (s, 3H), 3.21 - 3.28 (m, 2H), 4.05 (s, 3H), 4.06 (s, 3H), 4.63 - 4.69 (m, 1H), 5.97 (s, 1H), 6.31 (d, J = 5.1 Hz, 1H), 6.98 (s, 1H), 7.43 (s, 2H), 7.58 (s, 1H), 8.46 (d, J = 5.4 Hz, 1H) Mass analysis, found (FD-MS, m/z): 409 (M+) Example 3_9_ϊ N- ( 4-Chloro-2^methylphenyl ) -N ' ,{4- [ ( 6.7- dimethoxy-4-quinolyl ) oxy ] -2 , 5-dimethylphenyl}urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl )oxy] -2 , 5-dimethyl-. aniline (100 mg) was dissolved in chloroform (10 ml) and — riethylamine (1 ml), and a solution" of triphosgene (92 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min.

Next, 4-chloro-2-methylaniline (44 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, followed by extraction with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of chloroform, and a large amount of ether was added to the solution to precipitate a crystal which was then collected by filtration to give 118 mg (yield 78%) of the title compound. 1H-NMR (CDC13, 400 MHz): δ 2.16 (s, 3H) , 2.21 (s, 3H), 2.23 (s, 3H), 4.05 (s, 3H), 4.06 (s, 3H), 6.28 (d, J = 5.4 Hz, 1H), 6.30 (s, 1H), 6.32 (s, 1H) , 6.98 (s, 1H), 7.22 - 7.23 (m, 2H), 7.43 (s, 1H), 7.58 (s, 1H), 7.59 - 7.63 (m, 2H), 8.45 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 492, 494 (M++l) Example 4_Qj_ N-{4- [ ( 6 , 7-DimethQ y-4-quinc-lyl )oxy]-2 , -dimethylphenyl}-N ' - ( 4-fluoro-2-methylphenyl ^urea 4-[ (6,7-Dimethoxy-4-quinolyl)oxy]-2,5-dimethyl- aniline (100 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (92 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 4-fluoro-2-methylaniline (42 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of chloroform, and a large amount of ether was added to the solution to precipitate a crystal which was -tehen collected by filtration to give 108 mg (yield 74%) of the title compound. 1H-NMR (CDC13, 400 MHz): δ 2.15 (s, 6H), 2.30 (s, 3H), 4.05 (s, 3H), 4.06 (s, 3H), 6.24 (s, 2H), 6.28 (d, J = 5.1 Hz, 1H), 6.94 (s, 1H), 6.96 - 7.00 (m, 2H), 7.42 (s, 1H), 7.49 - 7.52 (m, 1H), 7.58 (s, .lH), 7.64 (s, 1H), 8.44 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 476 (M++l) Example 41: N-{4-[ ( 6.7-Dimethoxy-4-quino1 yl ^o y ]-2 r 5-dimethylphenyl}-N, - ( 3-fluoro-2-methoxyphenyl )urea 4-[ ( 6 , 7-Dimethoxy-4-quinolyl)oxy]-2 , 5-dimethyl-aniline (100 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (92 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 3-fluoro-o-anisidine (44 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 126 mg (yield 83%) of the title compound. 1H-NMR (CDClj, 400 MHz): δ 2.16 (s, 3H), 2.27 (s, 3H), 3.83 (d, J = 1.7 Hz, 3H), 4.04 (s, 3H), 4.07 (s, 3H), 6.31 (d, J = 5.1 Hz, 1H), 6.74 - 6.79 (m, 1H), 6.97 - 7.03 (m, 3H), 7.44 (s, 1H), 7.57 (s, 1H), 7.60 (s, 1H), 7.66 (s, 1H), 8.02 - 8.04 (m, 1H), 8.48 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 492 (M++l) Example !2i N-{4- [ ( 6.7-Dimethoxy-4-quinolyl ) oxy ] -2 , 5- dimethylphenyly-N' - ( 2-methylphenyl ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy ] -2 , 5-dimethyl- aniline (100 mg) was dissolved in chloroform (10 ml), ■ and o-toluyl isocyanate (46 : Was added to the solution. The mixture was stirred at room temperature overnight. Methanol was added to the reaction solution, and the solvent was removed by distillation under the reduced pressure. The residμe Was purified by chromatography on silica gel by- development with chloroform/acetone (2/1) to give 111 mg (yield 79%) of the title compound. 1H-NMR (CDClj, 400 MHz): δ 2.12 (s, 6H), 2.26 (s, 3H), 4.03 (s, 3H), 4.05 (s, 3H) , 6.27 (d, J = 5.1 Hz, 1H), 6.77 (s, 1H), 6.81 (s, 1H), 6.91 (s, 1H), 7.11 - 7.15 (m, 1H), 7.22 (s, 1H), 7.24 (s, 1H) , 7.42 (s, 1H), 7.59 (s, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.68 (s, 1H), 8.43 (d, J = 5.4 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 458 (M++l) Example 4_3j N-{4-[ ( 6.7-Dimethoxy-4-quinolyl )oxy ]-2.5-dimethylphenyl }-N ' - ( 2-methoxyphenyl ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy ] -2 , 5-dimethyl-aniline (100 mg) was dissolved in chloroform (10 ml), and 2-methoxyphenyl isocyanate (49 μΐ) was added to the solution. The mixture was heated under reflux overnight. Methanol was added to the reaction solution. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to quantitatively give the title compound. 1H-NMR (CDC13, 400 MHz): δ 2.14 (s, 3H), 2.24 (s, 3H), 3.75 (s, 3H), 4.03 (s, 3H), 4.07 (s, 3H), 6.31 (d, J = 5.1 Hz, 1H), 6.84 - 6.87 (m, 1H), 6.95 - 7.03 (m, 3H), 7.06 (s, 1H), 7.44 (s, 1H), 7.56 (s, 1H), 7.61 (s, 1H), 7.63 (s, 1H), 8.17 - 8.20 (m, 1H), 8.46 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 474 (M++l) Example 44: N- ( 5-Bromo-6-methyl-2-pyridyl ) -N' -{4- [ (6.7-dimethoxy-4-quinoly1 ) oxy ] -2.5-dimethylpheny1>urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy ] -2 , 5-dimethyl-aniline (100 mg) was dissolved in chloroform (10 ml) and triethylamine -(-1 ml), and a solution of triphosgene' (92 mg) in dichloromethane was then added to the . solution. The mixture was stirred at room temperature for 30 min. Next, .6-amino-3-bromo-2-methylpyridine (69 mg) was added to the reaction solution, and the mixture was stirred at room temperature overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of chloroform, and a larger amount of ether was added to the solution to precipitate a crystal which was then collected by filtration to give 80 mg (yield 48%) of the title compound.

^-NMR ( CDCI3 , 400 MHz): δ 2.18 (s 3H), 2.42 (s, 3H), 2.65 (s, 3H), 4.06 (S, 3H), 4.08 (s, 3H), 6.34 (d, J = 5.4 Hz, 1H), 6.57 (d, J = 8.5 Hz, 1H), 6.98 (s, 1H), 7.43 (s, 1H), 7.62 (s, 1H), 7.70 (s, 1H), 7.74 (d, J = 8.5 Hz, 1H), 8.05 (s, 1H) , 8.46 (d, J = 5.4 Hz, 1H), 11.17 (br, 1H) Mass analysis, found (ESI-MS, m/z): 537, 539 (M++l) Example 4_5_i N- ( 2.6-Dimethoxy-3-pyridyl ) - ' -{4- [ ( 6 f 7- dimethoxy-4-quinolyl ) oxy ] -2.5-dimethylpheny1 >urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl )oxy ] -2 , 5-dimethyl- aniline (100 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (92 mg) in dichloromethane was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 3-amino-2 , 6-dimethoxypyridine (70 mg) was added to the reaction solution, and the mixture was stirred at room temperature overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was . removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of -chloroform, and a large amount o-f-'ether was added to the solution to precipitate a crystal which was then collected by filtration to . give 124 mg (yield 79%) of the title compound.. .··. - - 1H-NMR (CDC13, 400 MHz): δ 2.17 (s, 3H), 2.27 (s, 3H), 3.89 (s, 3H), 3.95 (s, 3H), 4.06 (s, 3H), 4.07 (s, 3H), 6.31 (d, J = 5.1 Hz, 1H), 6.34 (d, J = 8.5 Hz, 1H), 6.36 (s, 1H), 6.74 (s, 1H), 6.99 (s, 1H), 7.44 (s, 1H), 7.57 (s, 1H), 7.60 (s, 1H) , 8.20 (d, J = 8.3 Hz, 1H), 8.46 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 505 (M++l) Example 6j N-{4-[ (6.7-Dimethoxy-4-quinolyl)oxy]-2.5-dimethylpheny1 }-N'- ( 4-methoxypheny1 \ urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl )oxy ] -2 , 5-dimethyl-aniline (100 mg) was dissolved in chloroform (4 ml), and 4-methoxyphenyl isocyanate (60 μΐ) was then added to the solution. The mixture was allowed to react at room temperature overnight. The solvent was removed by distillation under the reduced pressure. The residue was dissolved in a minor amount of chloroform, and a large amount of ether was added to the solution. The resultant precipitate was collected by suction filtration to give 110 mg (yield 74%) of the title compound.

^-NMR (CDC13, 400 MHz): δ 2.07 (s, 3H), 2.26 (s, 3H), 3.76 (s, 3H), 4.03 (s, 3H), 4.08 (s, 3H), 6.39 (d, J = 6.1 Hz, 1H), 6.80 (d, J = 9.0 Hz, 2H), 6.87 (s, 1H), 7.36 (d, J = 9.0 Hz, 2H), 7.55 (br, 1H), 7.62 (s, 1H), 7.67 (s, 1H), 7.80 (s, 1H), 8.19 (br, 1H), 8.27 (d, J = 6.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 474 (M++l) Example 47; N-{4- [ ( 6.7-Dimethoxy-4-quinolyl )oxy]-2-nitrophenyl >- ' -propylurea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl ) oxy] -2-nitroaniline (150 mg) was dissolved in chloroform (10 ml) and triethylamine (1.5 ml)/ and a solution of triphosgene (144 mg) in chloroform was then added to the solution. The mixture was heated under reflux for 5 min. Next, n-propylamine~~( 31 mg) was added. The mixture was- heated under reflux for additional 2 hr. A saturated aqueous sodium hydrogencarbonate solution, was added to the reaction solution, and the mixture was supported on diatomaceous earth, followed by . extraction with chloroform. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (4/1) to give 160 mg (yield 86%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 1.01 (t, J = 7.5 Hz, 3H), 1.59 - 1.69 (m, 2H), 3.27 - 3.34 (m, 2H), 4.05 (s, 3H), 4.06 (s, 3H), 4.95 - 5.01 (br, 1H), 6.47 (d, J = 5.4 Hz, 1H), 7.43 - 7.51 (m, 3H), 8.04 (d, J = 2.7 Hz, 1H), 8.53 (d, J = 5.4 Hz, 1H), 8.81 (d, J = 9.3 Hz, 1H), 9.74 -9.79 (br, 1H) Mass analysis, found (FD-MS, m/z): 426 (M+) Example i&j N- ( 2.4-Difluoropheny1 ϊ-Ν'-{4-[ί6.7-dimethoxy-4-quinolyl)oxy]-2-nitrophenyl >urea 4- [ ( 6 , 7-Dimethoxy-4-quinolyl )oxy ] -2-nitroaniline (100 mg) was dissolved in chloroform (10 ml) and triethylamine (1 ml), and a solution of triphosgene (96 mg) in chloroform was then added to the solution. The 5 mixture was heated under reflux for 5 min. Next, 2,4- difluoroaniline (45 mg) was added to the reaction solution, and the mixture was further heated under reflux overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was supported on diatomaceous earth, followed by extraction with chloroform. The solvent was removed by distillation under the reduced pressure. The residue was purified by thin-layer chromatography on silica gel by development with chloroform/acetone (3/1) to give 81 mg (yield 56%) of the title compound.

'H-NMR ( CDClj, 400 MHz): δ 4.05 (s, 3H), 4.06 (s, . . 3H), 6.50 (d, J = 5.1 Hz, IH), 6.91 - 6.98 (m, 3H), 7.45 • ;* "(s, 1H), 7.49 (s, 1H) , 7.50 7.54 (m, IB), 7.88 - 7.97 20 (m, IH), 8.05 (d, J = 2.9 Hz, IB), 8.54 (d, J = 5.1 Hz, IH), 8.77 (d, J = 9.3 Hz, 1H), 9.98 (s, IH) Mass analysis, found (FD-MS, m/z): 496 (M+) Example U_? N-{3.5-Dichloro-4-[ ( 6f 7-dimethoxy-4- quinolyl )oxy ] henyl}-N'-( 2.4-difluoropheny] )urea 3 , 5-Dichloro-4- [ ( 6 , 7-dimethoxy-4-quinolyl ) oxy ] - aniline (53 mg) was dissolved in chloroform (5 ml), and 2 , 4-difluoropheny1 isocyanate (34 μΐ) was added to the solution. The mixture was heated under reflux overnight. The solvent was removed by distillation under the 30 reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 56 mg (yield 74%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 4.05 (s, 3H), 4.09 (s, 35 3H), 6.26 (d, J = 5.4 Hz, IH), 6.86 - 6.93 (m, 2H), 7.05 (s, IH), 7.44 (s, IH), 7.46 (s, IH), 7.60 (s, 2H) , 7.64 (s, IH), 8.01 - 8.05 (m, IH), 8.48 (d, J = 5.4 Hz, IH) Mass analysis, found ( FAB-MS , m/z): 520, 522, 524 (M++l) Example 5Jh N- ( 2.4-Difluorophenyl ) - ' - ( 2-fluoro-4-{ [ 6-methoxy-7- ( 2-morpholinoethoxy ) -4-quinol yl ]oxy >phenyl )-urea N- ( 2 , 4-Difluorophenyl ) - ' - {2-fluoro-4- [ ( 7-hydroxy- 6-methoxy-4-quinolyl ) oxy ] phenyl }urea (20 mg), potassium carbonate (7 mg), tetra-n-butylammonium iodide (2 mg), and N- ( 2-chloroethyl )morpholine hydrochloride (10 mg) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at 70°C overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous magnesium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by thin-layer chromatography on silica gel by development with chloroform/methanol (30/1) to give 14 mg (yield -5-7%) of the title compound. -~ " 'H-NMR (CDC13, 400 MHz): δ 2.57 (t, J = 4.4 Hz, 4H), 2.88 (m, 2H), 3.69 (t, J = 4.4 Hz, 4H), 3.94 (s, 3H), 4.26 (t, J. = 5.9 Hz, 2H), 6.43 (d, J =.5.1 Hz, 1H), 6.77 - 6.95 (m, 4H), 7.35 (s, 1H), 7.43 (s, 1H), 7.96 - 8.02 (m, 1H), 8.13 - 8.17 (m, 1H), 8.44 (d, J = 5.1 Hz, 1H)'. Example 5_lj N- ( 2-Chloro-4-{ [ 6-methoxy-7- ( 2-morpholinoethoxy ) -4-quinolyl ]oxy>pheny] ) -N' - ( 2 .4-difluorophenyl >urea N-{2-Chloro-4-[ ( 7-hydroxy-6-methoxy-4-quinolyl ) -oxy ]pheny1 }-N'- (2, 4 -difluorophenyl) urea (174 mg) was dissolved in N,N-dimethylformamide (9 ml), and potassium carbonate (64 mg), tetra-n-butylammonium iodide (14 mg), and N-( 2-chloroethyl )morpholine hydrochloride (86 mg) were then added to the solution. The mixture was stirred at 70°C for 17 hr, and a saturated aqueous sodium hydrogencarbonate solution was then added to the reaction solution, followed by extraction with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (20/1) to give 75 mg (yield 35%) of the title compound.

^-NMR (CDC13, 400 MHz): δ 2.60 - 2.67 (m, 4H)f 2.95 (t, J = 6.0 Hz, 2H), 3.71 - 3.79 (m, 4H), 4.01 (s, 3H), 4.33 (t, J = 6.0 Hz, 2H), 6.50 (d, J = 5.1 Hz, 1H) , 6.85 - 6.97 (m, 2H), 7.09 - 7.17 (m, 2H), 7.22 - 7.27 (m, 2H), 7.42 (s, 1H), 7.50 (s, 1H), 7.97 - 8.01 (m, 1H), 8.28 (d, J = 9.0 Hz, 1H), 8.51 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 585, 587 (M++l) Example 52: N- ( 2.4-Difluorophenyl -N ' - ( 4-{ [ 6-methoxy-7- ( 2-morpholinoethoxy ^-4-quinolyl ]oxy}-2.5-dimethyl -phenyl)urea ■ . - ■ N- ( 4-{ [ 7- (Benzyloxy ) -6-methoxy-4-quinoly1 ]oxy}-2 , 5-dimethylphenyl)-N'-( 2, 4-difluorophenyl)urea (366 mg) was dissolved in Ν,Ν-dimethylformamide- ( 6 ml ) , and palladium hydroxide (366 mg) was adxled . to ' the solution. The mixture was stirred in a hydrogen atmosphere at room temperature overnight. The solvent . was removed by distillation under the reduced pressure. The residue was dissolved in chloroform and methanol. The reaction solution was filtered through Celite. Next, the solvent was removed by distillation under the reduced pressure. The residue (213 mg), potassium carbonate (109 mg), tetra-n-butylammonium iodide (12 mg), and N-(2-chloroethyl )morpholine hydrochloride (74 mg) were dissolved in Ν,Ν-dimethyIformamide (5 ml), and the solution was stirred at 70°C overnight. The solvent was removed by distillation under the reduced pressure. Water was added to the residue, and the mixture was extracted with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by thin-layer chromatography on silica gel by development with chloroform/methanol (10/1) to give 106 mg (yield 55%) of the title compound.

^-NMR (CDCI3, 400 MHz): δ 2.17 (s, 3H), 2.27 (s, 3H), 2.64 (t, J = 4.6 Hz, 4H), 2.96 (t, J = 6.0 Hz, 2H), 3.76 (t, J = 4.6 Hz, 4H), 4.03 (s, 3H), 4.34 (t, J = 6.0 Hz, 2H), 6.31 (d, J = 5.4 Hz, 1H), 6.47 (s, 1H), 6.81 - 6.92 (m, 3H), 7.00 (s, 1H), 7.43 (s, 1H) , 7.54 (s, 1H), 7.58 (s, 1H), 8.05 - 8.12 (m, lH), 8.47 (d, J = 5.4 Hz, 1H) Example 5_3_j N- ( 4-{ [ 6-Methoxy-7- ( 2-morpholinoethoxy ) -4-quinolyl ]oxy}-2.5-dimethylphenyl ) - ' - I 2-methoxyphenyl ) -urea N-( 4-{ [ 7- (Benzyloxy ) -6-methoxy-4-quinolyl ]oxy}-2 , 5-dimethylphenyl)-N'-( 2-methoxyphenyl)urea (363 mg) was dissolved in N,N-dimethylformamide (6 ml), and palladium hydroxide (363 mg) was added to the solution. The mixture was stirred in a hydrogen atmosphere at room temperature overnight. The solvent was . removed by distillation under the reduced pressure. The residue was-dissolved— in chloroform and methanol, and the solution was filtered through Celite. Next, the. solvent was removed by distillation under the reduced pressure. The residue (191 mg), potassium carbonate (219 mg), tetra-n-butylammonium iodide (12 mg), and N-(2-chloroethyl )morpholine hydrochloride (148 mg) were dissolved in N,N-dimethylformamide (5 ml). The solution was stirred at 70°C overnight. The solvent was removed by distillation under the reduced pressure. Water was added to the residue, and the mixture was extracted with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by thin-layer chromatography on silica gel by development with chloroform/methanol (10/1) to give 101 mg (yield 55%) of the title compound.

^-NMR (CDCI3, 400 MHz): δ 2.17 (s, 3H), 2.28 (s, 3H), 2.64 (t, J = 4.5 Hz, 4H), 2.96 (t, J = 5.9 Hz, 2H), 3.76 (t, J = 4.6 Hz, 4H), 3.83 (s, 3H), 4.04 (S, 3H), 4.34 (t, J = 6.0 Hz, 2H), 6.30 (d, J = 5.4 Hz, 2H), 6.86 - 6.90 (m, 1H), 6.96 - 7.06 (m, 3H), 7.16 (s, 1H), 7.43 (s, 1H), 7.57 (s, 1H), 7.59 (s, 1H), 8.11 - 8.16 (m, 1H), 8.46 (d, J = 5.4 Hz, 1H) Example 5j_j N- ( 2-Chloro-4-{ [ 6-metho y-7- ( 2- methoxyethoxy ) -4-quinolyl ] oxy>phenyl ) -N ' - ( 2 r 4- difluorophenyl )urea Sodium hydride (60 wt%, 153 mg) was added to dimethyl sulfoxide (2 ml), and the mixture was stirred 0 at 60°C for 30 min and was then cooled to room temperature. 4-Amino-3-chlorophenol hydrochloride (343 mg) was added to the reaction solution, and the mixture was stirred at room temperature for 10 min. Next, a solution of 4-chloro-6-methoxy-7- ( 2-methoxyethoxy ) - 5 quinoline (254 mg) in dimethyl sulfoxide (2 ml) was added to the reaction solution. The mixture was stirred at 110°C overnight. Water was added to the reaction solution, followed by extraction with chloroform. The ··'■." chloroform layer was then" washed with a . saturated 0 aqueous sodium hydrogencarbonate solution and was dried over anhydrous sodium sulfate. The solvent was removed by .distillation under the reduced . pressure.. The residue . was purified by chromatography on silica gel by development with chloroform/acetone (7/3) to give 332 mg 5 of a mixture containing 2-chloro-4-{ [ ( 6-methoxy-7-( 2- methoxyethoxy) -4-quinolyl] oxy}aniline as a major product. A 83 mg portion of the mixture was dissolved in chloroform (5 ml), and 2 , 4-difluorophenyl isocyanate (32 μΐ) was added to the solution. The mixture was heated 0 under reflux overnight. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 50 mg of the title compound . 1H-NMR (DMS0-d6, 400 MHz): δ 3.75 - 3.77 (m, 2H), 3.94 (s, 3H), 4.27 - 4.29 (m, 2H), 6.55 (d, J = 5.1 Hz, 1H), 7.04 - 7.09 (m, 1H), 7.25 - 7.36 (m, 2H), 7.42 (s, 1H), 7.50 (s, 1H), 7.51 (s, 1H), 8.09 - 8.15 (m, 1H), 8.24 (d, J = 9.0 Hz, 1H), 8.49 (d, J = 5.4 Hz, 1H), 8.82 (s, 1H), 9.31 (s, 1H) Example 5_5_j N- ( 2-Chloro-4-{ [ 6-methoxy-7- ( 2 -methoxyethoxy )-4-quinolyl ]oxy>phenyl )-N'-(2-methoxyphenyl ) urea Sodium hydride (60 wt%, 153 mg) was added to dimethyl sulfoxide (2 ml), and the mixture was stirred at 60°C for 30 min and was then cooled to room temperature. 4-Amino-3-chlorophenol hydrochloride (343 mg) was added to the reaction solution, and the mixture was stirred at room temperature for 10 min. Next, a solution of 4-chloro-6-methoxy-7-(2-methoxyethoxy )quinoline (254 mg) in dimethyl sulfoxide (2 ml) was added to the reaction solution, and the mixture was stirred at 110°C overnight. Water was added to the reaction solution,, followed by extraction with chloroform. The chloroform layer was then washed with a saturated aqueous sodium :hydrogencarbonate'"BOlution and was .. then dried . over anhydrous, sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue -was purified by chromatography on silica gel by development with chloroform/acetone (7/3) to give 332 mg of a mixture containing 2-chloro-4-{ [ ( 6-methoxy-7-(2-methoxyethoxy)-4-quinolyl]oxy}aniline as a main product. A 83 mg portion of the mixture was dissolved in chloroform (5 ml), and 2-methoxyphenyl isocyanate (35 μΐ) was added to the solution. The mixture was heated under reflux overnight. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/acetone (2/1) to give 31 mg of the title compound.

H-NMR (DMS0-d6, 400 MHz): δ 3.75 - 3.77 (m, 2H), 3.90 (s, 3H), 3.94 (s, 3H), 4.27 - 4.29 (m, 2H), 6.55 (d, J = 5.1 Hz, 1H), 6.89 - 7.05 (m, 3H), 7.24 - 7.27 (m, 1H), 7.42 (s, 1H), 7.48 (d, J = 2.7 Hz, 1H), 7.50 (s, 1H), 8.08 - 8.11 (m, lH), 8.18 - 8.22 (m, 1H), 8.49 (d, J = 5.4 Hz, 1H), 8.99 - 9.03 (m, 2H) Example 5_£j N- ( 2.4-Difluorophenyl ) - ' - ( 4-{ [ 6-methoxy-7- ( 2-methoxyethoxy ) -4-quinolyl ]oxy>-2.3-dimethylphenyl )- 5 urea N- ( 4- { [ 7- ( Benzyloxy ) -6-methoxy-4-quinolyl ] oxy}-2 , 3- dimethylphenyl ) -N' -(2, 4-difluorophenyl )urea (213 mg) was dissolved in N,N-dimethylformamide (5 ml) and triethylamine (1 ml), and palladium hydroxide (40 mg) 10 was added to the solution. The mixture was stirred in a hydrogen atmosphere at room temperature overnight . The reaction solution was filtered through Celite and was then washed with chloroform/methanol . The solvent was removed by distillation under the reduced pressure. A 90 15 mg portion of the residue (184 mg) was dissolved in N,N- dimethylformamide (1.5 ml), arid potassium carbonate (32 . mg) , tetra-n-butylammonium iodide ( 7 mg) , and 2-. -bromoethyl methyl -ether (32 - mg) were added to the : " solution. The mixture was stirr"eci at 70°C overnight . A 20 - saturated aqueous sodium . hydrogencarbonate solution was added to.: the reaction solution, and the mixture was extracted, with chloroform. - -The., chloroform layer was dried over anhydrous magnesium sulfate. The solvent was removed by distillation urider the reduced pressure. The 25 residue was. purified by thin-layer chromatography on silica gel by development with chloroform/acetone (2/1) to give 110 mg of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 1.97 (s, 3H), 2.17 (s, 3H), 3.31 (s, 3H), 3.70 (t, J = 4.4 Hz, 2H), 3.90 (s, 30 3H), 4.21 (t, J = 4.4 Hz, 2H), 6.18 (d, J = 5.1 Hz, 1H), 6.95 - 6.98 (m, 2H), 7.22 - 7.31 (m, 1H), 7.34 (s, 1H), 7.51 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 8.03 - 8.10 (m, 1H), 8.36 (d, J = 5.1 Hz, 1H), 8.38 (s, 1H), 8.79 (s, 1H) Example 5_Zi N- ( 4-{ [ 6-Methoxy-7- 12-methoxyethoxy ) -4- quinolyl ]oxy}-2.3-dimethylphenyl ) - ' - ( 2-methoxyphenyl ) - urea N- ( 4-{ [ 7- (Benzyloxy ) -6-methoxy-4-quinolyl ] oxy}-2 ,3- dimethylphenyl)-N'-(2-methoxyphenyl)urea (161 mg) was dissolved in N,N-dimethylformamide (4 ml) and triethylamine (1 ml), and palladium hydroxide (32 mg) was added to the solution. The mixture was stirred in a hydrogen atmosphere at room temperature overnight. The reaction solution was filtered through Celite and was washed with chloroform/methanol . The solvent was removed by distillation under the reduced pressure. A 110 mg portion of the residue (223 mg) was dissolved in N,N-dimethylformamide (1.5 ml), and potassium carbonate (23 mg), tetra-n-butylammonium iodide (5 mg), and 2-bromoethyl methyl ether (23 mg) were added to the solution. The mixture was stirred at 70°C overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous magnesium sulfate — The solvent was removed- by distillation under the reduced "pressure". The residue was purified by thin-layer chromatography on silica gel by development with chloroform/acetone (2/1) to give 89 mg of the title compound.

^- MR (DMSO-d6, 400 MHz): δ 2.00 (s, 3H), 2.17 (s, 3H), 3.70 (t, J = 4.2 Hz,. 2H) , 3.83 (s, 3H), 3.90 (s, 3H), 4.22 (t, J = 4.2 Hz, 2H), 6.19 (d, J = 5.1 Hz, 1H), 6.81 - 6.88 (m, 2H), 6.94 - 6.97 (m, 2H), 7.34 (s, 1H), 7.51 (s, 1H), 7.58 (d, J = 8.8 Hz, 1H) , 8.07 (d, J = 8.8 Hz, 1H), 8.36 (d, J = 5.1 Hz, 1H), 8.48 (s, 1H), 8.58 (s, 1H) Example 5_≤_i N- ( 2.4-Difluorophenyl \ - ' - i 4 - { [ 6-methoxy-7 - ( 2-methoxyethoxy-4-quinolyl ]oxy}-2.5-riimethylpheny] )urea N-(4-{ [ 7- ( Benzyloxy )-6-methoxy-4-quinolyl] oxy} -2 , 5-dimethylphenyl)-N'-(2,4-difluorophenyl)urea (366 mg) was dissolved in N,N-dimethylformamide (6 ml), and palladium hydroxide (366 mg) was added to the solution. The mixture was stirred in a hydrogen atmosphere at room temperature overnight. The solvent was removed by distillation under the reduced pressure. The residue was dissolved in chloroform and methanol, and the solution was filtered through Celite. Next, the solvent was removed by distillation under the reduced pressure. The residue (213 mg), potassium carbonate (109 mg), tetra-n- butylammonium iodide (12 mg), and 2-bromoethyl methyl ether (40 μΐ) were dissolved in N,N-dimethylformamide (5 ml), and the solution was stirred at 70°C overnight. The solvent was removed by distillation under the reduced pressure. Water was added to the residue, and the mixture was extracted with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue .was purified by thin-layer chromatography on silica gel by development with chloroform/methanol (10/1) to give 124 mg (yield 73%) of the title compound. 1H-NMR (CDC13, 400 MHz): ·δ 2.17 (s, 3H), 2.26 (s, 3H), 3.49 (s, 3H), 3.9G- (t, J = 4.8 Hz, 2H), 4.03 (s, 3H), 4.34 (t,. J = 4.8 Hz, 2H), 6..30 (d, J = 5.1 Hz, 1H), 6.57 (s, 1H) ,. 6.81 - 6.95 (m, 3H), 7.00 (s, 1H) , 7.43 (s, 1H),...7.55 .(s., 1H), 7.57 (s, 1H), 8.05 - 8.14 (m, 1H) , 8.46. (d, J = 5.4 Hz, 1H) Mass analysis, found (ESI-MS,. m/z ) : 524 (M++l ) Example 59: N- -{ [ 6-Methoxy-7- f 2-methoxyethoxy ) -4-quinolyl ] oxy> -2.5-dimethylpheny ) - ' - I 2-mpthoxypheny1 ) -urea N- ( 4-{ [ 7- (Benzyloxy ) -6-methoxy-4-quinolyl ]oxy}-2 , 5-dimethylphenyl)-N'-(2-methoxyphenyl)urea (363 mg) was dissolved in N,N-dimethylformamide (6 ml), and palladium hydroxide (363 mg) was added to the solution. The mixture was stirred in a hydrogen atmosphere at room temperature overnight. The solvent was removed by distillation under the reduced pressure, and the residue was dissolved in chloroform and methanol. The solution was filtered through Celite. Next, the solvent was removed by distillation under the reduced pressure. The residue (191 mg), potassium carbonate (110 mg), tetra-n- butylammonium iodide (12 mg), and 2-bromoethyl methyl ether (80 mg) were dissolved in Ν,Ν-dimethylformamide (5 ml), and the solution was stirred at 70°C overnight. The solvent was removed by distillation under the reduced pressure. Water was added to the residue, and the mixture was extracted with chloroform. The chloroform layer was dried over sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by thin-layer chromatography on silica gel by development with chloroform/methanol (10/1) to give 128 mg (yield 76%) of the title compound.

^-NMR (CDC13, 400 MHz): δ 2.17 (s, 3H), 2.28 (s, 3H), 3.49 (s, 3H), 3.83 (s, 3H), 3.90 (t, J = 4.8 Hz, 2H), 4.04 (s, 3H), 4.35 (t J = 4.9 Hz, 2H), 6.30 (d, J = 5.4 Hz, 1H), 6.33 (s, 1H), 6.86 - 6.90 (m, 1H), 6.96 -7.06 (m, 3H), 7.17 (s, 1H), 7.43. (s, 1H), 7.56 (s, IH), 7-.58 (s, 1H), 8.12 - 8.17 (m, 1H), 8.45 (d, J = 5.1 Hz, in) ■: - ■ ■ ■ ■ .. Mass analysis, found (ESI-MS,. m/z) : 518 (M++l ) Example ' 60: N- ( 4-.{ [ 7- ( Benzyloxy ) -6-me hoxy-4-quinolyl ]oxy}-2 , 3-dimethylphenyl ) -N ' - ( 2-^methoxyphenyl ) -urea 4-{ 11 - ( Benzyloxy ) -6<-methoxy-4-quinolyl ] oxy} -2 , 3-dimethylaniline (260. mg) was dissolved in N,N-dimethylformamide (5 ml), and 2-methoxyphenyl isocyanate (116 mg) was then added to the solution. The mixture was allowed to react at room temperature overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous magnesium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by thin-layer chrOmatography on silica gel by development with chloroform/acetone (2/1) to give 169 mg (yield 47%) of the title compound. 1H-NMR (DMS0-d6, 400 MHz): δ 1.99 (s, 3H), 2.02 (s, 3H), 3.83 (s, 3H), 3.90 (s, 3H), 5.25 (s, 2H), 6.18 (d, J = 5.3 Hz, 1H), 6.81 - 6.87 (m, 2H) , 6.95 (d, J = 6.1 Hz, 1H), 7.29 - 7.59 (m, 7H), 8.07 (d, J = 6.1 Hz, 1H), 8.35 (d, J = 5.3 Hz, 1H), 8.48 (s, 1H), 8.58 (s, 1H) Example 6_1J N--T2-Chloro-4- [ 6.7-dimethoxy-4- quinazolinyl ) oxy ]phenyl}-N ' - ( 2.4-difluorophenyl )urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinazolinyl ) oxy ] - aniline (214 mg) was dissolved in chloroform (5 ml), and 2, 4-difluorophenyl isocyanate (180 μΐ) was then added to 0 the solution. The mixture was allowed to react at 70°C for 4 hr, and a large amount of ether was added to the reaction solution. The resultant precipitate was collected by suction filtration to give 146 mg (yield 46%) of the title compound. 1H-NM (DMSO-d6, 400 MHz): δ 3.98 (s, 3H), 3.99 (s, ;·.-=. 3H), .7.03 - 7.10 (m, 1H) , 7.28 - 7.37 (m, 2H) , 7.40 (s, 1H),. 7.56 (s, 2H) , 8.08 - 8.21 (m, 2H), 8.57 (s, 1H), 8.80 (s, 1H), 9.30 -(s, 1H) Mass analysis, found (ESI-MS, m/z): 487, 489 (M++l) 0 Example 62; ■·■ N 2-Chloro-4- 6.7-dimet.hoxy-4- uinazolinyl^oxylphenyl V-N' -propylurea ^ , : .:. . · .· :2«Chloro-4-? [ (6,7-dimethOxy^4.-quinazolinyl)-oxy]~ aniline (5.13 g) was dissolved in chloroform (100 ml) and triethylamine (50 ml) , and a solution of triphosgene . (4.59 g) in chloroform (3 ml) was then . added to the solution. The mixture was stirred for 30 min. Next, n- propylamine (2.74 g) was added to the reaction solution, and the mixture was stirred for additional 2 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (50/1) to give 4.14 g (yield 64%) of the title compound.

^-NMR (DMS0-d6, 400 MHz): δ 0.91 (t, J = 7.3 Hz, 3H), 1.41 - 1.53 (m, 2H), 3.05 - 3.12 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H), 6.99 (t, J = 5.4 Hz, 1H), 7.22 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.38 (s, 1H) , 7.46 (d, J = 2.9 Hz, 1H), 7.54 (s, 1H), 8.04 (s, 1H), 8.20 (d, J = 9.3 Hz, 1H), 8.55 (s, 1H) Mass analysis, found (ESI-MS, m/z): 417 (M++l) Example 63 ; N-{4-[Y6.7-Dimethoxy-4-quinazolinyl)oxy]- phenyl >-N ' -ethylurea 4-[ ( 6, 7-Dimethoxy-4-quinazolinyl) oxy] aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml), and a solution of triphosgene (50 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, ethylamine hydrochloride (69 mg) was added to the reaction solution, and the mixture was further stirred at room temperature overnight. Methanol was added to the reaction solution, and the solution was purified by HPLC by development with chloroform/methanol to give 10 mg- (yield 16%) of the title compound. " ~ 1H-NMR (DMSO-d6, 400 MHz): δ 1.07 (t, J = 7.3 Hz, 3H), 3.11 --3.14 (m, 2Ή), 3.97 (s, 3H), 3.99 (s, 3H), 6.10 .(t, J = 5.4 Hz, lH), 7.14. (d, J = 9.0 Hz,. 2H), 7.37- (s, 1H), 7.46 (d, J = 9.0 Hz, 2H), 7.55 (s, 1H), 8.49 (br, 1H), 8.53. (s, 1H) Mass analysis, found (ESI-MS, m/z): 369 (M++l) Example 6Jj N-{ 4- f ( 6.7-Dimethoxy-4-quinazol i nyl ) oxy] -phenyl}-N ' -propylurea 4-[ ( 6, 7-Dimethoxy-4-quinazolinyl) oxy] aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml), and a solution of triphosgene (50 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, propylamine (21 μΐ) was added to the reaction solution, and the mixture was further stirred at room temperature overnight. Methanol was added to the reaction solution, and the solution was purified by HPLC by development with chloroform/methanol to give 30 mg (yield 47%) of the title compound.

^-N R (DMSO-d6, 400 MHz): δ 0.89 (t, J = 7.6 Hz, 3H), 1.41 - 1.50 (m, 2H), 3.04 - 3.08 (m, 2H) , 3.97 (s, 3H), 3.99 (s, 3H), 6.15 (t, J = 5.9 Hz, 1H), 7.15 (d, J = 8.8 Hz, 2H), 7.37 (s, 1H), 7.46 (d, J = 9.0 Hz, 2H), 7.55 (s, 1H), 8.48 (br, 1H), 8.53 (s, 1H) Mass analysis, found (ESI-MS, m/z): 383 (M++l) Example 6_5_j N-Butyl-N' -{4- [ ( 6.7-dimethoxy-4-gninazol i nyl ) oxy ]phenyl \urea 4-[ ( 6, 7-Dimethoxy-4-quinazolinyl) oxy] aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml), and a solution of triphosgene (50 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, butylamine (22 μΐ) was added to the reaction solution, and the mixture was further stirred at. room temperature overnight. Methanol was added to the reaction solution, and. the mixture was purified by HPLC by development with chloroform/methanor-to give 29 mg (yield 43%) of the" title compound. .<■■ 1H-NMR (DMSO-d6,- 400 MHz): δ 0.91 (t, J = 7.3 Hz, 3H) , 1.28. -. 1.47 (m, 4H), 3.07 - 3.12 (m, 2H) , 3.97 (s, 3H), 3.99 (s, 3H), 6.12 (t, J = 5.6 Hz, 1H), 7.15 (d, J = 8.8 Hz, 2H), 7.37 (s, 1H), 7.46 (d, J = 9.0 Hz, 2H), 7.55 .(s, 1H), 8.47 (br, 1H), 8.53. (s, lH) .

Mass analysis, found (ESI-MS, m/z): 397 (M++l) Example 6_6_j N-{4-f (6.7-Dimethoxy-4-quinazoliny1 ) oxy ] -phenyl}-N ' -pentylurea 4-[ (6,7-Dimethoxy-4-quinazolinyl)oxy]aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml), and a solutioin of triphosgene (50 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, amylamine (26 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 21 mg (yield 30%) of the title compound. 1H-NMR (D SO-d6 400 MHz): δ 0.89 (t, J = 7.1 Hz, 3H), 1.27 - 1.47 (m, 4H), 1.41 - 1.48 (m, 2H), 3.06 - 3.11 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H), 6.13 (t, J = 5.6 Hz, 1H), 7.15 (d, J = 9.0 Hz, 2H), 7.37 (s, 1H), 7.46 (d, J = 8.8 Hz, 2H), 7.55 (s, 1H), 8.47 (br, 1H), 8.53 (s, 1H) Mass analysis, found (ESI-MS, m/z): 411 (M++l) Exam le 6_7__ N- < sec-Butyl ) -N'.-{4- [ ( 6.7-dimethoxy-4- quinazolinyl ^oxy ]phenyl}urea 4-[ ( 6, 7-Dimethoxy-4-quinazolinyl )oxy] aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml), and a solution of triphosgene (50 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, sec- butylamine (23 μΐ) was added, and the mixture was stirred at room temperature overnight. Methanol was -added to the reaction solution, and the mixture was purified by HPLC by development with chioroform/methanol to give 33 mg (yield 49%) of the title compound. ·· ; 1H-NMR (DMSO-d6> 400 MHz) : δ 0.88 (t, J = 7.3 Hz, 3H), 1.08 (d, J = 6.6 Hz, 3H ) , 1.40 - 1.47 (m, 2H), 3.58 - 3.64 (m,. 1H), 3.97 (s, 3H), 3.99 (s, 3H), 5.98 (t, J = 8.1. Hz, 1H), 7.15 (d, J = 9.0 Hz, 2H), 7.37 (s, 1H), 7.46 (d, J = 9.0 Hz, 2H), 7.55 (s, 1H), 8.38 (s, 1H), 8.53 (s, 1H) Mass analysis, found (ESI-MS, m/z): 397 (M++l) Example N-Allyl-N' - 4-[ 6.7-Dimethoxy-4- quinazolinyl)oxy]phenyl}urea 4-[ ( 6, 7-Dimethoxy-4-guinazolinyl)oxy]aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml), and a solution of triphosgene (50 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, allylamine hydrochloride (31 mg) was added to the reaction solution, and the mixture was stirred at room temperature overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 21 mg (yield 33%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 3.73 - 3.76 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H), 5.07 - 5.21 (m, 2H), 5.84 - 5.92 (m, 1H), 6.28 (t, J = 5.6 Hz, 1H), 7.16 (d, J = 9.0 Hz, 2H), 7.38 (S, 1H), 7.47 (d, J = 9.0 Hz, 2H), 7.55 (s, 1H), 8.53 (s, 1H), 8.59 (s, 1H) Mass analysis, found (ESI-MS, m/z): 381 (M++l) .

Example 69: N-{4- [ ( 6.7-Dimethoxy-4-qu i nazolinyl ) -oxy ] henyl > -M ' - ( 2-propyny1 ) urea 4-[ ( 6, 7-Dimethoxy-4-quinazolinyl)oxy] aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml)> and a solution of triphosgene (50 mg) in chloroform was then added to the: solution.. The mixture was . stirred at, room temperature, for .30 min.. Next, propargylamin hydrochloride ( 31 mg ) was added to the reaction solution",- and. the mixture was. stirred at room temperature overnight.. - Methanol was added to the .reaction solution, and:, the- mixture was ^purified, by HPLC by. development; with, chloroform/methanol .:· to give 26 mg (yield 41%) of the title compound. .

H-NMR (DMSO-d6> 400 MHz) : δ 3.11 - 3.12- (m, 1H), 3.89 - 3.90 (m, 2H), 3.97 (s, 3H ) , : 3.99. ( s , 3H), 6.49 (t, J = 5.9 Hz, 1H), 7.17 (d, J = 9.0 Hz, 2H), 7.38 (s, 1H),. 7.48 (d, J = 8.8 Hz, 2H), 7.55 (s, 1H), 8.53 (s, 1H), 8.68 (s, IH) Mass analysis, found (ESI-MS, m/z): 379 (M++l) Example 7JL; N- ( 2.4-Difluorobenzyl ) - ' -{4- [ 16.7-dimethoxy-4-quinazolinyl ^oxy] phenyl }urea 4-[ ( 6, 7-Dimethoxy-4-quinazolinyl)oxy ] aniline ( 50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml), and a solution of triphosgene (50 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 2,4-difluorobenzylamine (22 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 32 mg 5 (yield 41%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 3.97 (s, 3H), 3.98 (s, 3H), 4.32 - 4.33 (m, 2H), 6.66 (t, J = 5.9 Hz, 1H), 7.06 - 7.10 (m, 1H), 7.16 (d, J = 8.8 Hz, 2H), 7.19 - 7.24 (m, 1H), 7.37 (s, 1H), 7.40 - 7.44 (m, 1H), 7.48 (d, J = 9.0 10 Hz, 2H), 7.55 (s, 1H), 8.52 (s, 1H), 8.69 (s, 1H) Mass analysis, found (ESI-MS, m/z): 467 (M++l) Example 71: N-{4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy] - phenyl }-N ' - ( 2-pyridylmethyl ) urea 4-[ ( 6, 7-Dimethoxy-4-quinazolinyl)oxy] aniline (50 15 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml)/ and' a solution of triphosgene (50 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for. 30 min. Next, 2,4- "*" " difluorobenzylamine (31 μΐ) was -added to the reaction 20 .solution, and. the mixture . was stirred at . room temperature overnight. Methanol was added to the reaction solution, and the mixture was purified by.. HPLC by development with chloroform/methanol to give 31 mg (yield 43%) of the title compound. 1H-NMR (DMS0-d6, 400 MHz): δ 3.42 (s, 2H),. 3.98 (s, 3H), 3.99 (s, 3H), 7.16 - 7,19 (m, 2H), 7.22 - 7.27 (m, 3H), 7.38 (s, 1H), 7.57 (s, 1H), 7.67 (d, J = 8.8 Hz, 2H), 7.88 - 7.92 (m, 1H), 8.46 - 8.48 (m, 1H), 8.54 (s, 1H), 8.87 (s, 1H), 12.19 (s, 1H) Mass analysis, found (FD-MS, m/z): 431 (M+) Example Ί2ι N-/2. -Difluorophenyl )-N' -{4- [ (6.7- djmethoxy-4-quina2olinyl)oxy ]phenyl >urea 4-[ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy] aniline (50 mg) was dissolved in chloroform (3 ml), and 2,4- 35 difluorophenyl isocyanate (24 μΐ) was then added to the solution. The mixture was heated under reflux overnight. The precipitated crystal was collected by filtration and was washed to give 55 mg (yield 72%) of the title compound.

XH-NMR (DMSO-d6 400 MHz): δ 3.98 (s, 3H) , 3.99 (s, 3H), 7.04 - 7.08 (m, 2H), 7.24 (d, J = 8.8 Hz, 2H), 7.29 - 7.35 (m, 1H), 7.38 (s, 1H), 7.54 (d, J = 9.0 Hz, 2H), 7.56 (s, 1H), 8.06 - 8.14 (m, 1H), 8.51 - 8.54 (m, 1H), 8.54 (s, 1H), 9.11 - 9.12 (m, 1H) Mass analysis, found (ESI-MS, m/z): 453 (M++l) Example 7_i_j N- 4-[ ( 6.7-Dimethoxy-4-quinazol inyl)oxy]-pheny )-N' - ( -fluorophenyl ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy ] aniline ( 50 mg) was dissolved in chloroform (3 ml), and p-fluorophenyl isocyanate (23 μΐ) was then added to the solution. The mixture was heated under reflux overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC . by development- with chloroform/methanol to give 26 mg (yield 36%) of the title compound.

^- MR (DMSO-d6, 400 MHz): δ 3.98 (s 3H), 3.9'9 (s, 3H) , 7.11 -· 7.15 (m, 2H) , 7.22 (d, J = 8...8 Hz , 2H ) , 7.38 (s, 1H) , 7.46 - 7.50 (m, 2H) , 7.54 (d, J = 9.0 Hz, 2H) , 7.5.6 (s, 1H), 8.54 ( s , lH) , 8.72-(s , 1H)...8.-75 (s, 1H) Mass analysis, found (ESI-MS, m/z): 435 (M++l) .

Example 111 N--f4-|" < 6.7-Dimethoxy-4-quinazo1 inyl ^oxy]-pheny1>-N' - ( 2-me hylphenyl ) urea 4-[ ( 6, 7-Dimethoxy-4-quinazolinyl)oxy] aniline (50 mg) was dissolved in chloroform (3 ml), and o-toluyl isocyanate (25 μΐ) was then added to the solution. The mixture was heated under reflux overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 30 mg (yield 41%) of the title compound.

^- MR (DMSO-d6, 400 MHz): δ 2.26 (s, 3H), 3.98 (s, 3H), 3.99 (s, 3H), 6.93 - 6.98 (m, 1H), 7.13 - 7.19 (m, 2H), 7.22 (d, J = 8.8 Hz, 2H), 7.38 (s, IH), 7.54 - 7.56 (m, 3H), 7.83 - 7.86 (m, 1H), 7.93 (s, 1H), 8.54 (s, 1H), 9.10 - 9.11 (m, 1H) Mass analysis, found (ESI-MS, m/z): 431 (M++l) Example 7_5__ N-{4- [ ( 6 , 7-Dimethoxy-4-qujnazolinyl )oxy ] -phenyl >- · - ( 2-methoxypheny1 \urea 4-[ (6,7-Dimethoxy-4-quinazolinyl)oxy]aniline (50 mg) was dissolved in chloroform (3 ml), and 2-methoxyphenyl isocyanate (27 μΐ) was then added to the solution. The mixture was heated under reflux overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 34 mg (yield 45%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 3.89 (s, 3H), 3.98 (s, 3H), 3.99 (s, 3H), 6.89 - 7.05 (m, 3H), 7.22 (d, J = 8.8 Hz, 2H), 7.38 (s, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.56 (s, 1H), 8.13 - 8.15 (m, 1H), 8.23 - 8.24 (m, ' 1H ) , 8.54 (s, 1H), 9.40 - 9.41 (m, lH) .

Mass analysis/ found (ESI-MS , m/z ) : 447 (Μ++1)· Example 76: N-{2-Chloro-4-[ /6r7-dimethoxy-4-quinazolinyl ) oxy ] phenyl }-N ' -ethylTirea 2-Chloro-4-[ ( 6, 7-dimethoxy-4-quinazolinyl )oxy ]- ■ aniline (200 mg) was dissolved in chloroform (5 ml). and triethylamine (1 ml) , and a solution of -triphosgene (179 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, ethylamine hydrochloride (246 mg) was added to the reaction solution, and the mixture was stirred at room temperature overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 159 mg (yield 65%) of the title compound. 1H-NMR (DMS0-d6, 400 MHz): δ 1.08 (t, J = 7.1 Hz, 3H), 3.11 - 3.16 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H), 6.96 (t, J = 5.6 Hz, 1H), 7.23 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.39 (s, 1H), 7.47 (d, J = 2.7 Hz, 1H), 7.55 (s, 1H), 8.02 (s, 1H), 8.20 (d, J = 9.3 Hz, 1H), 8.5V6 (s, 1H) Mass analysis, found (ESI-MS, m/z): 403 (M++l) Example 2J_i N-Buty1-N' - { 2-chloro-4 - [ ( 6.7-d i methoxy-4- qu inazol inyl \ ox ] henyl >urea 2-Chloro-4- [ { 6 , 7-dimethoxy-4-quinazolinyl ) oxy ] - aniline (50 mg) was dissolved in chloroform (5 ml) and triethylamine (1 ml), and a solution of triphosgene (45 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, butylamine (22 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature for additional 30 min. A saturated aqueous . sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. ;The chloroform layer was. dried over anhydrous, sodium sulfate.. .The solvent was removed by distillation under the reduced pressure. . The. residue was . purified by HPLC by development, with. chlOroform/methanol .. to . give. 30; mg . (yield 46% ) of the title compound . r . ^ .

. - . H-NMR - (DMSO-d6, 400 MHz ) : ■ δ .0.91- ( t , J = 7.3 Hz, 3H) , 1.31 - 1.46 (m, 4H) , 3.09· - 3.14 (m, 2H) , 3.97 (s, 3H), 3.99 (s, 3H), 6.96 (t,, J = 5.6 Hz, 1H), 7.23 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.39 (S, 1H), 7.47 (d, J = 2.7 Hz, 1H), 7.55. (s, 1H), 8.03 (s, 1H), 8.20 (d, J = 9.0 Hz, 1H) , 8.56 (s, 1H) Mass analysis, found (ESI-MS, m/z): 431 (M++l) Example 7_8j N-{2-Chloro-4- [ ( 6.7-dimethoxy-4-quinazolinyl ) oxy ]phenyl } - ' -pentylurea 2-Chloro-4-[ ( 6, 7-dimethoxy-4-quinazolinyl )oxy ] -aniline (50 mg) was dissolved in chloroform (5 ml) and triethylamine (1 ml), and a solution of triphosgene (45 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, amylamine (26 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature for additional 30 min. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 33 mg (yield 49%) of the title compound.

^-NMR (DMSO-d6, 400 MHz): δ 0.90 (t, J = 7.1 Hz, 3H), 1.24 - 1.34 (m, 4H), 1.43 - 1.48 (m, 2H), 3.08 - 3.14 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H), 6.97 (t, J = 5.1 Hz, 1H), 7.23 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.39 (s, 1H), 7.47 (d, J = 2.8 Hz, 1H), 7.55 (s, 1H), 8.03 (s, 1H), 8.20 (d, J = 9.0 Hz, 1H), 8.56 (s, 1H) Mass analysis, found (ESI-MS, m/z): 445 (M++l) Example 79 N- ( sec-Butyl ) -N' -{ 2-chT oro-4- [ (6.7- dimethoxy-4-quinazolinyl)oxy]phenyl}urea 2-Chloro-4- [ ( 6 , 7^dimethoxy-4-quinazolinyl ) oxy] - aniline (50. mg) was dissolved*™in chloroform (5 ml) and triethylamine (1 ml), and a solution of triphosgene (45 ;mg) in chloroform was then added to the solution. The mixture..was stirred at. room temperature for .30 min. Next, sec-butylamine (23 μΐ) was added to the reaction solution, and the mixture was stirred at. room temperature for additional 30 min. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 34 mg (yield 52%) of the title compound.

'H-NMR (DMSO-d6 400 MHz): δ 0.89 (t, J = 7.6 Hz, 3H), 1.09 (d, J = 6.6 Hz, 3H), 1.43 - 1.46 (m, 2H), 3.58 - 3.66 (m, 1H), 3.97 (s, 3H), 3.99 (s, 3H), 6.88 (d, J = 7.6 Hz, 1H), 7.22 (dd, J = 2.4 Hz, 9.3 Hz, 1H), 7.39 (s, 1H), 7.47 (d, J = 2.7 Hz, 1H), 7.55 (s, 1H), 7.98 (s, 1H), 8.23 (d, J = 9.0 Hz, lH), 8.55 - 8.56 (m, 1H) Mass analysis, found (ESI-MS, m/z): 431 (M++l) Example 8_0j N-Allyl-N ' --Γ 2-chloro-4- [ ( 6.7-dlmethoxy-4-quinazolinyl ^oxy]phenyl }urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinazolinyl ) oxy ] - aniline (50 mg) was dissolved in chloroform (5 ml) and triethylamine (1 ml), and a solution of triphosgene (45 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, allylamine hydrochloride (21 mg) was added to the reaction solution, and the mixture was stirred at room temperature for additional 30 min. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 45-mg. (yield 72%) of the title compound-.- , " . 1H-NMR (T>MSO-d6, 400. MHz): δ 3.76 - 3.79 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H)> 5.10 - 5.24 (m 2H) , 5^85 -5.94 (m,. 1H) , .7.11 (t, . J, =..5.4 Hz, 1H) , 7.24 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7,39 (s, 1H), 7.49 (d, J = 2.7 Hz, 1H), 7.55 (s, 1H), 8.14 (s, 1H), 8.19 (d, J = 9.0 Hz, 1H) , 8.56 (s, 1H) Mass analysis, found (ESI-MS, m/z): 415 (M++l) Example : BJJE N--f 2-Chloro-4-r [ 6.7-dimethoxy-4-quinazolinyl^oxy]phenyl }-N'-(2-propyny1 )urea 2-Chloro-4- [ ( 6, 7-dimethoxy-4-quinazolinyl )oxy ] -aniline (50 mg) was dissolved in chloroform (5 ml) and triethylamine (1 ml), and a solution of triphosgene (45 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, propargylamine hydrochloride (21 mg) was added to the reaction solution, and the mixture was stirred at room temperature for additional 30 min. The precipitated crystal was collected by filtration and was washed to give 38 mg (yield 61%) of the title compound.

'H-NMR (DMS0-d6, 400 MHz): δ 3.16 - 3.17 (m, 1H), 3.93 - 3.95 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H), 7.25 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.30 (t, J = 5.6 Hz, 1H), 7.39 (s, 1H), 7.50 (d, J = 2.7 Hz, 1H), 7.55 (s, 1H), 8.16 (d, J = 9.3 Hz, 1H), 8.18 (s, 1H), 8.56 (s, 1H) Mass analysis, found (ESI-MS, m/z): 413 (M++l) Example 8_2_ί N- { 2-Chi oro-4- [ ( 6.7-d i methoxy-4 -qnina ol inyl oxy ] phenyl >-N f 2.4-difluorobenzyl lurea 2-Chloro-4-[ ( 6 , 7-dimethoxy-4-quinazolinyl )oxy ]-aniline (50 mg) was dissolved in chloroform (5 ml) and triethylamine (1 ml), and a solution of triphosgene (45 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 2 , 4-difluorobenzylamine (22 μΐ:)"" was added to the reaction solution, and the mixture was stirred at room temperature for additional. 30 min. The precipitated crystal was collected, by filtration and was washed, to give 48 mg: (yield 64%) of' the title compound.

^H-NMR ( DMSO-d6 , 400 MHz ) : ·δ .3.97 (s, 3H) , 3.99 (s, 3H) , 4.33. - 4.36 (m, 2H) , 7.08 - · 7·.12 (m, 1Ή) , 7;.22 -7.28·. (m,: 2H), 7.39 (s, 1H) , 7.42 - 7.46 (ιη,..ΐΗ>, .7.49. (d, J = 2.7. Hz, 1H), 7.54 (s, 1H), 8.18 - 8.20 (m, 2H), 8.56 (s, 1H) . . Mass analysis, found (ESI-MS, m/z ) : .501. (M++l.) Example S3_i N--T 2-Ch] oro-4- [ ( 6.7-diniP hnyy-4-quinazolinyl )oxy ]phenyl}- ' - ( 2-pyridylmethyl ) rea 2-Chloro-4-[ ( 6 , 7-dimethoxy-4-quinazolinyl )oxy ] -aniline (50 mg) was dissolved in chloroform (5 ml) and triethylamine (1 ml), and a solution of triphosgene (45 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 2- (methylamino ) pyridine (19 μΐ) was added to the reaction solution, and the mixture was stirred at 60°C for additional one hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform.

The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 26 mg (yield 37%) of the title compound. 1H-NMR (CDC13, 400 MHz): δ 3.51 (s, 2H), 4.07 (s, 3H), 4.07 (s, 3H), 7.03 - 7.10 (m, 2H), 7.19 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.35 (s, 1H), 7.36 (d, J = 2.7 Hz, 1H), 7.54 (s, 1H), 7.76 - 7.81 (m, 1H), 8.38 - 8.43 (m, 1H), 8.56 (d, J = 9.0 Hz, 1H), 8.64 (s, 1H), 13.53 (s, 1H) Mass analysis, found (ESI-MS, m/z): 466 (M++l) Example 8_5_j N- 2-Chloro-4-[ ( 6.7-dimethoxy-4-qn i nazolinyl Vox ]phenyl }-N ' - ( 4-fluorophenyl ) urea ■ ■-'· 2-Chloro-4-[ (6, 7-dimethoxy-4-quinaz0linyl)oxy]-aniline (50 mg) was dissolved in chloroform (5 ml), and p-fluorophenyl isocyanate (21 μΐ). was then added to the solution. The mixture was stirred at · 60°C for one hr. The precipitated crystal was collected by "filtration and was : washed to give 57 mg- (yield 81%) of the title compound . \ /-■: '.· ;. - '\ ■'''■''· "'V ■ . - .·. .. .. . .- ... AH-NMR (DMSO-dj, 400 -MHz'")-:' δ 3,98· (s,- 3H) , 3.99 ( s , 3H) , 7.13 - 7.17 (m, 2H), 7.30 (dd, j:= 2.4 Hz, 8.8 Hz, 1H), 7.40 (s, 1H), 7.48 - 7.51 (m, . 2H ) , 7.55 - 7.56 (m, 2H), 8.21 (d, J = 9.0. Hz, 1H)., 8.31 (s, 1H), 8.57 (s, 1H) Mass analysis, found (ESI-MS, m/z): 469 (M++l) Example ■ 86: N-{2-Ch1 oro-4- [ ( 6.7-d i inethoxy-4-qu i nazol iny1 ) oxy ] phenyl }-N ' - ( 2-methoxypheny1 ) urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinazolinyl ) oxy ] -aniline (50 mg) was dissolved in chloroform (5 ml), and 2-methoxyphenyl isocyanate (24 μΐ) was then added to the solution. The mixture was stirred at 60°C for one hr. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 39 mg (yield 54%) of the title compound.

^-NMR (DMSO-d6, 400 MHz): δ 3.90 (s, 3H), 3.98 (s, 3H), 3.99 (s, 3H), 6.89 - 7.05 (m, 3H), 7.29 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.40 (s, 1H), 7.54 (d, J = 2.7 Hz, 1H), 7.56 (s, 1H), 8.09 - 8.16 (m, 2H), 8.58 (s, 1H), 8.96 - 9.02 (m, 2H) Mass analysis, found (ESI-MS, m/z): 418 (M++l) Example 8_2J N-{2-Chloro-4-[ ( 6.7-dimethoxy-4- guinazoliny1 ) oxy ] phenyl> -N · - ( 5-chloro-2-pyri dy1 ) urea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinazolinyl )oxy] -aniline (50 mg) was dissolved in chloroform (5 ml) and triethylamine (1 ml), and a solution of triphosgene (45 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, 2-amino-5-chloropyridine (23 mg) was added to the reaction solution, and the mixture was stirred at 60°C for additional one hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer wa∑S"" dried over anhydrous sodium sulfate. - The solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol - to give 39 mg (yield 53%) of the title compound.

'H-NMR (DMSO-d6, 400 MHz): δ 3.98 (s, 3H), 4.00 (s, 3H), 7.33 (dd, J = 2.7 Hz, 9.3 Hz, 1H), 7.40 (s, 1H), 7.43 - 7.48 (m, 1H), 7.56 (s, 1H), 7.60 (d, J = 2.7 Hz, 1H), 7.91 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 8.35 (d, J. = 8.8 Hz, 1H), 8.40 (d, J = 2.4 Hz, 1H) , 8.58 (s, 1H), 10.17 (s, 1H) Mass analysis, found (ESI-MS, m/z): 486 (M++l) Example 8_8_j N-{4-[ ( 6.7-Dimethoxy-4-quinazo] iny] ^oxy]-2- luorophenyl }-N' -propylurea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl ) oxy] -2-fluoro-aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.3 ml), and a solution of triphosgene (47 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min.

Next, propylamine (20 μΐ) was added to the reaction solution, and the mixture was further stirred at room temperature overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 9 mg (yield 14%) of the title compound.

'H-NMR (DMSO-d6, 400 MHz): δ 0.90 (t, J = 7.6 Hz, 3H), 1.43 - 1.49 (m, 2H), 3.05 - 3.10 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H), 6.61 (t, J = 5.6 Hz, 1H), 7.05 - 7.07 (m, 1H), 7.27 - 7.31 (m, 1H), 7.38 (s, 1H), 7.54 (s, 1H), 8.14 - 8.19 (m, 1H), 8.28 - 8.29 (m, 1H), 8.55 (s, 1H) Mass analysis, found (ESI-MS, m/z): 401 (M++l) Example 8_2J N-B yT -N ' -{4- [ ( 6 r 7-d imethoxy-4- qninazol i nyl )oxy] -2-fluoropheny] >urea 4-[ (e^-Dimethoxy^-quinazolinylJoxyl^-fluoro- aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.3 ml), and a solution of triphosgene (47 mg) in chloroform was . then added to the solution. The mixture was stirred at. room temperature" for 30 min.

Next, , butylamine (24 μΐ) was added ^ and the mixture was • further stirred at- room temperature overnight. Methanol was added , to the. reaction ,solution;, and the* mixture was purified by HPLC by development with chloroform/methanol to give 25 mg (yield 38%) of the title compound.

XH-NMR (DMS0-d6, 400 MHz): δ 0.91 (t, J = 7.3 Hz, 3H), 1.30 - 1.47 (m, 4H), 3.09 - 3.13 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H), 6.58 (t, J = 5.6 Hz, 1H), 7.04 - 7.07 (m, 1H), 7.28 - 7.31 (m, 1H), 7.38 (s, 1H), 7.54 (s, 1H), 8.14 - 8.19 (m, 1H), 8.26 - 8.28 (m, 1H), 8.55 (s, 1H) Mass analysis, found (ESI-MS, m/z): 415 (M++l) Example 9JJj N-( sec-Butyl )-N'-{4-[ < f> r 7-di¾ethoxy-4-quinazol inyl ) oxy ] -2-fluoropheny1 >urea 4-[ ( 6, 7-Dimethoxy-4-quinazolinyl)oxy ]-2-fluoro-aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.3 ml), and a solution of triphosgene (47 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min.

Next, sec-butylamine (25 μΐ) was added to the reaction solution, and the mixture was further stirred at room temperature overnight. Methanol was added to the reaction solution, and the mixture, was purified by HPLC by development with chloroform/methanol to give 12 mg (yield 18%) of the title compound.

H-NMR (DMSO-d6, 400 MHz): δ 0.89 (t, J = 7.6 Hz, 3H), 1.08 (d, J = 6.6 Hz, 3H), 1.39 - 1.48 (m, 2H), 3.58 - 3.64 (m, 1H), 3.97 (s, 3H) , 3.99 (s, 3H), 6.51 (d, J = 7.6 Hz, 1H), 7.04 - 7.08 (m, 1H), 7.30 (dd, J = 2.4 Hz, 11.7 Hz, 1H), 7.39 (s, 1H), 7.54 (s, 1H), 8.16 - 8.22 (m, 2H), 8.56 (s, 1H) Mass analysis, found (ESI-MS, m/z): 415 (M++l) Example 91 N-Allyl-N'--f4-[ ( 6.7-dimethoxy-4-quinazolinyl)oxy ] -^--fluorophenyl-}urea 4-[ ( 6, 7-Dimethoxy-4-quinazo.linyl )oxy]-2,-fluoro- -aniline (5.0 mg) was dissolved in chloroform (3 ml) and triethylamine (0.3- ml), and a solution, of triphosgene (47 mg). in chloroform was then added, to the solution. The mixture was stirred at room temperature for 30 min. Next, allylamine hydrochloride (-30 mg) was added to the reaction.·. solution,, and. the mixture . was; further, stirred at room temperature overnight. Methanol was added to the reaction solution,, and the mixture was purified by HPLC by development with chloroform/methanol to give 18 mg (yield 28%) of the title compound.

JH-NMR (DMSO-d6, 400 MHz): δ 3.75 - 3.79 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H), 5.08 - 5.22 (m, 2H), 5.84 -5.94 (m, 1H), 6.72 (t, J = 5.9 Hz, 1H), 7.06 - 7.08 (m, 1H), 7.30 - 7.33 (m, 1H), 7.39 (s, 1H), 7.54 (s, 1H), 8.13 - 8.18 (m, 1H), 8.40 (s, 1H), 8.56 (s, 1H) Mass analysis, found (ESI-MS, m/z): 399 (M++l) Example i2j N-{4-[ < 6.7-Dimethoxy-4-quinazo1 iny] )oxy]-2-fluorophenyl}-N'-f 2-propynyl )urea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl ) oxy] -2-fluoro-aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.3 ml), and a solution of triphosgene (47 mg) in chloroform was then added to the solution.

The mixture was stirred at room temperature for 30 min.

Next, propargylamine hydrochloride (29 mg) was added to the reaction solution, and the mixture was further 5 stirred at room temperature overnight. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by 10 distillation under the reduced pressure.. . The residue was washed with chloroform to give 21 mg (yield 33%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 3.15 (t, J = 2.4 Hz, 1H) , 3.91 - 3.94 (m, 2H), 3.97 (s, 3H) , 3.99 (s, 3H), 15 7.07 - 7.11- (m, 1H), 7.33 (dd, J = 2.4 Hz, 11.7 Hz, 1H), ■■:·· . - 7.3 (s, lH) , 7.54 (s, 1H) , 8.09 - 8.15 (m, 1H) , 8.47 - .8.48. (m, 1H) , 8.56 (s, 1H) .. ·= , .-.· v : ■...:■;.;...·..„.. -.Mass. analysis,. -m/z.,)..: 39.7- (M++l) ; Kxampfr - 93: N- (2 , 4^Difluorobenzyl-V-N■· - 4^ [ 6.7- ,·.■ 20 .dimethoxyT-4-quinazolinylAoxy ]-2-fluorophenyl >urea ., : " : ·.':·.·■■:.:. 4- [ (-.6;, 7-Dimethoxy-4-quinazolinyl ) oxy ]—2-fluoro- aniline (;50 ,-mg) was diss.olv.ed..· in. chloroform 3 ml)., and, : triethylamine (0.3 ml),- and a ..solution of triphosgene , (47 mg);. in chloroform, .was then .added to the solution. .25. The mixture was stirred at... room temperature for 30 min.

Next, 2 , 4-difluorobenzylamine (28 μΐ) was added to the reaction solution, and the mixture was further stirred at room temperature overnight. The precipitated crystal was collected by filtration and was washed to give 20 mg 30 (yield 26%) of the title compound.

:H-NMR (DMS0-d6, 400 MHz): δ 3.97 (s, 3H), 3.99 (s, 3H), 4.34 (d, J = 5.8 Hz, 2H), 7.07 - 7.11 (m, 3H), 7.21 - 7.27 (m, 1H), 7.30 - 7.33 (m, 1H), 7.39 (s, 1H), 7.41 - 7.47 (m, 1H), 7.54 (s, 1H), 8.12 - 8.16 (m, 1H), 8.46 35 - 8.47 (m, 1H), 8.55 (s, 1H) Mass analysis, found (FD-MS, m/z): 484 (M+) Example ϋι N- 12.4-Difluorophenyl ) -N ' -{ 4- [ ( 6.7- dimethoxy-4-quinazolinyl)oxy ]-2-fluorophenyl}urea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy ]-2-fluoro-aniline (50 mg) was dissolved in chloroform (3 ml), and 2 , 4-difluorophenyl isocyanate (29 μΐ) was then added to the solution. The mixture was stirred at 60°C overnight. The precipitated crystal was collected by filtration and was washed to give 50 mg (yield 67%) of the title compound.

XH-NMR (DMSO-d6, 400 MHz): δ 3.98 (s, 3H), 3.99 (s, 3H), ' 7.04 - 7.08 (m, 1H), 7.13 - 7.15 (m, 1H), 7.29 -7.40 (m, 3H), 7.55 (s, 1H), 8.10 - 8.23 (m, 2H) , 8.57 (s, 1H) 8.97 - 9.04 (m, 2H) Mass analysis, found (ESI-MS, m/z): 471 (M++l) Example 95: N-.{4-[ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy ]-2- luorophenyl } -N ' - ( 2-methylpheny1 ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl ) oxy ] -2-fluoro-aniline (50 mg) was dissolved in chloroform (3 ml), and o-toluyl isocyanate (30 μΐ) was then added to the solution. The mixture was stirred at 60°C overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 17 mg (yield 24%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 2.27 (s, 3H), 3.98 (s, 3H), 3.99 (s, 3H), 6.95 - 6.98 (m, 1H), 7.12 - 7.20 (m, 3H), 7.36 - 7.39 (m, 2H), 7.55 (s, 1H), 7.86 (d, J = 7.8 Hz, 1H), 8.21 - 8.26 (m, 1H), 8.35 (s, 1H), 8.57 (s, 1H) , 9.00 - 9.02 (m, 1H) Mass analysis, found (ESI-MS, m/z): 449 (M++l) Example 9_6j N-{4-[ (6.7-Dimethoxy-4-quina¾ol inyl)oxy]-2-fluorophenyl > -N ' - ( 2-methoxypheny1 ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy J -2-fluoro-aniline (50 mg) was dissolved in chloroform (3 ml), and 2-methoxypheny1 isocyanate (32 μΐ) was then added to the solution. The mixture was stirred at 60°C overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/metha ol to give 22 mg (yield 30%) of the title compound. 1H-NMR (D S0r-d6 400 MHz): δ 3.89 (s, 3H), 3.98 (s, 3H), 3.99 (s, 3H) , 6.88 - 7.04 (m, 3H), 7.11 - 7.14 (m, 1H), 7.35 - 7.39 (m, 1H), 7.40 (s, 1H), 7.56 (s, 1H), 8.12 - 8.15 (m, 1H.),. 8.19 - 8.25 (m, 1H), 8.57 (s, 1H), 8.75 - 8.78 (m, 1H), 9.26 - 9.29 (m, 1H) Mass analysis, found (ESI-MS , m/z ) : 465 (M++l) Example 97: N-{4-[ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy]-3-methylpheny1}-N' -propylurea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl ) oxy] -3-methyl-aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml), and a solution of triphosgene (48 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min.

Next, propylamine; (20 μΐ ) was added to the reaction solution, and the mixture was further stirred at room temperature overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 30 mg (yield 47%) of the title compound.

'H-NMR (DMSO-d6, 400 MHz): δ. 0.89 (t, J = 7.5 Hz, 3H), 1.41 - 1.50 (m, 211) , 2.03 (s, 3H), 3.03 - 3.08 (m, 2H), 3.98 (s, 3H), 3.99 (s, 3H), 6.13 (t, J = 5.4 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 7.28 (dd, J = 2.4 Hz, 8.5 Hz, 1H), 7.36 (d, J = 2.4 Hz, 1H), 7.38 (s, 1H), 7.58 (s, 1H), 8.39 (s, 1H), 8.50 (s, 1H) Mass analysis, found (ESI-MS, m/z): 397 (M++l) Example 98; N-Butyl-N' -{4- [ ( 6.7-dimethoxy-4-guinazolinyl ) oxy ] -3-methylpheny-i >urea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy ] -3-methyl-aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml), and a solution of triphosgene (48 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min.

Next, butylamine (24 μΐ) was added to the reaction solution, and the mixture Was further stirred at room Ill 2.4 Hz, 8.5 Hz, 1H) , : 7.39 (s, 1Ή ) , 7.43 (d, J = 2.4 Hz, 1H), 7.46 - 7.49 (m,; 2H), 7.59 (s, 1H), 8.51 (s, 1H), 8.66 (s, 1H) ,. 8.70 (s> 1H) Mass analysis, found (ESI-MS, m/z): 449 (M++l) Example 101; N- {4-[ ( 6.7-Dimethoxy-4^-quina oliny ) oxy] -3-methylpheny1}-N ' - ( 2-methoxyphenyl ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy ] -3-methyl-aniline (50 mg) was dissolved in chloroform (3 ml), and 2-methoxyphenyl isocyanate (26 μΐ) was then added to the solution. The mixture was heated under reflux overnight. Methanol was added to the reaction solution, and the mixture was pu&ified by ' HPLC by development with chloroform/methanol to give 41 mg (yield 55%) of the title compound. , ■■· 'H-NMR (DMSO-d6, .400 MHz): 5 2.07 (s, 3H), 3.89 (s, 3H), 3.99 (s,= 3H), 3.99 (s, 3H), 6.88 - 6.97 (m, 2H), 7.01 - 7.03. (m, 1H), 7.1'2 (d, J = 8.5 Hz, 1H), 7.35 (dd,. J = 2.4 Hz, 8.5 Hz, 1H , 7-39 (s, 1H), 7.44 (d, J = 2.4 Hz, 1H), 7.60 (s, lH); 8.13 - 8.15 (m, 1H), 8.23 (s, 1H), 8.52 (s, 1H), 9.33 (s, 1H) Mass analysis,, found (ESI-MS, m/z) : 461 (M++l) Example 102 : N-{4- [ ( 6 , 7-Dimeth0xy-4-quinazolinyl ) oxy] -2-meth lpheny1>- ' -pr'opylurea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy ;| -2-methyl-aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2. ml), and a solution of triphosgene (48 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min.

Next, propylamine (20 μΐ) was added to the reaction solution, and the mixture was further stirred at room temperature overnight. Methanol ' was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 30 mg (yield 47%) of the title compound.

:H-NMR (DMS0-d6, 400 MHz): δ 0.90 (t, J = 7.3 Hz, 3H), 1.42 - 1.51 (m, 2H), 2.21 (s, 3H), 3.04 - 3.09 (m, 2H), 3.97 (s, 3H),; 3.9? (s, 3H), 6.53 (t, J = 5.6 Hz, 1Η), 7.02 (dd, J =.2.7 Hz, 8.8 Hz, 1H), 7.08 (d, J = 2.7 Hz, 1H), 7.37 (s,. 1H) , 7.54 (s, 1H), 7.65 (s, 1H), 7.85 (d, J = 8.8 Hz, 1H), 8.53 (s, 1H) Mass analysis, found (ESI-MS, m/z): 397 (M++l) Example 103; ; N-Butyl-N ' -{4- [ ( 6 , 7-dimethoxy-4-quinazolinyl ;ioxyj-2-methylphenyl}urea 4- [ ( 6 , 7 Dimethoxy-jl-quinazolinyl ) oxy] -2-methyl-aniline (50 mg) was dissolved in chloroform (3 ml) and triethylamine (0.2 ml), and a, solution of triphosgene (48 mg) in chloroform was then added to the solution. The mixture was. stirred at room temperature for 30 min.

Next, butylamine (24 μΐ) was added to the reaction solution, and the mixture was further stirred at room temperature overnight., Methanol was added to the reaction solution, . and the mixture was purified by HPLC by development with /chloroform/methanol to give 37 mg (yield 56%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 0.92 (t, J = 7.1 Hz, 3H), 1.31 - 1.48 (m, 4H), 2.21 (s, 3H), 3.08 - 3.13 (m, 2H), 3.97 (s, 3H), 3.99 (s, 3H), 6.50 (t, J = 5.4 Hz, 1H), 7.02 (dd, J = 2.7 Hz, 8.8 Hz, 1H), 7.08 (d, J = 2.7 Hz, 1H), 7.37 (s'i, 1Ή), 7.54 (s, 1H), 7.64 (s, 1H), 7.86 (d, J = 8.8 Hz, 1H), 8.53 (s, 1H) Mass analysis^; found (ESI-MS, m/z): 411 (M++l) Example 104 N- ( 2.4-Difluorophenyl ) -N ' -{4- [ ( 6 , 7-dimethoxy-4-quiriazQlinyl)oxy]-2-methylphenyl}urea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy] -2-methyl-aniline (50 mg) was dissolved in chloroform (3 ml), and 2, 4-difluorophenyl isocyanate (23 μΐ) was then added to the solution. The mixture was heated under reflux overnight. The precipitated crystal was collected by filtration and was washed to quantitatively give the title compound.

^- MR (DMSO-d6, 400 MHz): 5 2.29 (s, 3Η)·, 3.98 (s, 3H), 3.99 (s, 3H), 7.03 - 7.11 (m, 2H), 7.16 (d, J = 2.7 Hz, 1H), 7.29, - 7.35 (m,| 1H) , 7.38 (s, 1H), 7.55 (s, 1H), 7.87 - 7.90 (m, lH), 8.13' - 8.19 (m, 1H), 8.36 - 8.39 (m, 1H), 8.55 (s, 1H) , 8-92 - 8.95. (m, lH) Mass analysis,! found (ESI-MS, m/z): 467 (M++l) Example 105; N-{4-[ ( 6.7-Dimethoxy-4-quinazolinyl ^oxy]-2- methylphenyl > -N ''- ( 4-flnorophenyl ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy] -2-methyl- aniline (50 mg) was dissolved in chloroform (3 ml), and p-fluorophenyl isocyanate (22 μΐ) was then added to the solution. The mixture was heated under reflux overnight. The precipitated crystal was collected by filtration and was washed to quantitatively give the title compound.

JH-NMR (DMS0-d6i, 400 MHz): 6 2.28 (s, 3H), 3.98 (s, 3H), 3.99 (s, 3H), 7.08 - 7.15 (m, 4H), 7.38 (s, 1H), 7.47 - 7.50 (m, 2H), 7.55 (s, 1H), 7.84 - 7.88 (m, 1H), 7.98 (s, 1H), 8.55 (s, 1H), 9.03 - 9.05 (m, 1H) Mass analysis, found (ESI-MS, m/z): 449 (M++l) Example 106: N-{4-[ < 6 .7-Dimethoxy-4-quina o1 inyHoxy]-2-methylphenyl}-N'- ( 2-methoxyphenyl ) urea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl ) oxy ] -2-methyl- aniline (50 mg) was dissolved in chloroform (3 ml), and 2-methoxyphenyl isocyanate (26 μΐ) was then added to the solution. The mixture was heated under reflux overnight. The precipitated crystal was collected by filtration and was washed to give 70 mg (yield 95%) of the title compound . 1H-NMR (DMSO-d6, 400 MHz): δ 2.29 (s, 3H), 3.90 (s, 3H), 3.98 (s 3H),' 3.99 '( s , 3H) , 6.87 - 6.97 (m, 2H), 7.02 - 7.04 (m, 1H) , 7.08 (dd, J = 2.9 Hz, 8.8 Hz, 1H), 7.14 (d, J = 2.7 Hz, 1H), 7.38 (s, 1H), 7.55 (s, 1H), 7.84 (d, J = 8.8 Hz, 1H), 8.13 - 8.15 (m, 1H), 8.55 (s, 1H), 8.58 (s, 1H), 8.61 - 8.62 (m, 1H) Mass analysis, found (ESI-MS, m/z ) : 461 (M++l) Example 107: N-{4^- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy] -2 -nitrophenyl}-^' -propylurea 4- [ ( 6 , 7-Dimethoxy-4-quinazolinyl )oxy]-2-nitro-aniline (50 mg) was dissolved in chloroform (10 ml) and triethylamine (0.2 ml), and a solution of triphosgene (43 mg) in chloroform was then added to the solution. anhydrous tetrahydrofuran ( 30 ' ml ) , and sodium hydride (60 wt% , .8;8. mg). was•■•■added to the solution. The mixture was stirred at room temperature for 15 min. Next, chloromethyl methyl - ether ( 67 μΐ) was added to the reaction solution, and ithe mixture was stirred at room temperature for, additional · 30. min. The solvent was removed by distillation under the reduced pressure, and water was added to. the residue. The mixture was extracted with , chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was : urified ' by HPLC by development with chlorofofm iTie'thanol: to give 18 mg (yield 18%) of the title compound.

JH-N R (DMSO-d6, ■ 400 MHz) : δ 0.89 (t, J = 7.6 Hz, 3H), 1.46 - 1.55 (m, 2Ή) , 3.20 (br, 2H), 3.48 (s, 3H), 4.07 (s, 3H), 4.08 (s, 3H), 4.54 (br, 2H), 7.29 (dd, J = 2.7 Hz, 8.5 Hz, 1H), 7.37 (s, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.50 (s, 1H) , 7.50 (d, J = 2.7 Hz, 1H), 8.66 (s, 1H) ' '■ r', '. V Mass analysis, found (ESI-MS, m/z): 461 (M++l) Example 110: -Acetyl-N-{2-chloro-4- [ ( 6 , 7-dimethoxy-4-quinazoliny1 )oxy ]phenyl>- ' -propylurea N-{ 2-Chlorio-4- [ ( 6 , 7-dimethoxy-4-quinazolinyl ) oxy] -phenyl}-N ' -propylurea (100 mg) was dissolved in anhydrous tetrahydrofuran (30 ml), and sodium hydride (60 wt%, 88 mg) was added to the solution. The mixture was stirred at room temperature for 15 min. Next, acetyl chloride (63 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature for additional 2 hr. The solvent was removed by distillation under the reduced pressure, and water was added to the residue. The mixture was extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/acetone to give 27 mg (yield 26%) of the title compound.

^-NMR (DMSO-d6, . 400 MHz):, δ 0.98 (t, J = 7.3 Hz, 3H), 1.59 - 1.68 (m, 2H), 2.04 (s, 3H), 3.27 - 3.36 (m, 2H), 4.07 (s, 3H), 4.08 (s, 3H), 7.31 - 7.33 (m, 1H), 7.35 (s, 1H), 7.41' (d, J = 9.0 Hz, 1H), 7.50 - 7.51 (ra, 2H), 8.63 (s, 1H), 9.08 (br, 1H) Mass analysis, found (ESI-MS,- m/z) : 459 (M++l) Example ; 111 ; N'-{2-Chloro-4- [ ( 6.7-dimethoxy-4- quinazolinyl ) oxy ] phenyl } -N-methyl-N-propylurea 2-Chloro-4-[ ( 6 , 7-d methoxy-4-quinazolinyl )oxy ]- aniline (56 mg), was dissolved in chloroform (4 ml) and triethylamine (0.3, ml), and a solution of triphosgene (50 mg) in chloroform was then added to the solution. The mixture was' stirred at room temperature for 30 min. Next, N-methylpropylamine (26 μΐ ) was added to the reaction solution,, and the mixture was stirred at room f' ' . temperature for ^additional one hr. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol . The solvent was removed by distillation, and the resultant crystal was washed. with hexane to give 42 mg (yield 58%) of the title compound.

'H-NMR (DMSO-d6, 400 MHz): δ 0.99 (t, J = 7.3 Hz, 3H), 1.64 -.1.74 (m, 2E\, 3.08 (s, 3H), 3.34 (t, J = 7.6 Hz, 2H), 4.07 (s, 3H), 4.08 (s, 3H), 7.00 (s, 1H), 7.17 (dd, J = 2.7 Hz, 9.3 Hz, 1H), 7.31 (d, J = 2.7 Hz, 1H), 7.38 (s, 1H), 7.53 (s, 1H), 8.41 (d, J = 9.0 Hz, 1H) , 8.64 (s, lH) Mass analysis, found (ESI-MS, m/z): 431 (M++l) Exam le 112'·; ; N'-{2-Chloro-4-[ ( 6.7-dimethoxy-4-quinazolinyl) oxy] phenyl }-N-ethyl-N-propylurea 2-Chloro-4- [ ( 6, 7-dimethoxy-4-quinazolinyl )oxy ] -aniline (80 mg) was dissolved in chloroform (3 ml) and triethylamine (0.3/ ml), and a solution of triphosgene (72 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 15 min. Next, N-ethylpropylamine (44 μΐ) was added to the reaction solution, ; arid the mixture was stirred at room temperature for additional 30 min. Methanol was added to the reaction solution, and the mixture was purified by HPLC by . development with chloroform/methanol. The solvent was removed by distillation. The resultant crystal . was washed witlv hexane to give 40 mg (yield 37%) of the title compound. 1H-NMR (DMSO-d6, 400 MHz): δ 1.00 (t, J = 7.3 Hz, 3H), 1.28 (t, J, = 7.1 Hz, 3H), 1.69 - 1.74 (m, 2H), 3.32 (t, J = 7.6 Hz, 2H), 3.43 (q, J = 7.1 Hz, 2H), 4.07 (s, 3H), 4.07 (s, 3H), 7.02 (s, IE), 7.17 (dd, J = 2.9 Hz, 9.2 Hz, 1H), 7.31 (d,, J = 2.7 Hz, 1H), 7.36 (s, 1H), 7.53 (s, 1H), 8.42 (d, J. = 9.0 Hz, 1H), 8.63 (s, 1H) Mass analysis, found (ESI-MS, m/z): 445 (M++l) Example ΊΊ3: N'-{2-Chloro-4-[ ( 6.7-dimethoxy-4-quinazolinyl )oxy]phenyl}-N, N-dipropylurea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinazolinyl )oxy] -aniline (100 mg) was dissolved in chloroform (3 ml) and triethylamine (0.3 ml), and a solution of triphosgene (90 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 15 min. Next, dipropylamirie (62 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature for additional 30 min. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol. The solvent was removed by distillation, and the resultant crystal was washed with .hexane to give 48 mg (yield 35%) of the title compound.

^H-NMR (DMSO-d6, 400 MHz): 6 0.99 (t, J = 7.3 Hz, 6H), 1.66 - 1.76 (m, 4H), 3.32 (t, J = 7.8 Hz, 4H), 4.07 (s, 3H), 4.07 (s, 3H), 7.03 (s, 1H), 7.16 (dd, J = 2.7 Hz, 9.3 Hz, 1H), 7.31 (d, J = 2.7 Hz, 1H), 7.34 (s, 1H), 7.52 (s, 1H), 8.43 (d, J = 9.0 Hz, 1H), 8.63 (s, 1H) Mass analysis, found (ESI-MS, m/z): 459 (M++l) Example 114: N-Butyl- ' -{2-chT oro-4- [ ( .7-dimethoxy-4-quinazolinyl) oxy ]phenyl}-N-methylurea .' ' . ·'; 1L8 2-Chloro-4-[ (6 ,7-dimethoxy-4-quinazolinyl )oxy ]-aniline (80 mg) was: dissolved -in chloroform (3 ml) and triethylamine (.0.3 ml),, and a solution of triphosgene (72 mg) in chloroform was then added to the solution. The mixture was stirred' at room temperature for 15 min.

Next, N-methylbutylamine (43 μΐ) was added to the reaction solution, and the mixture was stirred at room temperature for additional 30 min. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development, with chloroform/methanol. The solvent was removed by distillation, and the resultant crystal was 1washed "with hexane to give 26 mg (yield 24%) of the title compound.

'H-NMR (DMSO-d6, 400 MHz): δ 0.99 (t, J = 7.3 Hz, 3H), 1.3.8 - 1.43 (m,, 2H), 1,62 - 1.66 (m, 2H), 3.07 (s, 3H), 3.40 (t, J = 7.3 Hz, 2H), 4.07 (s, 3H), 4.07 (s, 3H), 7.00 (s, 1H ) , 7.17 (dd, J = 2.7 Hz, 9.3 Hz, 1H) , 7.31 ( d , J = 2.7, Hz, 1jH ) , 7.36. (s, 1H), 7.53 (s, 1H), 8.41 (d, J = 9.3 Hz, 1H)„ 8.63 (s, 1H) Mass analysis, found (ESI-MS, m/z): 445 (M++l) Example j 115; ; ' N'--f 2-Chloro-4- [ ( 6.7-dimethoxy-4-quinazoliny1 ) oxy ]phenyl}-N- ( 4-chloropheny1 ) -N-methylurea 2-Chloro-4- [ ( 6 , 7-dimethoxy-4-quinazolinyl ) oxy ] -aniline (80 mg) was dissolved in chloroform (3 ml) and triethylamine (0.3 ml), and a: solution of triphosgene (72 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 15 min. Next, 4-chloro-N-methylaniline (35 μΐ) was added to the reaction solution, and the mixture was heated under reflux for additional 30 min. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development 'with chloroform/methanol, and the solvent was removed by distillation. . The resultant crystal was washed with ether to g ve 83 mg (yield 69%) of the title compound. :' ^- R (DMSO-d6, 400 MHz): δ 3.36 (s, 3H), 4.06 (s, 3H), 4.07 (s, 3H) , 6.89 (s, 1H), 7.17 (dd, J = 2.7 Hz, to give 41 mg (yield 70%) of the title compound.

XH-NMR (DMSO-d6, 400 MHz): δ 2.68 (d, J = 4.4 Hz, 3H), 3.97 (s, 3H), 3.99 (s, 3H), 6.86 - 6.88 (m, 1H), 7.21 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.37 (s, 1H), 7.43 (d, J = 2.7 Hz, 1H), 7.53 (s, 1H), 8.07 (s, 1H), 8.17 (d, J = 9.0 Hz, 1H) , 8.54 (s, 1H) Mass analysis, found (ESI-MS, m/z): 389 (M++l) Example 118 ; f -{2-ChlQro-4- [ ( , 7-dimethoxy-4-guinazoliny1 ) oxy ]phenyl\- .N-dimethylurea 2-Chloro-4-[ ( 6 ,.7-dimethoxy-4-quinazolinyl )oxy] -aniline (50 mg) was dissolved in chloroform (2 ml) and triethylamine (0*5 ml),; and a solution of triphosgene (48 mg) in chloroform was then added to the solution. The mixture was stirred at room temperature for 30 min. Next, the reaction solution was cooled to -78°C, and dimethylamine hydrochloride (250 mg) was added to the cooled reaction solution. The temperature of the mixture was spontaneously raised, and the mixture was further stirred at room temperature overnight. Methanol was added to the reaction solution, and the mixture was purified by HPLC by development with chloroform/methanol to give 33 mg (yield 53%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 3.11 (s, 6H), 4.12 (s, 3H), 4.20 (s, 3H), 7.05 (s, 1H), 7.17 (dd, J = 2.4 Hz, 9.3 Hz, 1H), 7.31 (d, J = 2.4 Hz, 1H), 7.59 (s, 1H), 8.15 (s, 1H), 8.46 (d, J = 9.3 Hz, 1H), 8.82 (s, 1H) Mass analysis, found (ESI-MS, m/z) : 403 (M++l) Example 119: __ N- ( 2-Chloro-4- [ 6-methoxy-7- ( 3-morpholinopropoxy ) -4-quinazolinyl ]oxy}phenyl ) -N' -propyl-urea N-{2-Chloro-4- [ ( 7-hydroxy-6-methoxy-4-quinaz-olinyl) oxy] henyl}-N' -propylurea (75 mg), potassium carbonate (51 mg), and 1 , 3-dibromopropane (76 μΐ) was dissolved in N,N-dimethylformamide (4 ml), and the solution was stirred at room temperature for 3 hr. The solvent was removed by distillation under the reduced pressure. Water was added to the residue, and the mixture was extracted; with chloroform. The organic layer was dried over anhydrous sodium; sulfate. The solvent was removed by distillation under the reduced pressure. The residue was washed with . ether to give 74 mg (yield 78%) of N-(4-{ [ 7- (.l-br.6mopropoxy)-6-methoxy-4-quinazolinyl]- oxy}-2-chlorophehyl) -N' -propylurea as an intermediate. The intermediate, (74 mg.) , potassium carbonate (51 mg), and morphollne (13Ό τ μΐ) were dissolved in N,N- dimethylfo mamide i'('4 ml), and the solution was stirred at room temperature- overnight. The solvent was removed by distillation.'.under' the reduced pressure. A saturated aqueous sodium, hydrogencarbonate solution was added to the residue 'and" .the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate. The. solvent was removed by distillation under the reduced, pressure . The residue was purified by chromatography ; on silica gel by development with chloroform/methanoi: to give 49 mg (yield 63%) of the title compound.

'H-NMR (CDCI3,.400 MHz): δ 0.89 (t, J = 7.44 Hz, 3H), 1.41 - 1.50 (m, 2H), 1.97 (t, J = 6.83 Hz, 1H), 2.33 - 2.49 (m, 4H), 3.04 - 3.09 (m, 2H), 3.32 - 3.38 (m, 4H), 3.52 - 3.68 (m, 3H) , 4.03 (s, 3H), 4.23 - 4.29 (m, 1H), 4.32 (t, J = 5.89 Hz, 1H), 6.98 (t, J = 5.49 Hz, 1H), 7.21 (dd, J = 2.68, 9.03 Hz, 1H), 7.36 (s, 1H), 7.46 (d, J = 2.68 Hz, 1H), 7.53 (d, J = 7.81 Hz, 1H), 8.03 (s, , N-{2-Chloro-4-[ ( 7-hydroxy-6-methoxy-4-quinaz-olinyl)oxy ]phenyl}- ' -propylurea (72 mg), potassium carbonate (30 mg), and 1 , 2-dibromoethane (62 μΐ) were dissolved in N,N-dimethylformamide (4 ml), and the solution was stirred at room temperature for 3 hr. The solvent was removed by distillation under the reduced pressure. Water was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium. sulfate. The solvent was removed by distillation under the reduced pressure. The residue was washed with:; ether to give 40 mg (yield 45%) of N- ( 4-{ [7- ( 2-bromoethoxy ) -6-methoxy-4-quinazolinyl] - oxy}-2-chlorophenyl ) -N' -propylurea as an intermediate. The intermediate (45 mg), potassium carbonate (30 mg), and morpholine., (80 μΐ) were dissolved in N,N- dimethylformamide ( 2 ml ) , and the solution was stirred at room temperature overnight.1 The solvent was removed by distillation under the reduced pressure. A saturated aqueous sodium hydrogencarbonate solution was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under; the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/riiethanol to give 42 mg (yield 56%) of the title compound. 1H-NMR ( CDC13, 400 MHz): δ 0.89 (t, J = 7.32 Hz, 3H) , 1.43 - 1.49 (m, 2H)., 2.32 - 2.38 (m, 2H), 2.66 (bs, 1H), 2.79 (t, J = 5.86 Hz, IH), 3.04 - 3.09 (m, 2H), 3.29 -3.36 (m, 4H), 3.53 (m, 1H), 3.57 - 3.59 (m, 2H), 3.96 (s, 3H), 4.31 (t, J = 5.85 Hz, IH) , 6.98 (m, 1H), 7.21 -7.23 (m, IH), 7.41 (s, 1H), 7.46 - 7.47 (m, 1H), 7.55 (d, J = 12.69 Hz, IH), 8.03 (s, IH), 8.19 (d, J = 9.27 Hz, IH), 8.55 (d, J = 5.37 Hz, IH) Mass analysis, found (ESI-MS, m/z): 517 (M++l) Example 121; N- ( 2-Chloro-4-{ [7- ( 3-hydroxypropoxy) -6- carbonate (20 mg), and ^-bromo-l-propanol (62 μΐ) were dissolved in N,N-dimethyIformamide (4 ml), and the solution was stirred at room temperature for 3 hr. The Hz, 1H) , 8.55 (s, 1H) Mass analysis/ found (ESI-MS, m/z): 447 (M++l) Example 123; : N- ( 2-ChlorQ-4-{ [ 6-methQxy-7- (4-pyridylmethoxy) -4-quinazolinyl ]oxyVphenyl ) - ' -propylurea A starting . compound (N—{2-chloro-4-[ ( 7-hydroxy-6-methoxy-4-quinaz0linyi)oxy]phenyl}-N'-propylurea, 80 mg), potassium carbonate (138 mg), and 4-chloromethylpyridine hydrochloride (41 mg), were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at 80°C for 3 hr. Water was added to the reaction mixture, followed by extraction with chloroform-propanol (3/1). The organic -layet was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC to give 65 mg (yield 66%) of the title compound.

H-NMR (CDC13, 400 MHz): δ 0.96 (t, J = 7.6 Hz, 3H), 1.53 - 1.64 (m, 2H), 3.25 (dd, J = 7.3 Hz, 12.9 Hz, 2H), 4.07 (s, 3H), 5,32 (s, 2H), 6.66 (s, 1H), 7.14 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.27 (s, 1H), 7.29 (d, J = 2.7 Hz, 1H), 7.41 (d, J.= 5.9 Hz, 2H), 7.54 (s, 1H), 8.24 (d, J = 9.0 Hz, 1H), 8.59, (s, 1H), 8.63 (d, J = 6.1 Hz, 2H) - Mass analysis, found (ESI-MS, m/z): 494 (M++l) Example 124 ; N- [ 2-Chloro-4- ( { 6-methoxy-7-[ ( 5-morphol inopentyl ^oxy] -4-quinazoliny1>oxy)phenyl ] — ' — propylurea N-{2-Chloro-4- t ( 7-hydroxy-6-methoxy-4-quinaz-olinyl )oxyjphenyl}-II' -propylurea (70 mg), potassium carbonate (30 mg), and pentamethylene bromide (80 μΐ) were dissolved in N, -dimethylformamide (5 ml), and the solution was stirred at room temperature for 3 hr. The solvent was removed by distillation under the reduced pressure. Water was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 43 mg (yield 46%) of N-[4-( {7-( 5-bromopentyl )oxy}-6-methoxy-4- quinazolinyl)oxyi-2-phlbrophenyl]-N'-propylurea as an intermediate . , The .. irjtermediate (43 mg), potassium carbonate (30 mg), arid morpholine (70 μΐ) were dissolved in N,N-dimethylformamide (4 ml),, and the solution was stirred at room, temperature overnight. The solvent was removed by distillation under the reduced pressure. A saturated aqueous sodium hydrogencarbonate solution was added to the residue and the mixture was extracted with chloroform. : The organic layer was dried over anhydrous sodium sulfate,1 and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol to give 30 mg (yield 68%) of the title compound. 1H-NMR (CDC13, 400 MHz) : δ 1.71 (t, J = 7.32 Hz, 3H), 2.28 (t, J = 7.20 Hz, 2H), 2.63 (m, 2H), 3.08 - 3.14 (m, 5H), 3.29 - 3.30- (m, 5H), 3.47 (bs, 1H), 3.73 (m, 1H), 3.86 - 3.90 (m, 2H), 4.36 (t, J = 4.65 Hz, 3H), 4.46 (t, J = 4.76 Hz, 1H), 4.77,(s, 1H), 4.99 (t, J = 6.34 Hz, 2H), 7.80 (m, 1H), 8.02 (dd, J = 2.68 Hz, 9.27 Hz, 1H), 8.18 (s, 1H), 8.27 (d, J = 2.68 Hz, 1H), 8.34 (s, 1H), 8.85 (s, 1H), 9.00 (d, J = 9.03 Hz, 1H), 9.35 (s, 1H) Mass. analysis, found (ESI-MS, m/z ) : 559 (M++l) Example T 5: N-{2-Chloro-4-r ( 6-methoxy-7-{ [5-(ltf-l r2f 3-triazol-l-yljperityljoxy^-quinazolinyljoxyjphenyl}-!^-propylurea , Triazole (0.41 ml), l-bromo-5-chloropentane (1.0 ml), tetrabutylammonium iodide (10 mg), and a 3 M aqueous sodium hydroxide solution (1 ml) were dissolved in acetone (10 ml),, and the solution was stirred at 50°C for 18 hr. "Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography by development with chloroform to give an intermediate (390 mg) .

A starting 'compound (N—(2-chloro-4- [ ( 7-hydroxy-6-methoxy-4-quinazolinyl)bxy] phenyl }-N' -propylurea, 80 mg) , potassium carbonate: (138 mg), and the above intermediate (52 mg) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution, was ' stirred at 120°C for 5 hr. Water was added to the paction mixture, and the mixture was extracted, with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced mg), potassium carbonate (138 mg), and 4-chloromethylpyridine hydrochloride (49 mg) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate. The solvent was .removed by distillation under the reduced pressure. The residue was purified by HPLC to give 57 mg (yield 56%). of the title compound.

^-NMR (CDC113, 400 ίΗζ):' δ 1.26 (t, J = 7.3 Hz, 6H), 3.41 (q, J = 7.1 Hz, 4H), 4.08. (s, 3H), 5.32 (s, 2H), 6.98 (s, 1H); 7.14 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.27 (s, pressure. Water was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was washed, with ether to give 43 mg (yield 46%) of N-(4-{[7-(4-rbrdmobutoxy)-6-methoxy-4-quinazolinyl]-oxy}-2-chlorophenyl) -N' -propylurea as an intermediate. The intermediate (43 mg), potassium carbonate (30 mg), and morpholine . (40 μΐ) were dissolved in N,N-dimethylformamide (4.ml),, and the solution was stirred at room temperature, overnight. < The solvent was removed by distillation under the reduced pressure. A saturated aqueous sodium hydrogencarbonate solution was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol to give 23 mg (yield 53%) of the title compound.

^-NMR (CDClj, 400 MHz): δ 0.99 (t, J = 7.32 Hz, 3H), 1.56 - 1.62 (m, 13H), 2.00 - 2.08 (m, 2H), 3.26 - 3.28 (m, 2H), 4.04 (s, 3H), 4.24 (m, 2H), 4.72 - 4.77 (m, 1H), 6.65 (s, 1H), 6.99 (s, 1H), 7.19 - 7.26 (m, 1H), 7.30 (s, ,; . i 1H), 7.32 - 7.34 (m, 1H), 7.51 (s, 1H), 8.25 (d, J = 9.03 Hz, lH) , 8.61 (s, 1H) Mass analysis, found (ESI-MS, m/z): 545 (M++l) Example 128: N- [ 2-Chloro-4- ( { 6-methoxy-7- [ 2- ( 4-methylpiperaz ino ) ethoxy ] -4-quinazolinyl }oxy ) phenyl ] - ' -propylurea N-{2-Chloro-4-[ ( 7-hydroxy-6-methoxy-4-quinaz-olinyl)oxy] phenyl }-N' -propylurea (60 mg), potassium carbonate (30 ■ rag) ? and 1 , 2-dibromoethane (70 μΐ) were dissolved in N, N-dimethylformamide (4 ml), and the solution was stirred, at room temperature for 3 hr. The solvent was removed by distillation under the reduced pressure. Water was added to the residue, and the mixture was extracted wi-th chloroform. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 46 mg (yield 62%) of N-(4-< [ 7- (2-bromoethoxy ) -6-methoxy-4-quinazolinyl ] -oxy} -2-chlorophenyl)-N' -propylurea as an intermediate. The intermediate (46, mg), potassium carbonate (20 mg), and N-methylpiperazine (50 μΐ) were dissolved in N,N-dimethyIformamide (3 ml), and the solution was stirred at room temperature overnight. The solvent was removed by distillation under the reduced pressure. A saturated aqueous sodium hydrogencarbonate solution was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol to . give 24 mg (yield 50%) of the title compound.

^-NMR (CDC13, 400 MHz): δ 0.99 (t, J = 7.32 Hz, 3H), 1.61 - 1.64 (m, 211), .2.75 (m, 2H), 3.00 - 3.16 (m, 4H), 3.25 - 3.16 (m, 4H), 3.25 - 3.29 (m, 2H), 4.02 (s, 3H), 4.27 - 4.35 (m, 2H), .4.78 - 4.83 (m, 2H), 5.33 (s, 3H), 6.69 (s, 1H), 7.17 (dd, J = 2.68 Hz, 9.03 Hz, 1H), 7.31 olinyl )oxy ]phenyl}-^N;'r-propylurea (65 nig), potassium dimethylformamide (3 ml), and the solution was stirred at room temperature , overnight . The solvent was removed by distillation under the reduced pressure. A saturated aqueous sodium hydrogencarbonate solution was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography . on silica gel by development with chloroform/methanol to give 21 mg (yield 55%) of the title compound. / ^-NMR (CDCI3 , 400 MHz): δ 0.98 (t, J = 7.32 Hz, 3H), 1.59 (m, 2H), 1.94 (bs, 1H), 3.23 (m, 2H), 4.03 (s, 3H), 4.07 - 4.15- (m, 4H), 4.76 (m, 4H), 5.35 (s, 3H), 7.10 -7.17 (m, 1H), 7.28 (s, 3H), 7.40 (s, 1H), 7.54 (s, 1H), 8.37 (d, J = 9.03 Hz, 1H), 8.64 (s, 1H) Mass analysis,! found (ESI-MS, m/z): 504 (M++l) Example 130:· '· - [ 2-Chl0ro-4- ( { 6-methoxy-7- [ 3- ( 4-methylpiperazino propoxy]-4-quinazolinyl>oxy ^phenyl 1-Nf- propylurea N-{2-Chloro-4- [ ( 7-hydroxy-6-methoxy-4-quinaz-oliny1 ) oxy ] phenyl } -N ',-propylurea (75 mg), potassium carbonate (3(3 mg), ,; and { 1 , 3-dibromopropane (75 μΐ) were dissolved in Ν,Ν-dim thylformamide (4 ml), and the solution was stirred at room temperature for 3 hr. The solvent was removed by distillation under the reduced pressure. Water Was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over, anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was. washed with ether to give 50 mg (yield 52%) of N- ( -{ f 7- ( 3-bromopropoxy) -r6-methoxy-4-quinazolinyl ] -oxy}-2-chlorophehyl)-N'-propylurea as an intermediate. The intermediate (30 mg), potassium carbonate (20 mg), and N-methylpiperazihe (40 μΐ) were dissolved in N,N-dimethylformamide (3 nil), , and the solution was stirred at room temperature overnight. The solvent was removed by distillation under ' the reduced pressure. A saturated aqueous sodium hydrogericarbonate solution was added to the residue, and' the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, arid the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development wit chloroform/methanol to give 20 mg (yield 63%) of the title compound. 1H-^NMR (CD'C13, 400 MHz): δ 0.99 (t, J = 7.32 Hz, 3H), 1.58 - 1.62 (m, 2H), 2.25 - 2.50 (m, 3H), 2.70 - 2.85 (m, 3H), 2.92 - 2.98 (m, 3H), 3.25 (m, 2H), 4.04 (s, 3H), 4.25 (m, 2H), .4.83 (m, 3H), 5.34 (s, 3H), 6.70 (s, IH), 7.21 (dd, J = 2.68, 9.03 Hz, IH), 7.26 (s, 2H), 7.31 (s, IH), 7.49 (s ; IH,),, ,8.18' (d, J = 9.27 Hz, IH), 8.59 (s, IH) ■ " residue was washed with ether to give an intermediate. Triphosgene (.90 mg)./. was added to a solution of the intermediate , and' .triethylamine ( 0.027 ml) in chloroform (1 ml) at Q°C', ".'and the' mixture , was stirred for 30 min. The reaction · mixture was copied to 0°C, and diethylamine (0.044 ml) was then added dropwise to the cooled reaction mixture. , The temperature of the mixture was raised to room 'temperature over a period of 2 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, followed by extraction with chloroform-prdpanol (3/1 ) .' The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC to give 30 mg (yield 29%) of the title compound. 1H-NMR (CDCI3, 400 MHz): δ 1.26 (t, J = 7.1 Hz, 6H), 3.41 (q, J = 7.1 Hz, 4H), 4.03 (s, 3H), 4.53 (t, J = 4.9 Hz, 2H), 4.94 (t, J = .5.1 Hz, 2H) , 6.98 (s, 1H), 7.13 (dd, J = 2.7 Hz,' 9.0 Hz, 1H), 7.26 (s, 1H), 7.73 (s, 1H), 7.94 (s, lH), 8.38 (d, J = 9.0 Hz, 1H), 8.60 (s, 1H) Example 132; : 3-{ [4-(3-Chloro-4-{ [ (diethylamino)-carbonyl ] amino}phenoxy ) -6-methoxy-7-quinazolinyl ]oxy>-propyl-N . -diethylcarbamate A starting ' compound (N'-{2-chloro-4-[ ( 7-hydroxy-6-methoxy-4-quinazolihy1 ) oxy.] phenyl } - , N-diethylurea , 83 mg), potassium carbonate (138 mg), and 3-bromo-l-propanol (0.027 ■ ml) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at 80°C for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1)." . The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give an intermediate. Triphosgene (90 mg) was added to a solution of the intermediate and triethylamine (0.027 ml), in chloroform (1 ml) at 0°C, and the mixture was stirred for 30 min. The reaction mixture was cooled to 0°G, and , diethylamine (0.044 ml) was then added dropwise to the cooled reaction mixture. The temperature of the mixture was raised to room temperature over a period of 2 hr. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform-propanol ( 3/1 ) . The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC to give 19 mg (yield 17%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 1.04 (t, J = 7.1 Hz, 6H), 1.22 (t, J = 7.3 Hz, 6H), 3.09 (q, J = 7.1 Hz, 4H), 3.36 (q, J = 7.1 Hz, 4H), 3.75 (t, J = 6.3 Hz, 2H), 3.97 (s, 3H), 4.29 (t, J = 6.1 Hz, 2H), 6.93 (s, 1H), 7.10 (dd, J = 2.7 Hz, 9.0 Hz, lH), 7.24 (d, J = 2.7 Hz, 1H), 7.27 (s, 1H), 7.45 (s, 1H), 8.33 (d, J = 9.3 Hz, 1H), 8.55 (s, 1H) Example 133; N- [ 2-Chloro-4- ( { 6-methoxy-7- [ - ( -pyridylthio ) propoxy 1 -4-quinazolinyl \oxy ) phenyl ]-N' -propylurea A starting compound (N-(4-{ [7-(3-bromopropoxy)-6-methoxy-4-quinazolinyl ]oxy}-2-chlorophenyl ) - ' -propyl- urea, 80 mg ) , .; potassium carbonate (138 mg), and 4-mercaptopyridine . . (22 mg) were dissolved in N,N- dimethylformamide ( 1 ml) , and the solution was stirred at room temperature for, 3 hr. Water was added to the reaction mixture^' and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was washed with; ether to give 60 mg (yield 72%) of the title compound. 1H-NMR (CDC13, 40,0 MHz ) : δ 0.91 (t, J = 7.6 Hz, 3H), 1.50 - 1.60 (m, 2H); 2.24 - 2-32 (m, 2H), 3.11 - 3.24 (m, 4H), 3.99 (s, 3H);. 4.25 (t, J = 5.9 Hz, 2H), 4.70 - 4.80 (m, 1H), 6.62 (a, 1H), 7.11 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.11 - 7.16 (m, 2H), 7.23 (s, 1H), 7.25 (d, J = 2.7 Hz, 1H), 7.45 (s, lH), 8.19 (d, J = 9.0 Hz, lH), 8.30 - 8.34 (m, 2H), 8.55 (s, 1H ) Mass analysis, found (ESI-MS, m/z): 554 (M++l) Example 134 ; W-{2-!ChlOro-4- [ ( 6-methoxy-7-{3- [ (1-methyl-lH-1 ,2,3 f 4-tetrazol-5-yl ) thio]propoxy}-4-quinazolinyl ) -oxy ] phenyl } - ' -propylurea A starting compound (N-(4-{ [7-(3-bromopropoxy)-6-methoxy-4-quinazolihyl ] oxy} -2-chlorophenyl ) -N ' -propylurea, 80 mg), potassium carbonate (138 mg), and 5-mercapto-l-tetrazple (23 mg) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at room temperature for 3 hr. Water was added to the reaction mixture, -and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 71 mg (yield 85%) of the title compound. , 1H-NMR (CDCI3, 400 MHz): δ 0.91 (t, J = 7.3 Hz, 3H), 1.51 - 1.56 (m, 2H), 2.39 - 2.48 (m, 2H), 3.17 - 3.23 (m, 2H), 3.56 (t, J = 7.1 Hz, 2H), 3.86 (s, 3H), 3.97 (s, 3H), 4.27 (t, J = 5.9 Hz, 2H), 4.75 - 4.82 (m, 1H), 6.63 mixture was extracted with chloroform/2-propanol (4/1). The organic layer- was dried over anhydrous sodium sulfate. The solvent" was removed by distillation under the reduced pressure. The residue was washed with ether to give 451 mg (yield 71%) of N- ( 4-{ [ 7- ( 3-bromopropoxy ) -6-methoxy-4-quinazolinyl ]oxy}-2-chlorophenyl}-N ' -propy1-urea. N- ( 4-{;[ 7- ( 3-Bromopropoxy ) r-6-methoxy-4-quinaz-olinyl]oxy}-2-chlorophenyl}-N'-propylurea (70 mg), potassium carbonate ·( 5,4 mg), and piperidine (39 μΐ) were dissolved in' , -dimethylformamide (2 ml), and the solution, was stirred at room temperature overnight. The solvent was removed by distillation under the reduced pressure. A saturated aqueous sodium hydrogencarbonate solution was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (20/1) to give 35 mg (yield 50%)"of the title compound.

'H-NMR , (CDC13, 400 MHz) : δ ,0.98 (t, J = 7.6 Hz, 3H), 1.46 (br, 2H) , .1.54 - 1.66 (m, 8H), 2.15 (br, 2H), 2.44 (br, 2H), 2.55 (br, 2H)* 3.20 - 3.30 (m, 2H), 4.04 (s, 3H), 4.27 (t;., J. = 6 J 6 Hz!, 2H), 4.77 (t, J = 5.9 Hz, 1H), potassium carbonate (40. mg), and N-methylpiperazine (50 μΐ) were dissolved in N,N~dimethylformamide (1 ml), and the solution was stirred at room temperature overnight. The solvent was removed by distillation under the reduced pressure. · , ;A saturated aqueous sodium . .. ! ··.· 5 hydrogencarbonate solution was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol to give 20 mg (yield 44%) of the title compound. 1H-NMR (CDCI3, 400 MHz): δ 0.98 (t, J = 7.3 Hz, 3H), 1.56 - 1.65 (m, 2H), 1.77 (br, 4H), 2.31 (s, 3H), 2.53 (br, 2H), 2.71 (br, 2H), 2.97 (t, J = 6.1 Hz, 3H), 3.24 - 3.29 (m, 2H), 4.04 (s, 3H), 4.32 (t, J = 6.1 Hz, 2H), 4.83 (br, 1H), .6,.69; (,s,| lH), 7.16 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.30 (s, 1H) , 7.31.(s, 1H) , 7.55 (s, 1H), 8.25 (d, J = 9.0 Hz, 1H), 8.62 ^-NMR (CDC13, 400 MHz): δ 0.98 (t, J = 7.6 Hz, 3H), 1.58 - 1.64 (m, 2H), 1.71 (br, 4H), 2.31 (s, 3H), 2.53 (br, 2H), 2.71 (br, .2H) , 2.11 - 2.17 (m, 2H), 2.30 (s, 3H), 2.59 - 2.62 (m, 2H) , 3.24 - 3.29 (m, 2H), 4.04 (s, 3H), 4.26 (t '.'J, = 6.6 Hz, 2H), 4.80 (br, lH), 6.67 (s, lH), 7.17 ( dd, J - '= 2.7 Hz, 9.0 Hz, 1H), 7.31 (s, 1H), 7.31 (s, 1H) , 7.52 (s, 1H), 8.25 (d, J = 9.0 Hz, 1H), 8.61 (s, 1H) ; ( . L Mass analysis, found, ,(ESIrMS , , m/z ) : 543 (M++l) Example 138: Nr ( 2-Chloro-4-{ [ 7-methoxy-6- ( 2-pyridyl-methoxy ) -4-quinazolinyl ] pxy} henyl ) - ' -propylurea A starting . compound (N-{2-chloro-4- [ ( 6-hydroxy-7-methoxy-4-quinazoli.nyl )oxy ] henyl}-N' -propylurea, 80 mg), potassium carbonate (138 mg), ^nd 2- (chloromethyl)pyridine hydrochloride (41 mg) were dissolved in ,N-dimethylformamide (1 ml), and the solution was stirred at 120°G for 3 hr. Water was added to the reaction' mixture, and the mixture was extracted with chloroform^propanol (3/1). The organic layer was dried over . anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was ^washed with ethyl acetate to give 54 mg (yield 55%) of the title-compound.

^- MR (CDC13, 400 MHz): δ 0.91 (t, J = 7.6 Hz, 3H), 1.51 - 1.58 (m, 2H), 3.17 - 3.22 (m, 2H), 4.02 (s, 3H), 4.69 (br, lH), 5.36 (s, 2H), 6.57 (s, 1H), 7.08 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.21 - 7.29 (m, 2H), 7.53 - 7.55 (m, 2H), 7.66 - 7.71 (m, 1H), 8.15 (d, J = 9.0 Hz, 1H), 8.55 - 8.57 (m, 2H) Mass analysis, found (ESI-MS, m/z): 494 (M++l) Example 139: N- ( 2-Chloro-4-{ [ 7-methoxy-6- ( -morpholino-propoxy ) -4-quinazolinyl ]oxy}phenyl ) - ' -propylurea A starting compound (N-(4-{ [6-(3-propoxy)-7-methoxy-4-quinazolinyl ]oxy}-2-chlorophenyl ) -N' -propylurea, 54 mg), potassium carbonate (138 mg), and morpholine (0.017. , ml) were dissolved in N,N-dimethylformamide (1 .ml , and the solution was stirred at 120°C for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation , under the reduced pressure. The residue was washed with ethyl acetate to give 42 mg (yield 77%) of the title compound.

'H-NMR (CDCI3, -400 MHz): δ 0.91 (t, J = 7.6 Hz, 3H), 1.47 - 1.59 (m, 4H), .1.88 - 2.00 (m, 2H), 2.35 - 2.48 (m, 4H), 3.20 (dd J..= r7.,3 Hz, 12.9 Hz, 2H), 3.62 - 3.74 (m, 4H), 3.97 (s, 3H), 4. 5 (t, J = 6.3 Hz, 2H), 4.74 - 4.80 (m, 1H), 6.63 ('s, 1H), 7}.09 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.24 (d, J = 2.7 Hz, lH)', 7.42 (s, 1H), 8.18 (d, J = 9.0 Hz, 1H) , 8.54 (s, 1H) Mass analysis, found (ESI-MS, m/z): 530 (M++l) Example 140: N-{2-Chloro-4- [ ( 6-{3- ( 2-hydroxyethyl ) - (methyl ) amino ]propoxy}-7^methoxy-4-quinazolinyl ) oxy] -phenyl} -N ' -propylurea A starting compound ( -(4-{ [6-(3-bromopropoxy)-7-methoxy-4-quinazolinyl]oxy},-2-chlorophenyl ) -N' -propyl-urea, 51 mg), potassium carbonate (68 mg), and 2- (methylaminojethanol , (15 mg) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at 80°C for 3 hr. Water was added to the reaction mixture, and- the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium, sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 25 mg (yield 48%) of the title compound.

^- MR (CDCI3, 400 MHz): δ 0.95 (t, J = 7.6 Hz, 3H), 1.53 - 1.62 (m, 2H), 2.08 - 2.15 (m, 2H), 2.30 (s, 3H), 2.58 (t, J = 5.4 Hz, 2H), 2.68 (t, J = 7.1 Hz, 2H), 3.21 - 3.26 (m:, 2H), /3.60 (t, J = 5.4 Hz, 2H), 4.02 (s, 3H), 4.23 (t, J = 6.3 Hz, 2H), 5.06 (t, J = 5.6 Hz, 1 Hz), 6.79 (s, 1H), 7.13 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.27 -7.28 (m, 2H), 7.48 (s, 1H), 8.21 (d, J = 9.0 Hz, 1H), 8.58 (s, 1H) Example 141: N-<2-Chloro-4-{[6-methoxy-7-r2-pyridyl-methoxy ) -4-quinolyl 1oxy henyl ) - ' -propylurea A starting, compound (N-:{2-chloro-4- [ ( 7-hydroxy-6-methoxy-4 -quinolyl) pxy ] phenyl } -N ' -propylurea , 80 mg ) , potassium carbonate (138 mg), and 2-chloromethylpyridine hydrochloride (41 mg) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at 80°C for 3;'!4hr · Water was added to the reaction mixture, and, J-'thfe; 'mixture was extracted with chloroform-propanol (3/1). ' The organic layer was dried over anhydrous sodium sulfate. The solvent was removed by distillation under the reduced pressure. The residue was purified by ÷ HPLC to give 81. mg (yield 82%) of the title compound. '. ■·; .

JH-NMR (CDClj, 400 MHz):; ft 0.97 (t, J = 7.6 Hz, 3H), 1.54 - 1.65' (m,. 2H)> ¾ i.5 (dd, J = 7.1 Hz, 12.9 Hz, 2H), 4.05 (s, 3H), 4.75 - 4.82 (m, IH ) 5".42 (s, 2H), 6.46 (d, J = 5.4 Hz, 1H) , 6; 67 (s,' lH) , 7.08 (dd, J = 2.9 Hz, 9.0 Hz, 1H) , 7.19 (d, J = 2.7 Hz, IH), 7.44 (s, 1H) , 7.53 (s, IH), 7.56 (d, J = .7.8 Hz, Iff), 7.69 (dt, J = 2.0 Hz, 7.8 Hz, IH) , 8.25 (d, J = 9.0 Hz, IH), 8.46 (d, J = 5.1 Hz, IH), 8.61 (d, J = 4.6 Hz, IH) Mass analysis, found (ESI-MS, m/z): 493 (M++l) Example 142; ' N-Y 2-Ghloro-4-{ [ 6-methoxy-7- ( 3-pyri dyl -methoxy ) -4-quinolyl ] oxy>phenyl ) -N ' -propylurea A starting compound (N-{2-chloro-4~[ ( 7-hydroxy-6-methoxy-4-quinolyl) oxy] phenyl }-N' -propylurea, 80 mg), potassium carbonate (138 mg), and 3-chloromethylpyridine hydrochloride (41 . mg) were dissolved in N,N-dimethylformamide ( 1 ml ) , and the solution was stirred at 80°C for 3 hr. Water was added to the reaction mixture, and' the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC to give 70 mg (yield 71%) of the title compound . ' ■ 1 ■ 1H-NMR (.CDC13, 400 MHz) : δ 0.97 (t, J = 7.3 Hz, 3H), 1.54 - 1.65 (m, 2H):, 3.25 (dd, J = 7.3 Hz, 12.9 Hz, 2H), 4.02 (s, 3H), 4.82 - 4.90 (m, 1H), 5.30 (s, 2H), 6.47 (d, J = 5.4 Hz, IE), 6.72 (s, 1H), 7.09 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.19 (d, J = 2.7 Hz, 1H), 7.32 (dd, J = 4.9 Hz, 7.8 Hz, 1H), 7.47 (s, ΪΗ), 7.52 (s, 1H), 7.84 (d, J = 7.8 Hz, 1H), 8.26 (d, J = 9.3 Hz, 1H), 8.47 (d, J = 5.4 Hz, 1H), 8.58 (d, J = 3.2 Hz, 1H), 8.75 (s, 1H) Mass analysis, found (ESI-MS, m/z): 493 (M++l) Example 143: N- ( 2-Chl oro-4- [ 6-methoxy-7- ( 4-pyridyl-methoxy ) -4-quinolyl ] oxy}phenyl ) - ' -propylurea A starting compound (N-{2-chloro-4- [ ( 7-hydroxy-6-methoxy-4-quinOlyl ) oxy ] phenyl }-N' -propylurea, 80 mg), potassium carbonate (138 mg),, and 4-chloromethylpyridine hydrochloride (41 mg) were dissolved in N,N-dimethylformamide ( 1 ml ) , and the solution was stirred at 80°C for 3 hr.: Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1).. The organic layer was dried over anhydrous sodium sulfate', and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC to give 71 mg (yield 71%) of the title compound .

^-NMR (CDClj, 400 MHz): δ 0.97 (t, J = 7.6 Hz, 3H), 1.54 - 1.65 (m, 2H), 3.25 (dd, J = 7.1 Hz, 12.9 Hz, 2H), 4.05 (s, 3H), 4.86 - 4.92 (m, 1H), 5.32 (s, 2H), 6.48 (d, J = 4.7 Hz, 1H), 6.73 (s, 1H), 7.08 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.19 (d, J = 2.9 Hz , lH), 7.38 (s, 1H), 7.41 (d, J = 6.1 Hz, 2H), 7.54 (s, 1H), 8.26 (d, J = 9.0 Hz, 1H), 8.46 (d, J = 5.4 Hz, 1H), 8.61 (d, J = 6.1 Hz, 2H) Mass analysis, found (ESI-MS, m/z): 493 (M++l) Example 144 N- ( 2-Chloro-4-{ [ 6-methoxy-7- ( 2-morpholinoethoxy ) -4-quinolyl ] oxy>phenyl^-N' -propyl urea A starting- compound (N-{2-chloro-4- [ ( 7-hydroxy-6-methoxy-4-quinoiyl )oxy ] henyl}-N' -propylurea, 100 mg) , potassium carbonate (172 mg), and 1 , 2~dibromoethane (0.086 ml) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at room temperature for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ehloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the . solvent was . removed by distillation under the reduced pressure. The residue was washed with ether to give an-, [intermediate (-N- ( 4-{ [ 7- ( 2-bromoethoxy ) - 6-methoxy-4-quinolylJ oxy}-2-chlorophenyl ) - ' -propylurea ) . The intermediate, ^potassium carbonate (138 mg), and morpholihe (0.17 ml).- were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at 80°C for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ehloroform-propanol (3/1). ,;The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified . by^ . '. chromatography on silica gel by development with ehloroform/methanol to give 70 mg (yield 54%) of the title compound.

^-NMR (CDCI3, ; 400 MHz) : δ 0.91 (t, J = 7.6 Hz, 3H), 1.50 - 1.59 (m, 2H), 2.57 (t, J = 4.6 Hz, 4H), 2.88 (t, J = 5.9 Hz, 2H), 3.18 - 3.23 (m, 2H), 3.68 (t, J = 4.6 Hz, 4H), 3.94 (s, 3H), 4.26 (t, J = 5.9 Hz, 2H), 4.98 (t, J = 5.3 Hz, '2H); 6,41 (d'r J = 5.3 Hz, 1H), 6.74 (br, 1H), 7.03 (dd,'j = 2.7 Hz, 9:0 Hz, 1H), 7.14 (d, J = 2.7 Hz, lH), 7.34 (s, lH),. 7.43 (s, 1H), 8.42 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 515 (M++l) E ample 145 ; [ 2-Chloro-4- ( {6-methoxy-7- [ 2- ( lH-1 r 2 P 3-triazol-l-yl ) ethoxy ] -4-quinolyl}oxy ) phenyl ]-N'-propylurea A starting compound (N-{2-chloro-4- [ ( 7-hydroxy-6-methoxy-4-quinolyl) oxy] phenyl}-N' -propylurea, 80 mg), potassium carbonate (138 mg), and 2- ( lH-1 , 2 , 3-triazol-l-yl) ethyl 4-methyl-l-benzenesulfonate (59 mg) were dissolved in N, N-dimethylformamide (1 ml), and the solution was : stirred at 120°C for 5 hr. Water was added to the reaction mixtures and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform-methanol to give 92 mg (yield 92%) of the title compound. 1H-NMR (CDClj, 400 MHz): δ 0.97 (t, J = 7.6 Hz, 3H), 1.57 - 1.63 (m, 2H), 3.23 - 3.28 (m, 2H), 4.01 (s, 3H), 4.52 (t, J = 5.1 Hz, 2H), 4.81 (br, 1H), 4.93 (t, J = 5.1 Hz, 2H), 6.47 (d, J = 5.4 Hz, 1H), 6.69 (s, 1H), 7.08 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.18 (d, J = 2.7 Hz, 1H), 7.37 (s, 1H), 7.51 phenyl ) - ' -propylurea A starting compound (N-{2-chloro-4- [ ( 7-hydroxy-6-methoxy-4-quinoly )oxy]phenyl}-N' -propylurea, 80 mg), potassium carbonate (138 mg), and 3-bromo-l-propanol (0.027 ml) w,ere, dissolved in - Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was: added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 94 mg (yield 100%) of the title compound.

'H-NMR (CDCI3, 400 MHz).: δ 0.92 (t, J = 7.6 Hz, 3H), 1.45 - 1.62 (m, 2H), 2.09 - 2.18 (m, 2H), 3.21 (dd, J = 7.1 Hz, 12.9 Hz, 2H), 3.87 (t, J = 5.6 Hz, 2H), 3.94 (s, 3H), 4.31 ft, J = 6.1 Hz, 2H), 4.81 - 4.87 (m, 1H), 6.42 (d, J = 5.1 Hz, 1H), 6.69 (s, 1H), 7.03 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.14 (d, J = 2.7 Hz, 1H), 7.36 (s, 1H), 7.43 (s, 1H),' 8.20 (d, J = 9.0 Hz, 1H), 8.42 (d, J = 5.4 Hz, 1H) Example 148: N-[ 2-Chloro-4- ( 6-methoxy-7-[ 2- ( 4-methy1-piperazino ) ethoxy ] -4-quinolyl}oxy )phenyl ] - ' -propylurea A starting compound (N-(4-{ [ 7- ( 2-bromoethoxy) -6-methoxy-4-quinolyl]oxy}-2-chlorophenyl ) -N' -propylurea, 50 mg), potassium carbonate (138 mg), and 1-methylpiperazine (0.055 ml) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 54 mg (yield 100%) of the title compound.

^- MR (CDCI3, 400 MHz): δ 0.92 (t, J = 7.3 Hz, 3H), A starting compound (N- ( 4-{ [ 7- ( 2-bromoethoxy) -6-methoxy-4-quinolyl ]oxy}-2-chlorophenyl ) - ' -propylurea, 50 mg), potassium carbonate (138 mg), and 2- (methylamino)ethanol ,(0.040 ml) were dissolved in N,N-dimethylformaniide (.1 ml), and the solution was stirred at room temperature for 18 nr.. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed .with ether to give 53 mg (yield 106%) of the title compound.. >H-NMR (CDCl3, .400 MHz): δ 0.97 (t, J = 7.6 Hz, 3H), 1.54 - 1.65. (m, 2H) , 2.42 (s, 3H), 2.69 (t, J = 5.1 Hz, 2H), 3.00 (t, J =; 5.6 Hz, 2H), 3.26 (dd, J = 7.1 Hz, 12.7 Hz, 2H), 3.64. (t, J = 5.1 Hz, 2H), 3.99 (s, 3H), 4.26 (t, J;= 5.6 Hz, 2H), 4.66 - 4.69 (m, 1H), 6.46 (d, J = 5.1 Hz, 1H), 6.70 (s, 1H), 7.09 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.1? (d, J = 2.7 Hz,. 1H), 7.39 (s, 1H), 7.47 (s, 1H), 8.24 (d, J = 9.0 Hz, 1H), 8.47 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z ) : 503 (M++l) Example 151; ; N- ( 2-Chloro-4-{ [ 6-methoxy-7- (3-morpholinopropoxy ) -4-quinolyl ] oxy}phenyl ) -N ' -propylurea A starting compound (N-(4-{ [7-(3-bromopropoxy)-6-methoxy-4-quinolyl] oxy}-2-chlorophenyl )-N' -propylurea, 52 mg), potassium' carbonate (138 mg), and morpholine (0.044 ml) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 23 mg .(yield 44%), of the title compound. 1H-NMR (CDCI3, 400 MHz): δ 0.92 (t, J = 7.6 Hz, 3H), 1.49 - 1.60 (m, 2H), 2.02 - 2.11 (m, 2H), 2.40 - 2.47 (m, 4H), 2.52 (t, J = 7.1 Hz, 2H), 3.21 (dd, J = 7.1 Hz, 12.9 Hz, 2H), 3.62 - 3.69 (m, 4H), 3.95 (s, 3H), 4.20 (t, J = 6.6 Hz, 2H), 4.70 - 4.78 (m, 1H), 6.41 (d, J = 5.1 Hz, 1H), 6.64 (s, lH), 7-04 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.15 (d, J = 2.7' Hz,. IH), 7.37 (s, 1H), 7.43 (s, 1H), 8.20 (d, J = 9.0 Hz, 1H) , 8.42 (d, J = 5.4 Hz, 1H) Example 152.■■ N- [-2 -Chloro-4- ( 6-methoxy-7- { [ 3 - ( 4-methy1-pipera i not propoxy .]'-4-quinolyl }oxy.) phenyl ]-N' -propylurea A starting compound (N-(4-{ [7-(3-bromopropoxy)-6-methoxy-4-quinolyl ]oxy}-j2-chlorophenyl ) -N' -propylurea, 52 mg), potassium .carbonate (138 nig), and 1-methylpiperazine . , ,(;0..05.5, ml ) were' dissolved in N,N-dimethylformamide . (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, ,: and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed' with ether to give 41 mg (yield 76%) of the title compound. 1H-NMR1 ( CDCI3 , 400 MHz ) : δ 0.92 (t, J = 7.6 Hz, 3H), 1.49 - 1.64 (m, ;2H) ,,.' 2.02 - 2.10 (m, 2H), 2.23 (s, 3H), 2.30 - 2.56 (m, 8H) , '2.52 (t, J = 7.3 Hz, 2H) ,' 3.20 (dd, J = 7.1 Hz, 12.9 Hz, 2Η),, 3.94 (s, 3H), 4.19 (t, J = 6.8 Hz, 2H), 4.83 - '4.92 (m, lH), 6.40 (d, J = 5.1 Hz, 1H), 6.69 (s, 1H), 7.03 (dd, J = 2.9 Hz, 9.3 Hz, 1H), 7.14 (d, J = 2.7 Hz, 1H), 7.35 (s, 1H), 7.42 (s, 1H), 8.19 (d, J = 9.0 Hz, lH), 8.42 (d, J = 5.4 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 542 (M++l) Example 153: N- [2-Chloro-4- ( 6-methoxy-7- { [ 3- ( Ί Η—Λ .2 r 3— triazol- 1-yl ) ropoxy ] -4-quinolyl }oxy ) phenyl ] - ' -propylurea " Triazole (0.41 ml), l-bromo-3-chloropropane (0.79 ml), tetrabutylammonium iodide (10 mg), and a 3 M aqueous sodium hydroxide solution (1 ml) were dissolved in acetone (10 ml), and the solution was stirred at 50°C for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with . chloroform. The organic layer was dried '.over ; anhydrous sodium sulfate, and the solvent was removed by. distillation under the reduced pressure. The residue was purified by chromatography by development with chloroform to give an intermeidate (327 mg ) .

A starting compound, (N-{2-chloro-4-[ ( 7-hydroxy-6-methoxy-4-quinolyl)qxy]phenyl}-N' -propylurea, 80 ng), potassium carbonate , (138^ mg)>, and the intermediate (42 mg) were dissolved in N,N-dimethylformamide (1 ml), and the solution was* stirred at 80°C for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 23 mg (yield 23%) of the title compound.

^-NMR (CDClj, 4.00 MHz): δ 0.91 (t, J = 7.3 Hz, 3H), 1.48 - 1.60 (m, .2H) , 2.27 - 2.36 (m, 2H), 3.20 (dd, J = 6.8 Hz, 12.9 ;Hz, 2H), 3.,97 (s, 3H), 4.06 (t, J = 5.9 Hz, 2H), 4.21 (t, J = 6.8 Hz, 2H), 6.39 (d, J = 5.4 Hz, 1H), 6.90 (s, 1H), 6.98 - 7.04 (m, 2H), 7.12 (d, J = 2.7'Hz, 1H), 7.30 (s, 1H) , 7.44 - 7.48 (m, 2H), 8.22 (d, J = 9.0 Hz, 1H), 8.41 (d, J —5.4 Hz, 1H) Example 155: N-{2-Chloro-4- [ ( 7-{ 2- [di( 2-hydroxyethyls -amino ]ethoxy}-6-methoxy-4-quinolyl ) oxy] henyl}-N' -propylurea A starting .compound (N-(4-{ [7-(2-bromoethoxy)-6-methoxy-4-quinoiyl]oxy}-2-chlorophenyl ) -N' -propylurea, 50 mg), potassium carbonate (138 mg), and 1-methylpiperazine (0.055 ml) were dissolved in N,N-dimethylformamide (1 ml), and the mixture was stirred at room temperature for- 18 hr. -Water was added to the reaction mixture, arid the mixture was extracted with chloroform-propanol ( 3/1 ) . The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 46 mg (yield 92%) of the title compound. 1H-NMR (CDCI3, 400 MHz): δ 0.92 (t, J = 7.3 Hz, 3H), 1.50 - 1.60 (m, 2H), 2.74 (t, J = 4.9 Hz, 4H), 3.04 (t, J = 4.9 Hz, 2H), 3.15 - 3.24 (m, 2H), 3.60 (t, J = 5.1 Hz, 4H), 3.94 (s, 3H), 4.17 (t, J = 5.0 Hz, 2H), 6.41 (d, J = 5.4 Hz, 1H),"6.75 (s, 1H), 7.04 (dd, J = 2.4 Hz, 8.8 Hz, lH), 7.14 (d, J,= 2.7 Hz, 1H), 7.38 (s, 1H), 7.43 (s, 1H), 8.19 (d, J = 9.0 Hz, 1H), 8.42 (d, J = 5.4 Hz, 1H) Example 156; ;■ N-{2-Chloro-4- [ < 7-{3- [di ( 2-hydroxyethyl ) - amino ]propoxy}-6-methbxy-4->quinoly1 )oxy]phenyl}-N' - propylurea A starting compound (N-(.4-{ [7-(3-bromopropoxy)-6- methoxy-4-quinolyl ]oxy}-2-chlorophenyl ) -N' -propylurea, 52 mg), potassium carbonate (138 mg), and diethanolamine (53 mg) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic -layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give -41 mg (yield 82%) of the title compound.

XH-NMR (CDC1,, 400 MHz) :: δ 0.89 (t, J = 7.3 Hz, 3H), 1.46 - 1.56 (m, , 2H) , 1.97 - 2.05 (m, 2H), 2.63 (t, J = 5.1 Hz, 4H) , .2.69 (t, J = 6.1 Hz, 2H) , 3.19 (dd, J = 7.1 Hz, 13.2 Hz, 2H), 3.60 (t, J = 4.9 Hz, 4H), 3.94 (s, 3H), 4.32 (t, J = 5.9 Hz, 2H), 5.27 - 5.35 (m, 1H), 6.37 (d, J = 5.4 Hz, 1H), 6.94 (s, 1H), 7.01 (dd, J = 2.9 Hz, 9.0 Hz, 1H), 7.10 (d, J = 2.7 Hz, 1H), 7.42 (s, 1H), 7.53 (s, 1H), 8.19 (d, J = 9.0 Hz, 1H), 8.35 (d, J = 5.4 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 547 (M++l) Example 157 '. N-{2-Chloro-4-[ (7-{3-[ (2-hydroxyethyl) (methyl ¾ amino]propoxy}-6-methoxy-4-qui nolyl )oxy]-phenyl >-N ' -propyl urea A starting compound (N- ( 4-{ [ 7- ( 3-bromopropoxy) -6-methoxy-4-quinolyl ]oxy}-2-chlorophenyl ) -N' -propylurea, 52 mg), potassium carbonate (138 mg), and 2-(methylamino ) ethanoli (0/040 ml) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was . wastied , with ether to give 51 mg (yield 98%) of the title compound.

!H-NMR (CDC13, -400 MHz): 6 0.91 (t, J = 7.6 Hz, 3H) , 1.45 - 1.59. (lit, 2H),..2.05 (t, J = 6.8 Hz, 2H), 2.24 (s, 3H) , 2.51 (t, J,= 5.1 Hz, 2H), 2.59 (t, J = 7.1 Hz, 2H) , 3.20 (dd, J = 6.8 Hz ,12.9 Hz , 2H) , 3.57 (t, J = 5.4 Hz, 2H), 3.95 (s, 3H)', 4.22, (t, J = 6.3 Hz, 2H) , 5.00 - 5.08 (m, 1H), 6.40 (d, ,J .= 5.1 Hz, 1H), 6.79 (s, 1H), 7.03 (dd, J = 2.7 Hz, 9.0 Hz; 1H), 7.13 (d, J = 2.7 Hz, 1H) , 7.426 (s, 1H) ,. 7.433 (s, 1H), 8.19 (d, J = 9.0 Hz, 1H) , 8.40 (d, J =. 5.4; Hzr,: ;1H) Mass analysis, found (ESI-MS, m/z): 517 (M++l) Example 158: - [ 2-Chloro-4- ( {6-methoxy-7- [ 4- Π Η-Λ f 2.3-triazol-1 -yl ) butoxy ] -4 -quinolyl } oxy ) phenyl ] -N ' -propyl-urea . . 1 Triazole (0.41. ml), l-bromo-4-chlorobutane (0.93 ml), tetrabutylammonium iodide (10 mg), and a 3 M aqueous sodium hydroxide solution (1 ml) were dissolved in acetone (10 ml), and. the solution was stirred at 50°C for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by , distillation under the reduced pressure. The -residue was purified by chromatography by development with chloroform to give an intermediate (1-( 4-chlorobutyl ) -lH-1 , 2 , 3-triazole, 314 mg).

A starting ' compound (N-{2-chloro-4- [ ( 7-hydroxy-6-methoxy-4 -quinolyl )6xy] phenyl }- ' -propylurea, 80 mg), potassium carbonate (138 mg), and the intermediate (48 mg) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at 80°C for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with chioroform-propanol (3/1) . The organic layer was dried over anhydrous sodium sulfate, and the solvent was temoyed by » distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 42 mg ■;' . ,. "■■ ■■: , ·■ 151 (yield 40%) of the iitle compound .

^-N R · GDCl 3 , 46.0 MHz ) : ; δ 0.96 (t, J = 7.3 Hz, 3H), 1.54 - 1.65 (m, 2H)V i.88 - 1.98: (m, 2H), 2.14 - 2.24 (m, 2H), 3.26 (dd, j = 6.6 Hz, 13.2 Hz, 2H), 3.99 (s, 3H), 4.20 (t, J = 5.9 Hz, 2H) , 4.55 (t, J = 7.1 Hz, 2H), 5.00 - 5.06 (m, 1H) , / 6.'46 (d, J = 5.4 Hz, 1H), 6.80 (s, 1H), 7.08 (dd; J = 2.7 Hz; 9.0 Hz, 1H) , 7\l9 (d, J = 2.7 Hz, 1H), 7.37 (s, lH) '7-49 (s, lH), 7.68 ~ 7.72 (m, 2H), 8.26 (d, J = «'β.Ό' Hz>; 1H" , 8.4J (d, J = 5.1 Hz, 1H) Mass analysis, 'found (ESI-MS, m/z): 525 (M++l) Example 159; N-{2-Chloro-4-:[ ( -methoxy-7--( [ 5- ( IH-l , 2 , 3-triazol-1^yl ) pentyl ] oxy}-4^quinoly1 ) oxy ] phenyl }- ' -propylurea Triazole (0.41 ml), l-bromo-5-chloropentane (1.0 ml), tetrabutylammonium iodide (10 mg), and a 3 M aqueous sodium hydroxide solution (1 ml) were dissolved in acetone ( 10' ml ) ,' and the solution was stirred at 50°C for 18 hr. Water was: added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was , purified by chromatography by development with chloroform to give an intermediate (1-( 5-chloropentyi- H-l , 2 , 3-rtriazole, 390 mg) .

A starting "compound (N-{2-chloro-4- [ ( 7-hydroxy-6-methoxy-4-quinolyl)oxy]phenyl}-N' -propylurea, 80 mg), potassium carbonate (138 mg), and the intermediate (51 mg) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at 80°C for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 33 mg (yield 31%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 0.92 (t, J = 7.6 Hz, 3H), 1.47 - 1.59 (m, 2H), 1.'85 - 2.03 (m, 4Η), 3.21 (dd, J = 6.6 Hz, 13.2 Hz, 2H), 3.94 (s, 3H), 4.11 (t, J = 6.3 Hz , 2H), 4.38 (t, J = 7.1 Hz, 2H), 4.86 - 4.94 (m, 1H), 6.41 (d, J = 5.4 Hz, 1H), 6.71 (s, 1H), 7.03 (dd, J = 2.4 Hz, 9.0 Hz, 1H), 7.14 (d, J = 2.7 Hz, 1H), 7.31 (s, 1H), 7.43 (s, lH), 7.51 (s, 1H), 7.64 (s, 1H), 8.20 (d, J = 9.0 Hz, lH), 8.41 - (d, J = 5.4 Hz, 1H) Mass analysis found (ESI-MS, m/z): 539 (M++l) Example 160: N- [ 2-Chloro-4- ( {7- [ 4- ( 1 ff-l-imi dazolyl ) -butoxy ] -6-methoxy-4-quinolyl }oxy ) phenyl ] -N ' -propylurea Imidazole (680 mg), l-bromo-4-chlorobutane (0.93 ml), tetrabutylammonium iodide (10 mg), and a 3 M aqueous sodium hydroxide solution. (1 ml) were dissolved in acetone ( 10 ml) ,» and the solution was stirred at 50°C for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with ; chloroform. The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography by development with chloroform to give an intermediate (1-( 4-chlorobutyl ) -lH-imidazole, 756 mg) .

A starting compound (N-{2-chloro-4- [ ( 7-hydroxy-6-methoxy-4 -quxnolyl) oxy] phenyl }-N' -propylurea, 80 mg) , potassium carbonate (138 mg), and the intermediate (48 mg) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at 80°C for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was drxed over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 29 mg (yield 28%) of the title compound. 1H-NMR (CDC13, 400 MHz): δ 0.96 (t, J = 7.3 Hz, 3H), 1.54 - 1.65 (m, 2ti ) , 1.83 - 1.95 (m, 2H), 1.98 - 2.08 (m, 2H), 3.25 (dd, J; = 6.8 Hz, 12.7 Hz, 2H), 4.00 (s, 3H), 4.10 (t, J = 7.1 Hz, 2H), 4.20 (t, J = 6.1 Hz, 2H), 5.08 - 5.1 = 5.1 Hz, 1H), 6.83 (s, 1H), 6.97 7.08 (dd, J = 2.9 Hz, 9.3 Hz, 1H), lH), 7.37 (s, 1H), 7.49 (s, 1H), J = 9.0 Hz, 1H), 8.46 (d, J = 5.4 Hz, 1H) 1.'; Example - 161; N-(2^Chloro-4-{ [6-methoxy-7-(4-pyridyl-methoxy) -4-qu inazolinyl ]oxy}phenyl ) - ' - ( 2.4-difluoro-phenyl)urea A starting compound (N'-{2-chloro-4-[ (7-hydroxy-6-methoxy-4-quinazolinyl ) oxy ] henyl}-N' - ( 2 , 4-difluoro-phenyl)urea, 80 ; mg)., potassium carbonate (138 mg), and 4-chloromethylpyridine hydrochloride (41 mg) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to .the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure.' The 'residue was washed with ether to give 50 mg (yield 52%) of the title compound. 1H-NMR (CDCI3, 400 MHz): δ 4.03 (s, 3H), 5.46 (s, 2H), 7.03 - 7.11 (m, 1H), 7.28 - 7.38 (m, 1H), 7.47 (s, 1H), 7.50 (d, J = 5.9 Hz, 2H), 7.56 (d, J = 2.7 Hz, 1H), 7.61 (s, 1H), 7.'95 (s, 1H), 8.09 - 8.18 (m, 1H), 8.19 (d, J = 9.0 Hz, 1H) 8.57 (s, 1H), 8.63 (d, J = 5.9 Hz, 2H), 8.81 (s, IH), 9.30 (s, 1H) Example 162; N- ( 2-Chloro-4-{ [ 6-methoxy-7- ( -morpholino-ethoxy) -4-quinazolinyl ]oxy>phenyl ) - ' - ( 2 r 4-di fΊ linro-phenyl ) urea A starting compound (N'-{2-chloro-4-[ ( 7-hydroxy-6-methoxy-4-quinazolinyl ) oxy]phenyl}-N' - ( 2 , 4-difluoro-phenyl)urea, 100 mg), potassium carbonate (857 mg), and 1 , 2-dibromoethane , (f0.' 85 ml) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction, mixture, and the mixture was extracted with chloroform-propanol. (3/1). The organic layer was dried chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with, ether to give 53 mcj (yield 89%) of the title compound. 1H-NMR (ODCl-j, 400 MHz ) : δ 2.06 - 2.16 (m, 2H), 2.43 - 2.57 (m, 4H), 2.56. (t, J = 6.8 Hz, 2H), 3.68 - 3.75 (m, 4H), 4.03 (s, ; 3Ηί) , "·4.27 (t, J = 6.6 Hz, 2H), 6.79 - 6.91 (m, 2H) , 7.Γ4 (s>. 1H) ; 7.19 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.28 (s, : 1H)> .7.29 (d, J .= ..9.0 Hz, 1H), 7.33 (s, 1H), 7.49 ( s , 1H )., 8.26. ( d, J '■= 9.0 Hz, IH), 8.61 (s, 1H) Mass analysis,' found (ESI-MS, m/z): 600 (M++l) Example 164: N- [ 2-Chloro-4- ( / 6-methoxy-7- f 3- ( 4-methyl- pi perazino Vpropoxy ]-4-quinazoliny1 >ox ) phenyl ] -N ' - / 2.4- difluorophenyl ) urea A starting compound (N- ( 4- [7- ( 3-bromopropoxy ) -6-methoxy-4-quinazplinyl ]oxy}^2-chlorophenyl ) -N' - (2,4- difluorophenyl)urea, 59 mg), potassium carbonate (138 mg), and 1-methylpiperazine (0.055 ml) were dissolved in N,N-dimethylformamide . (1 ml), and the solution was stirred at room . temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 58 mg (yield 95%) of the title compound.

^H-NMR: (CDCI3, - 400 MHz) : δ 2.01 - 2.12 (m, 2H), 2.23 (s, 3H)I , 2 ,23 - 2.80 (m, , 8H) , 2.51 (t, J = 7.1 Hz, 2H), 3.97 (s, 3H) ,. 4.20 (t,' J = 7.2 Hz, 2H), 6.73 - 6.87 (m, 2H), 7.13 (dd, J = 2.7 Hz, 9.0 Hz, IH), 7.24 (d, J = 2.7 Hz, IH), 7.27 (s, IH), 7.30 (s, IH), 7.44 (s, IH), 7.91 - 8.00 (m, 2H), 8.21 (d, J = 9.0 Hz, IH), 8.56 (s, IH) Example 165; N-{2-Chloro-4-[ (7-{3-[ (2-hydroxyethyl)- (methyl ) amino ] propoxy} -6-methoxy-4-quinazol iny1 ) oxy ] -phenyl} -H ' - ( 2.4-di£luorophenyi )urea A starting compound (N-(4-{ [7- (3-bromopropoxy) -6-methoxy-4-qiinazoiinyl ]oxy}-2-chlorophenyl ) -N ' - ( 2 , 4-difluorophenyl ) urea, 59 mg), potassium carbonate (138 mg), and 2- (methylamino ) ethanol (0.040 ml) were dissolved in, N,N-dimethylformamide (1 ml), and the solution was stirred .a£ room temperature for 18 nr. Water was added to the. reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent, was removed by distillation under the reduced pressure. .The residue was washed with ether to give 58 mg (yield 100% ) of the title compound.

^- R . (CDC13, '400 MHz): δ 2.06 - 2.16 (m, 2H), 2.30 (s, 3H), 2.57 (t, J = 5.1 Hz, 2H), 2.65 (t, J = 6.8 Hz, 1H), 3.63 (t, J = 5.4 Hz, 2H) , 4.02 (s, 3H), 4.28 (t, J = 6.1 Hz, 2H), 6.79. -* 6,91 (m, 2H), 7.18 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.28 (d, J = 2.7 Hz, 1H), 7.37 (s, 1H), 7.48 (s, 1H) , 7.96 : -' 8.06 (m, 2H) , 8.26 (d, J = 9.0 Hz, 1H) , 8.59 (s, 1H) Mass analysis, found (ESI-MS, m/z): 588 (M++l) Example 166: N- [ 2-Ghl()ro-4- ( < 6-methoxy-7 - [ 2- ( 4-methyl-piperazino ) ethoxy ] -4-guinolyl }oxy )phenyl ] -N ' - ( 2 f 4-difluorgphenyl ) urea A starting compound (N- ( 4-{ [ 7- ( 2-bromoethoxy) -6-methoxy-4-quinolyl ]oxy}-2-chlorophenyl ) -N' - ( 2 , 4-difluorophenyl )urea, 50 mg), potassium carbonate (138 mg), and 1-methylpiperazine (0.055 ml) were dissolved in N,N-dimethylf0rmamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction . mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 48 mg (yield 93%) of the title compound. , ^-NMR (C ci3> · 4'06 MHz): δ 2.31 (s, 3H), 2.40 - 2.75 (m, 8H), 2.95 (t, J = 6.1 Hz, 2H), 3.99 (s, 3H), 4.31 (t, J = 5.9 Hz, 2H), 6.48 (d, J = 5.1 Hz, 1H), 6.85 - 6.96 (m, 3H), 7.12 (dd, J = 2.7 Hz, 9.0 Hz, 1H), 7.15 (s, 1H), 7.22 (d, J = 2.7 Hz, 1H), 7.40 (s, 1H), 7.47 (s, 1H), 7.94 - 8.03 (m, IH), 8.25 (d, J = 9.0 Hz, 1H), 8.49 (d, J = 5.1 Hz, 1H) Example 167 ; ■ N-{2-ChlQro-4- [ ( 7-{2-[ (2- ydroxyet yl)- (methy1 ) amino ] e hoxy} -6-methoxy-4-quinoly1 ) oxy ] henyl} - ' - ( 2 , 4-difluorophenyl ) ¾rea A starting compound (N-(4-{ [ 7- ( 2-bromoethoxy ) -6-methoxy-4-quino>lyl ] oxy} -2-chlorophenyl ) - ' - ( 2 , 4 - difluorophenyl );urea 50 ' mg)., potassium carbonate (138 mg), and 2- (methylamino ) ethanol (0.040 ml) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer, was dried over anhydrous sodium sulfate, and the solvent . was removed by distillation under the reduced pressure. The residue was washed with ether to give 48 mg (yield 97%) of the title compound. 1H-NMR.(CDC13, 4,00 MHz ) : δ 2.44 (s, 3H), 2.71 (t, J = 4.9 Hz, 2H), 3.02 (t, J = 5.6 Hz, 4H), 3.66 (t, J = 5.1 Hz, 2H), 3.97 (s, 3H), 4.27 (t, J = 5.6 Hz, 2H) , 6.46 (d, J = 5.4 Hz, 1H), 6.80 - 6.93 (m, 2H), 7.11 (dd, J = 2.7 Hz, 9.0 Ηζ, ΙΗ),; 7.19 (d, J = 2.7 Hz, 1H), 7.45 (s, 1H), 7.96 - 8.04 (m, 1H), 8.25 (d, J = 9.0 Hz, 1H), 8.48 (d, J = 5.1' Hz, 1H) Example 168; N- I 2-Chloro-4-{ \ 6-methoxy-7- ( -morpholino-propoxy \ -4-quii^olyl loxy>phenyl ) -N ' -( 2.4-difluorophenyl ) -urea A starting compound (N- ( 4-{ [ 7- ( 3-bromopropoxy ) -6-methoxy-4-quiholyl]oxy}-2-chlorophenyl ) -N' -(2,4-difluorophenyl) urea, 50 mg), potassium carbonate (138 mg), and morpholine (0.044 ml) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous' sodium .sulfate/ and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 32 mg (yield 64%) of the title compound. 8.10 (m, 1H), 8.32 (d, J = 9.0 Hz, 1H), 8.42 (s, 1H), dissolved in N, N-dimethylformamide (5 ml), and the solution was stirred at room temperature for 3 hr. The solvent was removed ;by distillation under the reduced pressure. Water was added to the residue, and the mixture was extracted with chloroform/2-propanol (4/1). The organic layer was, dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 53 mg (yield 41%) of N-(4-[7-(3-bromopropoxy ) -6-methoxy-4-quinazolinyl ]oxy-2-methoxy-phenyl}- ' -propylurea . N- ( 4-{ [ 6- ( 3-Bromopropoxy ) -7-methoxy-4-quinazolinyl ] oxy}-2-chlorophenyl}- '-propylurea (50 mg) , potassium carbonate (60 mg), and N-methylpiperazine . (100 μΐ) were dissolved in N,N- dimethylformamide (2 ml), and the solution was stirred at room temperature for 16 hr. The solvent was removed by distillation under the reduced pressure. A saturated aqueous sodium hydrogencarbonate solution was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by chromatography on silica gel by development wit;h chloroform/methanol to give 22 mg (yield 42% ) of the - title compound. 1H-NMR, (CDCI3, 400 MHz): δ 0.97 (t, J = 7.6 Hz, 3H), 1.56 - 1.60 (m, 2H), 2.14 (br, 2H), 2.50 (br, 4H), 2.58 (br, 2H), 3.23 - 3.26 (m, 2H), 3.74 (br, 4H), 3.87 (s, 3H), 4.04 (s, 3H), 4.27 - 4.31 (m, 2H), 4.62 - 4.64 (m, 1H), 6.65 (s, lH), 6.79 - 6.85 (m, 2H), 7.33 (s, 1H), 7.53 (s, lH), 8.10 ,(d, J = 8.5 Hz, 1H), 8.62 (s, 1H) Mass analysis, found (ESI-MS, m/z): 526 (M++l) Example 172: U- 12.4-Pifluorophenyl ) —N ' — ( 2—methoxy-4-{ [6-methoxy-7-(3-morpholinopropoxy)-4-quinazolinyl]oxy>-phenyl)urea N- ( 2 , 4r-Difluorophenyl j -N' -4-[ ( 7-hydroxy-6-methoxy-4-quinazolinyl ) oxy ] -2-methoxyphenylurea (375 mg), potassium carbonate (442 mg), and 1 , 3-dibromopropane (242 mg) were dissolved in N,N-dimethylformamide (5 ml), and the solution was stirred at room temperature for 3 hr. The solvent was removed by distillation under the reduced pressure. Water was added to the residue, followed by extraction with ethyl acetate. The organic layer was dried over . anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 210 mg (yield 45%) o;'f N-{4-[7-(3-bromopropoxy)-6-methoxy-4-quinazolinyl ]oxy-2-methoxyphenyl}-N' - ( 2 , 4-difluoro-phenyl)urea. -(4-{ [6-(3-Bromopropoxy) -7-methoxy-4-quinazolinyl]oxy}-2-chlorophenyl}-N'-propylurea (130 mg), triethylamine (0.5 ml), and morpholine (0.5 ml) were dissolved in. N'>N-dimethylf0rniamide (4 ml), and the solution was stirred at room temperature for 18 hr. The solvent was removed by distillation under the reduced pressure. A. saturated aqueous . sodium hydrogencarbonate solution was added to the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous εοείΐμιη .1 sulfate, and the solvent was removed by distiiiation, ;under the reduced pressure. The residue was purified, by chromatography on silica gel by development with chloroform/methanol to give 81 mg (yield 62%) of the title compound.

'H-NMR (CDG13, 400 MHz): δ 1.97 - 2.00 (m, 2H), 2.39 (br, 4H), 2.49 - 2.51 (m, 2H), 3.58 - 3.60 (m, 4H), 3.88 (s, 3H), 3.98 (s, 3H), '4.25 (t, J = 6.3 Hz, 2H), 4.27 - 4.31 (m, 2H) ,; 4.62 - 4.64 (m, 1H) , 6.84 (dd, J = 2.7 Hz, 8.8 Hz, lH), 7.Q3 -' 7.07 (m 2H), 7.28 - 7.34 (m, 1H), 7.38 (s, 1H) , 7.55 (s, 1H) , 8.11 - 8.17 (m, 2H), 8.55 (s, 1H), 8.74 (s, lH), 9.18 (s, 1H) Mass analysis,' found (ESI-MS, m/z): 596 (M++l) dibromopropane( 0.10 ml) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give an intermediate. The intermediate, potassium carbonate (138 mg), and morpholine (0:040 ml) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at room temperature^ for ; 18 hr. Water was added to the reaction mixture,' and .the mixture was extracted with at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation iunder the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 65 mg (yield 67%) of the title compound.

^-NMR (CDCI3, 400 MHz): δ 0.95 (t, J = 7.3 Hz, 3H), 1.52 - 1.69 (m, 2H) , 3.24 (dd, J = 7.3 Hz, 12.9 Hz, 2H), 3.82 (s, 3H) , 4.06 (s, 3H), 4.63 - 4.69 (m, 1H), 5.32 (s, 2H), 6.46 (d, J = 5.4 Hz, 1H), 6.68 (d, J = 2.7 Hz, 1H) , 6.77 (dd, J = 2.4 Hz, 8.5 Hz, 1H), 7.37 (s, 1H), 7.42 (d, J = 6.1 Hz, 2H) , 7.59 (s, 1H) , 8.14 (d, J = 8.5 Hz, 1H) , 8.43 (d, J = 5.4 Hz, . IH), 8.61 (d, J = 6.1 Hz, 2H) Example 175: N-Ethyl-N'-( 4-{ [ 6-methoxy-7- ( 2-morpholino- ethoxy ) -4-qujnolyl ]oxy }-2.5-dimethylphenyl )urea A starting ' compound (N-ethyl-N' -{4-[ ( 7-hydroxy-6-methoxy-4-quinolyl)oxy]-2,5-dimethylphenyl}urea 76 mg) , potassium carbonate : (138 mg), and 1 , 2-dibromoethane (0.085 ml) were, dissolved in N,N-dimethyIformamide (1 ml), and the' solution was stirred at room temperature for 18 hr. Water was. added to ,the reaction mixture, and the mixture was "extracted with chloroform-propanol (3/1). The organic .layer ' . was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give ah, intermediate (N- ( 4-{ [ 7- ( 2-bromoethoxy ) -6-methoxy-4-quinolyi ]:oxy} -2 , 5-dimethylphenyl ) -N ' -ethylurea). The intermediate, potassium carbonate (138 mg), and. morphpline '(0.044 ml) were dissolved in N,N-dimethylformamide. ,( 1 : ml , arid the solution was stirred at room temperature for : 18. hr . Water was added to the reaction mixture,' and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous - sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 72 mg (yield 73%) of the title compound.

^-NMR ( CDClj , 400' MHz ) : ,6 1.10 (t, J = 7.3 Hz, 3H), 2.07 (s, 3H), 2.16 (s 3H), 2.53 - 2.59 (m, 4H), 2.88 (t, J = 5.9 Hz, 2H), 3.20 - 3.30 (m, 2H), 3.66 - 3.71 (m, 4H), 3.96 (s, 3H) , 4.26 (t, J = 5.9 Hz, 2H), 4.73 - 4.82 (m, 1H), 6.16 (s, lH), 6.23 (d, J = 5.4 Hz, 1H) , 6.88 (s, 1H), 7.35 (s,. 1H), 7.40i(s, lH), 7.50 (s, 1H), 8.38 (d, J = 5.1 Hz, lH) E ample 176 : N-'f 4- ( -f 6-Methoxy-7- f 3- ( 4-methyl i perazino ) -propoxy ] -4-quinoly1 }oxy ) -2.5-dimethylphen l ] -N ' -propylurea A starting compound (N-{4- [ ( 7-hydroxy-6-methoxy-4-quinolyl )oxy] -2, 5-dimethylphenyl}-N' -propylurea, 80 mg), potassium carbonate (138 mg), and 1,3- dibromoprppane( 0.10 ml) were dissolved in N,N-dimethylformamide (-1 ml), and the solution was stirred at room temperature for 18 hr. · Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol : (3/1) . The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give an intermediate ( N- ( 4- { [ 7- ( 3 -bromopropoxy ) -6-methoxy-4-quinoly1 ] oxy} -2,5-dimethylphenyl)-N'-propylurea) . The intermediate, potassium carbonate (138 mg), and 1-methylpiperazine (0.055 ml) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the mixture was stirred at room temperature for 18 hr. Water was . added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic . layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 33, mg (yield 31%) of the title compound.

XH-NMR (CDCI3, 400 MHz): δ 0.91 (t, J = 7.6 Hz, 3H), 1.50 - 1.58 (m, 2H), 2.07 - 2.20 (m, 2H), 2.12 (s, 3H), 2.23 (s, 3H), 2.28 (s, 3H), 2.33 - 2.70 (m, 10H), 3.21 (dd, J = .7.3 Hz, 13.4 Hz, 2H), 4.00 (s, 3H), 4.24 (t, J = 6.6 Hz, 2H), 4.64 - 4.76 (m, 1H), 5.95 - 6.05 (m, 1H), 6.27 (d, J = 5.1 Hz, 1H), 6.95 (s, 1H), 7.39 - 7.43 (m, 2H), 7.54 (s, IH), 8.42 (d, J = 5.1 Hz, 1H) Mass analysis, found (ESI-MS, m/z): 536 (M++l) Example 177: N- ( 2.4-Difluorophenyl ) -N' - [ 4- ( {6-methoxy-7-[ 2- (lH-1.2.3-triazol-l-yl ) ethoxy ] -4-qui nolyl >oxy ) -7. -dimethylphenyl ]urea A starting " compound (N-(2,4-difluorophenyl)-N'-{4-[ ( 7-hydroxy-6-methoxy-4-quinolyl ) oxy ] -2 , 5-dimethyl-phenyl}urea, 93 mgj, potassium carbonate (138 mg), and 2- ( lH-1 , 2 , 3-triazol-l-yl}ethyl 4-methyl-1-benzene-sulfonate, (52 mg) · were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at, 80°C for 5 hr. Water was added to the reaction mixture, and t!he mixture was extracted with chloroform-propanol (·3'/1) .· · The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 33 mg (yield ; 30%) of the title compound. 1H-NMR (CDC13, · 400 MHz ) : δ 2.10 (s, 3H), 2.19 (S, 3H), 4.01 (s, 3.H) , 4.51 . (t, J = 4.9 Hz, 2H), 4.93 (t, J = 5.4 Hz, 2H )' , :4.94: (s^J.lH), 6.28 (d> J = 5.1 Hz, 1H), 6,75 - 6.88 (m, 2H), 6.90 (s, lH), 7.36 (s, 1H), 7.58 (s, 1H), 7.60 (s, 1H), 7.73 (s, 1H), 7.99 (s, 1H), 8.08 (dd, J = 9.3 Hz, 15.1 Hz, 1H), 8.41 (d, J = 5.1 Hz, 1H) Example 178 : ' - ( 2-Chloro-4--{ [ 6-methoxy-7- ( 2-morpholino-ethoxy ) -4-quinazolinyl ] oxy}phenyl ) -N , N-dimethylurea A starting compound (N'-{2-chloro-4-[ ( 7-hydroxy-6-methoxy-4-quinazplinyi ) oxy] phenyl}-N, N-dimethylurea, 80 mg), potassium carbonate (138 mg), and 1 , 2-dibromoethane (0.085 ml) were' dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 nr.'. Wate was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give an intermediate (N'-(4-{ [7-(2-bromoethoxy) -6-methoxy-4--quinazolinyl ]oxy}-2-chlorophenyl )-N, N-dimethylurea ) . The intermediate, potassium carbonate (138 mg), and morpholine (0.043 ml) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 72 mg (yield 72%) of the title .compound. mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the; solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give an intermediate (N'-(4-{ [7-(4-bromobutoxy) -6-methoxy-4-quinazolinyl ]oxy}-2-chloro-phenyl)-N, N-dimethylurea ) . The intermediate, potassium carbonate (138 mg), and morpholine (0.043 ml) were dissolved in N,N-dimethylformamide (1 ml), and the solution was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was driedi over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 47 mg (yield 44%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 1.67 - 1.77 (m, 2H), 1.93 - 2.03 (m, 2H) , 2.39 - 2.50 (m, 4H), 3.67 (s, 6H), 3.64 - 3.75 (m, 4H), 4.02 :(s, 3H), 4.21 (t, J = 6.6 Hz, 2H), 6.97 (s, 1H) , .7.16 (dd, J = 2.7 Hz, 9.3 Hz, 1H), 7.26 (s, 1H), 7.28 (s, 1H) , : 7.29 (d, J = 2.7 Hz, 1H), 7.48 (s, 1H), 8.36 (d, J = 9.3 Hz, 1H), 8.59 (s, 1H) under the reduced pressure. The residue was purified by HPLC by development with chloroform/methanol to give 37 mg (yield 60%) of the title compound. 1H-NMR (CDCI3, 400 MHz): δ 3.07 (s, 6H), 3.82 (s, 3H), 4.06 (s, 3H), 4.87 (s, 2H), 6.97 (s, 1H), 7.14 (dd, J = 2.7 Hz, 9.0 Hz, lH), 7.18 (s, 1H), 7.29 (d, J = 2.7 Hz, 1H), 7.54 (s, IH), 8.36 (d, J = 9.0 Hz, 1H), 8.60 (s, 1H) Example 182: N'-[ 2-Chloro-4- ( { 6-methoxy-7- [ 3- ( 4-methylpiperazin ) rqpoxy| -4-quinazQlinyl }oxy) henyl ] -N, N-dimethylurea A starting compound (Ν' -{2-chloro-4- [ ( 7-hydroxy-6-methoxy-4-quxnazolinyl ) oxy]phenyl}-N,N-dimethylurea , 400 mg), potassium carbonate (966 mg), and 1,3-dibromopropahe (0.51 ml) were dissolved in N,N-dimethylformamide (5 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol '( 3/1 ) . The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 398 mg (yield 78%) of an intermediate (N'-(4-{ [ 7-( 3-bromopropoxy)-6-methoxy-4-quinazolinyl ]oxy}-2-chlorophenyl ) -N,N-dimethylurea) . The intermediate (51 mg), potassium carbonate (138 mg), and 1-methylpiperazine (0.055 ml) were dissolved in Ν,Ν-dimethylformamide (1 ml), and the solution was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the reduced pressure. The residue was washed with ether to give 46 mg (yield 85%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 2.06 - 2.16 (m, 2H), 2.29 (s, 3H), 2.30 - 2.60 (m, 10H), 3.07 (s, 6H), 4.02 (s, 3H), 4.25 (t, J = 6.8 Hz, 2H), 6.96 (s, 1H), 7.15 (dd, J = 2.7 Hz, 9.0 Hz, 1H) , 7.29 (d, J = 2.7 Hz, 1H), 7.30 (s, 1H), 7.48 (s;, 1H), 8.36 (d, J = 9.0 Hz, 1H), 8.59 (s, 1H) Mass analysis, ·, found (ESI-MS, m/z) : 529 (M++l) Example : 183:, (methyl) amino]propdxy}-6'-methox.y-4-quinazo inyl) oxy]- phenyl}-N,N-dime hylur ai ' - A starting compound (N'-{2-chloro-4-[ ( 7-hydroxy-6-methoxy-4-quinazoliny1 )oxy]phenyl}-N,N-dimethylurea, 400 mg), potassium carbonate (966 mg), and 1,3-dibromopropane : (.0.51 ml) were dissolved in N,N-dimethylformamide (5.ml), and the mixture was stirred at room temperature for 18 hr. Water was added to the reaction mixture,". and ' ¾the mixture was extracted with chloroform-propanol (3/i). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under the. reduced pressure. The residue was washed with ether to give 398 mg (yield 78%) of an1 intermediate (N'-(4-{ [7-(3-bromopropoxy)-6-methoxy-4-quinazblinyl ]oxy}-2-chlorophenyl. ) -NjN-dimethylurea) . ■ The , intermediate (51 mg), potassium carbonate (138 mg) ,. : and 2-(methylamino)ethanol (0.040 ml) were dissolved .in N, -dimethylformamide (1 ml). The mixture was stirred at room temperature for 18 hr. Water was added to the reaction mixture, and the mixture was extracted with chloroform-propanol (3/1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was; , removed by i distillation under the reduced pressure. The residue was washed with ether to give 49 mg (yield 97%) of the title compound.

'H-NMR (CDCI3, 400 MHz): δ 2.01 - 2.11 (m, 2H), 2.25 (s, 3H), 2.52 (t, J = 5.1 Hz, 2H), 2.61 (t, J = 7.1 Hz, 2H), 3.03 (s, 6H), 3.57 (t, J = 5.1 Hz, 2H), 3.98 (s, 3H), 4.23 (t, J = 6.6 Hz, 2H), 6.92 (s, 1H), 7.10 (dd, J = 2.7 Hz, 9.3 Hz, 1H), 7.24 (d, J = 2.7 Hz, 1H), 7.31 (s, 1H), 7.44 (s, .1H) , 8.31 (d, J = 9.0 Hz, 1H), 8.54 (s, 1H) Mass analysis, found (ESI-MS, m/z): 504 (M++l) Example 184; N- ( 2-Chloro-4-{ [ 6-methoxy-7- ( 3-pi eridino-propoxy ) -4-auinazolinyl 1 oxylphenyl ) - ' -methylurea N-{2-Chloro-4-[ (7-hydroxy-6-methoxy-4-quinaz- t olinyl )oxy]phenyl}-,N' --methylurea (2.0 g) was dissolved in Ν,Ν-dimethylformamide (50 ml), and triphenylphosphine (2.8 g ) , piperidinopropanol (0.9 g ) , and diethyl azodicarboxylate. (1.9 g) were added to the solution. The mixture was : stirred, at room, temperature for 2 hr. Triphenylphosphine (2.8 g), piperidinopropanol (0.6 g), and diethyl 'azodicarboxylate (1.9 g) were then again added to the reaction solution, followed by stirring at room temperature for additional 10 hr. The solvent was removed by distillation, under the reduced pressure. The residue was purified by chromatography on silica gel by development with chloroform/methanol (20/1) to give 650 mg (yield 25%) of the.;title compound.

^-NMR (D SO-d6, 400 MHz): δ 1.37 - 1.43 (m, 2H), 1.43 - 1.53 (m, 4H), 1.96 - 2.00 (m, 2H), 2.29 - 2.50 (m, 6H), 2.68 (d, J = 4.6 Hz, 3H), .3.97 (s, 3H), 4.23 (t, J = 6.3 Hz, 2H), 6.82 -» 6^85 (m, 1H), 7.23 (dd, J = 2.7 Hz, 9.0 Hz, lH), 7.38 (s, 1H), 7.47 (d, J = 2.7 Hz, 1H), 7.54 (s, 1H), 8.07 . (s, lH), 8.17 (d, J = 9.0 Hz, 1H), 8.55 (s, 1H) Mass analysis, .found (ESI-MS, m/z): 500 (M++l) Example 185: N- < 2-Chloro-4—( [ 6-methoxy-7- ( -piperidino-propoxy ) -4-quin'azolinyl ] oxy}phenyl ) - ' -ethylurea N-{2-Chloro-4- [ ( 7-hydroxy-6-methoxy-4-quinaz-olinyl )oxy]phenyl}-N' ^-ethylurea (2.7 g) was dissolved in Ν,Ν-dimethyIformamide: ' (30 ml), and triphenylphosphine(3.6 g), piperidinopropanol. (1.2 g), and diethyl azodicarboxylate (2.4 g) were added to the solution. The mixture was stirred at room temperature for 2 hr. Triphenylphosphine (3.6 g), piperidinopropanol (0.8 g), and diethyl; azodicarboxylate (1.9 g) were then again added . to the : reaction solution. The mixture was stirred at room temperature for additional 10 hr. The solvent was removed by distillation under the reduced pressure, and the residue was purified by chromatography on silica gel by development with chloroform/methanol (20/1) to give 1.5 g (yield 42%) of the title compound. 1H), 8.08 - 8.15 (m, 1H), 8.24 (d, J = 9.0 Hz, 1H), 8.49 (d, J = 5.4 Hz, 1H), 8.60 - 8.63 (rii, 1H), 8.81 - 8.83 (m, 1H) , 9.30 - 9.31 (m, 1H) Mass analysis, found (ESI-MS , m/z ) : 563 (M++l) The structures of the compounds described in the examples are as follows . ta EC EC ' . EC EC ·. X EC EC EC . EC EC EC EC - EC EC EC EC EC EC EC ps! (X EC EC • EC ' EC '. EC EC EC EC EC EC OS EC EC EC . K · EC EC EC EC ' EC EC el EC EC EC ■EC · EC EC EC EC EC o O O o O O o O o O EC EC EC EC EC EC EC EC EC EC o O υ ϋ O O o O O 0-5 EC EC . EC EC EC EC EC EC EC EC EC EC . EC ' ' EC EC EC EC EC EC EC N O O . O O O O O O O O d EC EC EC EC EC EC EC EC o O o ■ O O ϋ O . ϋ O CO CO LO CO t— 00 ı73 rc ώ ' K . " ■ X rc rc rc rc rc 1 -.

PS rc rc rc rc rc rc ■ ■ ac ■ ■ . X rc rc rc rc rc in m , • re ' X rc rc rc X rc o o o o o o υ O o m m rn m rc' ■ X ■ rc rc rc rc X SC rC rc o o CJ rc re rC ;rc rc X rc rc X o o o b o o o o o o m m m K . re X: rc rc rc X rc o o . O o o o CJ CJ o o o ό o o o o o o m m i m rn X S3 rc a: • re rc rc rc rc rc o o CJ o o o o o o • o rc rc ■ rC re rc rc rc rc rc IE rc rc rc re rc rc rc rc rc o CJ o ■ CJ o o o o o u re rc re rc · rc rc rc re ■ rc o o (J •G u o o o o o co O LO c— oo CT5 o CO CS1 CO CO CO CO CO O o O O 0 O O 0 0 0 0 X 33 ' 33 .33 33 . 33 X X X X Pi CJ O O . O 0 CJ 0 O CJ o o O O . O 0 O 0 O O S3 33 33 33 ' . ■ 33 33 X X X X pi O o u . a- O a O 0 CJ 0 Pi 33 33 33 33 33 X X X X 33 33 . 33 .33 33 X X X X X l CJ o 0 . CJ CJ 0 0 - CJ 0 to . ■ c— X X X X X X X X X X X X X X X o o o o o X 35 X X id X X o o o o o o o o 2 z X X X X id id id id id id id id id i o o o o o o o o o x x x ic id id id X X X X X u o o o u o o X id id id id id i id id X a o u u u o o υ x 32 32 32 32 32 32 X X X x 32 32 32 32 32 32 X X X 32 32 32 EC 32 32 32 X X X 32 32 X X P3 O O 32 32 32 X a a X 32 X X X 32' 32 32 32 O o X X CJ X 32 32 32 32 X . X X X o CJ CJ J O J o a CJ CJ X X 32 32 32 32 X X X X 32 32 32 32 32 32 X X X X CJ O J CJ a o o o J o 32 32 32 32 32 32 X X X X O J a a O CJ J CJ o oo r> o to to  o Pi ffi ffi ffi ffi ffi ffi ffi ffi ffi 06! tc ffi ffi ffi ffi ffi ffi ffi ffi 03 Pi ffi ffi ffi ffi ffi ffi ffi ffi ffi Pi ac ffi ffi ffi M ffi ffi ffi ffi i o O O o O O fx. i ffi ffi ffi ffi ffi ffi ffi ffi ffi Pi ffi ffi ffi ffi ffi W .. ffi ffi o o O o o O O o o Pi ffi ffi ffi ffi e ffi ffi ffi ffi O o u a υ o o O o o o o o o o o Pi ffi ffi ffi ffi X ffi ffi ffi ffi o a o o υ o o O o Pi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi N o o a o u o o o o X! 2 2 2 2 2 2 2 2 2 1 C to oo o oo oo oo OO oo C CO CO i EC EC EC EC EC EC EC EC EC EC i EC EC EC EC EC EC EC EC EC EC i EC EC EC EC EC EC EC EC EC EC i EC EC EC EC EC EC EC EC EC EC i ^ . fn EC EC EC EC EC EC EC EC EC EC EC EC EC o o O o EC EC EC EC EC EC EC EC EC EC o O O O O O o O O O Pi EC EC EC EC EC EC EC EC EC EC. O o O O O o O O O O o o o o o o o o o o (¾ EC EC EC EC EC EC EC EC EC EC o O ■ O o o O O O O o EC EC EC EC EC EC EC EC EC EC EC EC EC EC EC EC EC EC EC EC O O O O a a O O O O X 2 2 2 2 2 2 2 2 2 — to c— oo σ> o n o — Pi EC X EC EC EC EC EC EC EC 1 ΕΠ o EC X EC EC EC EC EC O Pi pe Pi X X X EC EC EC EC EC Ed EC Pi' X as X EC EC EC EC EC EC EC X EC EC EC EC o O Pti X ■ u O o o 2 2 o O EC CtJ o . EC X EC EC EC. EC Ed d i "X EC X EC EC X EC Si Ed Ed o o o O o O O O o o Pi . X a EC EC EC EC EC EC EC Ed o o O a O O o o o o o o o o o o o o Pi X EC EC EC Ed EC EC EC EC d O o o o O O O Pi EC EC X EC EC EC EC EC EC EC X X X EC EC EC EC EC Ed CO EC a υ O o O υ O u o z 2 2 Z 2 2 2 2 2 2 o o < -¾· cr> o to o r— σ¾ o B pa o OS a a B a a a a a a a r- Pi B a a a . a a a a a a P-5 o o o o CJ o o o J CJ B a a ' a • a a K.. a a PS a a a a a a a a a CO ! a a a a a a a a a O o o o o a O CJ υ X 2 2 2 2 2 2 2 2 2 —1 -"3· O S —1 < — 1 1 —l .—1 ■r— 1 1 EC o EC EC Ed Ed EC EC EC EC EC o S EC EC EC EC EC EC EC EC S EC EC EC EC EC EC EC EC EC S EC EC EC EC EC EC EC EC EC S o o o ό o o o o c_> S EC EC EC EC EC EC EC EC o O O O O o O O O o m rn i i EC EC EC Ed Ed .Ed EC Ed Ed Ed O υ o o CJ o O o o o S EC EC EC Ed Ed EC Ed EC Ed EC EC EC EC EC Ed EC Ed Ed Ed EC S! o O O o o o o o u . ! 2 2 2 2 2 2 2 2 2 2 C to oo CD 3 C 3 C-3 < 3 CO X Z R1 R2 R: R R5 R6 R7 Ra R9 R 10 131 N CH H CH30 N^N' H H C I H H H CH3CH; H2 137 N CH H -N N^^O^ CH30 H H C 1 H H H H 138 N CH H L JL o CHsO H H C 1 H H H H 139 N CH H ° Nv CH3O H H C 1 H H H H I 140 N CH H HO^/N^^0^ CH3O H H C 1 H H H H m o pi 53 53 53 53 53 53 53 53 53 53 P-3 53 53 53 53 53 53 53 53 53 53 Pd 53 53 53 53 53 53 53 53 53 Pd 53 53 53 53 53 53 53 53 Pi o o o 53 53 53 53 53 53 53 53 i 53 53 53 53 53 5! 53 53 53 53 53 53 53 53 53 53 53 to a o O O O O O o υ υ 53 53 53 53 53 53 51 53 53 X a υ O O o O O O O O to C ı88 EC EC EC Pi EC EC EC EC EC EC EC o O O Pi C ■ EC EC EC EC EC EC EC EC EC n i EC EC EC EC EC EC EC EC EC EC EC EC EC Pi EC EC EC EC EC υ O EC EC o o O O O Pi EC EC EC EC EC EC - EC o O o a o O o Pi EC EC. EC EC EC EC EC EC EC EC Pi EC EC EC EC EC EC EC EC EC O O o O o o o o o o Pi EC EC EC EC EC EC EC EC EC EC o a υ O ( u O U U U ci . EC EC EC Ed EC EC Ed EC EC EC EC EC EC EC EC EC EC EC EC EC N a O O a O O O O O O EC EC EC EC Ed X Z z O O υ O υ Z Z Z »— t CO ■β· to c— oo σ> e— c— r— t— c— c— c— c— i o o o a a i a a a i a a a a a a i a a a a a i o o o S. a a -a . a a i a a a a a o o o o O o i a a a a a a o o o o i a a a a a a 3 a a a a a a o o o o o a z Z Z z Z o O -«· L O oo oo oo oo OO oo .—1 f— 1 Pharmacological Tes Example li Measurement of inhibitory activity against activation of MAPK within vascular endothelial cells induced by VEGF stimulation Human funicular venous vascular endothelial cells (purchased from Chronetics) were cultured in an EGM-2 medium (purchased from Chronetics) within an incubator containing 5% carbon dioxide until 50 to 70% confluent, and the culture was inoculated into wells, containing the same medium, in a 96-well flat-bottom plate in an amount of 1.5 x 10s per well. After cultivation at 37°C overnight, the medium was replaced by an EBM-2 medium containing 0.5% fetal calf serum (purchased from Chronetics), followed by cultivation for 24 hr. A solution of the test compound in dimethyl sulfoxide was added to each well, and the cultivation was continued at '37°C for additional one hr. A human recombinant vascular endothelial growth factor (hereinafter abbreviated to "VEGF" ) was added to a final concentration of 50 ng/ml, and the stimulation of cells was' carried out at 37°C for 8 min. The medium was removed, the cells were washed with phosphate buffered saline (pH 7.4),. and 10 μΐ of a solubilization buffer (Tris buffered saline (pH 7.4) containing 1% Triton XI00, 2 mM sodium orthovanadylate, and 1 mM disodium ethylenediaminetetraacetate) was then added thereto. The mixture was shaken at 4°C for one hr to solubilize the cells. An equal amount of Tris buffered saline containing 1% sodium laurylsulfate was added to and thoroughly mixed with the solution. This solution (2 μΐ) was adsorbed on a PVDF filter by dot blotting, and this filter was subjected to immunoblotting with anti-tyrosine phosphorylated MAPK antibody (purchased from Daiichi Pure Chemicals).

The level of phosphorylated MAPK was quantitatively determined with a densitometer, and the percentage phosphorylated MAPK in the presence of the test compound was determined by presuming the level of phosphorylated MAPK with the addition of VEGF in the absence of the test compound to be 100% and the level of phosphorylated MAPK in the absence of the test compound and VEGF to be 0%. The test compound concentration (ICS0) necessary for inhibiting 50% of the activation of MAPK was calculated based on the percentage of phosphorylated MAPK.

The results were as summarized in Table 1.

Table 1 Pharmacological Test Example 2; Measurement of inhibitory activity against KDR phosphorylation by ELTSA NIH 3T3 cells (Sawano A et al. Cell Growth & Differentation, 7, 213-221 (1996), "Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor") prepared by transfection of human KDR were cultured in a DMEM medium containing 10% fetal calf serum (purchased from GIBCO BRL) within a 5% carbon dioxide incubator until 50 to 70% confluent. The harvested cells were inoculated into wells, containing the same medium, in a collagen-type one-coat 96-well flat-bottom plate in an amount of 1.5 x 104 per well, followed by cultivation at 37°C overnight. The medium was then replaced by a DMEM medium containing 0.1% fetal calf serum. A solution of the test compound in dimethyl sulfoxide was added to each well, and the cultivation was continued at 37°C for additional one hr. A human recombinant vascular endothelial growth factor (hereinafter abbreviated to "VEGF") was added to . a final concentration of 100 ng/ml, and the stimulation of cells was carried out at 37°C for 2 min. The medium was removed, the cells were washed with phosphate buffered saline (pH 7.4), and 50 μΐ of a solubilization buffer (20 mM HEPES (pE 7.4), .150 mM NaCl, .0..2% Triton X-100, 10% glycerol, 5 mM sodium orthovanadylate, 5 mM disodium ethylenediaminetetraacetate, and 2 mM Na4P207) was then added thereto. The mixture was shaken at 4°C for 2 hr to prepare a cell extract.

Separately, phosphate buffered saline (50 μΐ, pH 7.4) containing 5 μg/ml of anti-phospho-tyrosine antibody (PY20; purchased from Transduction Laboratories) was added to a microplate for ELISA (Maxisorp; purchased from NUNC), followed by standing at 4°C overnight to form a solid phase on the wells. After washing of the plate, 300 μΐ of a blocking solution was added, followed by standing at room temperature for 2 hr to perform blocking. After washing, the whole quantity of the cell extract was transferred to the wells, and the plate was then allowed to stand at 4°C overnight. After washing, an anti-KDR antibody (purchased from Santa Cruz) was allowed to react at room temperature for one hr, and, after washing, a peroxidase-labeled anti- rabbit Ig antibody (purchased from Amersham) was allowed to react at room temperature for one hr. After washing, 5 a chromophoric substrate for peroxidase (purchased from Sumitomo Bakelite Co., Ltd.) was added thereto to initiate a reaction. After a suitable level of color development, a reaction termination solution was added to stop the reaction, and the absorbance at 450 nm was 10 measured with a microplate reader. . The KDR phosphorylation activity for each well was determined by presuming the absorbance with the addition of VEGF and without the addition of the medicament to be 100% KDR phosphorylation activity and the absorbance without the 15 medicament and VEGF to be 0% KDR phosphorylation activity. The concentration of the test compound was varied on , several levels , the inhibition (..% ) of KDR phosphorylation was determined for each case, and the concentration . of the test compound necessary for 20 inhibiting. 50% of KDR- phosphorylation ( IC50). was Λ · calculated. - . - .··-.··.

,.··:·■·. .. The results were as summarized in Table 2.

Table 2 Pharmacological Test Example 3: Karyomorphosis test A375 human melanoma cells (2 x 104) (obtained from Japanese Foundation for Cancer Research) were incolulated on a culture slide (manufactured by Falcon) and were cultured at 37°C. After the elapse of 5 hr from the initiation of the cultivation, the test compound was added to 10 μΜ and 1 μΜ, and the cultivation was continued for additional 48 hr. After the fixation of cells, 50 μg ml propidium iodide solution containing ribonuclease (200 μg/ml) was added to stain nuclei. The stained nuclei were observed under a fluorescent microscope to analyze the nuclei for abnormality of karyomorphosis. The change in karyomorphosis for test compounds was evaluated as (2+) when the change in karyomorphosis ' of cells took place at 1 μΜ;' was evaluated as ( + ) when the change in karyomorphosis of cells took place at 10 μΜ; and was evalauted as (-) when the change in karyomorphosis of cells, did not take place at 10 μΜ. ( . ' · . .. - The results were as summarized in Table 3.

Table 3 pharmacological Test Example 4_t Antitumor ef ect on human glioma cells (GL07V . .

Human glioma cells GL07. (obtained - from Central Laboratories for Experimental Animals) were transplanted into nude mice. When the tumor volume became about 100 mm3, the mice were grouped. In this case, grouping was carried out so that each group consisted of four mice and the average tumor volume was even among the groups. The test compound was orally or intraperitoneally administered at a dose of 20 mg/kg to the test groups every day once a day for 9 days, while the medium was administered to the control group in the manner as in the test groups. The tumor growth inhibition rate (TGIR) was calculated as follows: The tumor growth inhibition rate (TGIR) = (1 - Tx/Cx) x 100 wherein Cx represents the volume of tumor at day x for the control group when 144461/2 198 the tumor volume at the day of the start of the administration was presumed to be 1; and Tx represents the volume of tumor for test compound administration groups .

The tumor growth inhibition rate for representative examples of a group of compounds according to the present invention is shown in Table 4.

Material which is outside the scope of the claims does not constitute part of the claimed invention.

Table 4 (Part 1) TGIR, % = Tumor growth inhibition rate Table 4 (Part 2 ) TGIR, % = Tumor growth inhibition rate

Claims (1)

1. 201 A compound selected from the group of compounds consisting of propylurea ethylurea urea pentylurea or a pharmaceutically acceptable salt or solvate A pharmaceutical composition comprising as an active ingredient a compound according to claim or a pharmaceutically acceptable salt or solvate A compound according to claim or a pharmaceutically acceptable salt or solvate for use as a Use of a compound according to claim or a pharmaceutically acceptable salt or solvate for the manufacture of a therapeutic agent for use in the treatment of a disease selected from the group consisting of diabetic chronic and 202 compound represented by formula or a pharmaceu ically acceptable salt or solvate wherein X and Z each represent CH or represents a hydrogen any one of R2 and R3 represents unsubstituted alkoxy and the other represents group wherein represents a halogen amino on which one or two hydrogen atoms are optionally substituted by optionally substituted by hydroxyl or group wherein and which may be the or represent a hydrogen atom or alkyl which alkyl is optionally substituted by hydroxyl or or group wherein represents a saturated or unsaturated to carbocyclic or heterocyclic group substituted by alkyl and is 0 or and p is an integer of 1 to represents a hydrogen atom and which e the same or represent a hydrogen a halogen or provided that and do not simultaneously represent a hydrogen and which may be the same or represent a hydrogen or the alkyl portion 203 of which alkyl or alkylcarbonyl is optionally substituted by a halogen amino which is optionally substituted by alkyl optionally substituted by or a saturated or unsaturated to carbocyclic or heterocyclic and represents C2 e or alkynyl and alkynyl each are optionally substituted by halogen atom or or wherein n is an integer of 0 to 4 and represents a saturated or unsaturated to carbocyclic or heterocyclic group which is optionally substituted by a halogen or alkoxy and is optionally condensed with other saturated or unsaturated to ring or heterocyclic ring to form a bicyclic The compound according to claim wherein and represent hydrogen The compound according to claim 5 or wherein X represents N or Z represent A compound represented by formula or a pharmaceutically acceptable salt or solvate wherein X represents CH or any one of and represents unsubstituted alkoxy and 204 the other represents group wherein represents a halogen on which one or two hydrogen atoms are optionally substituted by optionally substituted by hydroxyl or group wherein and which the same or represent a hydrogen atom or alkyl which alkyl is optionally substituted by hydroxyl or or group wherein represents a saturated or unsaturated to carbocyclic or heterocyclic group optionally substituted by alkyl and m is 0 or and p is an integer of 1 to and which may be the same or represent a hydrogen a halogen or provided that and R26 do not simultaneously represent a hydrogen and which may be the same or represent a hydrogen or the alkyl portion of which alkyl or alkylcarbonyl is optionally substituted by a halogen C amino which is optionally substituted by alkyl optionally substituted by or a saturated or unsaturated to carbocyclic or heterocyclic and represents alkynyl and alkynyl each are optionally substituted by a halogen atom or or wherein q is an integer of 0 to 4 and R32 represents a saturated or unsaturated carbocyclic or heterocyclic group which is optionally substituted by a halogen or alkoxy and is optionally condensed with other saturated or unsaturated or carbocyclic ring or heterocyclic ring to form a bicyclic The compound according to claim 8 wherein and represent The compound according to claim wherein the unsubstituted 205 alkoxy group represented by or R22 represents The compound according to claim wherein p is an integer of 1 to The compound according to claim wherein represents a saturated or unsaturated or carbocyclic or heterocyclic The compound according wherein at least one of and R26 represents a halogen The compound according to wherein X represents or any one of and represents alkoxy and the other represents group and represent a hydrogen represents a halogen or and represent a hydrogen and represents or alkynyl and alkynyl each are optionally substituted by a halogen atom or or wherein g is an integer of 0 or 1 and represents or naphthyl which 206 py and naphthyl are optionally substituted by a halogen or The compound according to claim wherein represents unsubstituted alkoxy and represents group The compound according to claim 14 or wherein represents hydrox amino on which one or two hydrogen atoms are optionally substituted by alkyl optionally substituted by or group wherein represents a saturated or unsaturated heterocyclic containing 1 to 4 nitrogen atoms and optionally substituted by or a saturated or unsaturated heterocyclic group containing one or two selected nitrogen and oxygen atoms and optionally substituted by alkyl and is 0 and p is an integer of 1 to The compound according to any one of claims 14 to wherein p is The compound according to any one of claims 14 to wherein R represents group wherein represents an unsaturated heterocyclic group containing one or two nitrogen atoms and optionally substituted by alkyl and is 0 The compound according to any one of claims 14 to wherein represents group wherein represents an unsaturated heterocyclic group containing one or two nitrogen atoms and optionally substituted by alkyl and is 0 and p is The compound according to claim 18 or 207 wherein represents optionally substituted The compound according to claim wherein X represents CH or any one of and represents alkoxy and the other represents group and represent a hydrogen represents a halogen Ci or any one of or both and represent a group other than a hydrogen and represents or alkynyl and alkynyl each are optionally substituted by a halogen atom or or wherein q is an integer of 0 or 1 and represents or naphthyl which and naphthyl are optionally substituted by a halogen or The according to wherein represents unsubstituted alkoxy and represents group The compound according to claim 21 or wherein represents amino on which one or two hydrogen atoms are optionally substituted by alkyl optionally substituted by or group wherein represents a saturated or unsaturated heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by or a saturated or unsaturated heterocyclic group containing one or two selected from nitrogen and oxygen atoms optionally substituted by alkyl and is 0 and p is an integer of 1 to The compound according to any one of claims 21 144461 208 to 23 wherein p is 25 The compound according to any one of claims 21 to 23 wherein represents group wherein represents an unsaturated heterocyclic group containing one or two nitrogen atoms and optionally substituted by alkyl and is 0 The compound according to any one of 21 to 23 wherein represents group wherein represents an unsaturated heterocyclic group containing one or two nitrogen atoms and optionally substituted by C alkyl and is 0 and p is 27 The compound according to 25 or wherein represents optionally substituted 28 according to claim 8 wherein X represents or any one of and represents alkoxy and the other represents group and represent a hydrogen represents a halogen ar represents a hydrogen represents a group other than a hydrogen and represents or CJ t alkynyl and alkynyl each are optionally substituted by a halogen atom or or wherein g is an integer of 0 1 and represents or which and are optionally substituted by a halogen or 29 The compound according to claim 28 wherein 209 represents unsubstituted alkoxy and represents group The according to claim 28 or wherein represents amino on which one or two hydrogen atoms are optionally substituted by alkyl optionally substituted by or group R wherein represents a saturated or unsaturated heterocyclic group containing 1 to nitrogen atoms and optionally substituted by or a saturated or unsaturated heterocyclic group containing one or two selected from nitrogen and oxygen atoms and optionally substituted by alkyl and is 0 and p is an integer of 1 to The compound according to any one of claims 28 to wherein p is The compound according to any one of claims 28 to wherein represents group wherein represents an unsaturated heterocyclic group containing one or two nitrogen atoms and optionally substituted by alkyl and is 0 The compound according to any one of claims 28 to wherein represents group wherein represents an unsaturated heterocyclic group containing one or two nitrogen atoms and optionally substituted by alkyl and TO is 0 and p is compound according to claim 32 or 33 wherein represents optionally substituted The compound according to claim wherein X represents or 210 any one of and unsubstituted t and the other represents group and represent a hydrogen and represent a halogen or and represent hydrogen represents or alkynyl and alkynyl each are optionally substituted by a halogen atom or or wherein q is an integer of 0 or 1 and represents or naphthyl which and naphthyl are optionally substituted by a halogen or The compound according to claim wherein represents unsubstituted alkoxy and represents group compound according to claim 35 or wherein represents amino on which one or two hydrogen atoms are optionally substituted by alkyl optionally substituted by or group wherein represents a saturated or unsaturated heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by or a saturated or unsaturated heterocyclic group containing one or two selected from nitrogen and oxygen atoms and optionally substituted by alkyl and is 0 and p is an integer of 1 to The compound according to any one of claims 35 to wherein p is compound according to any one of claims 35 to wherein represents group wherein represents an unsaturated heterocyclic 211 group containing one or two nitrogen atoms and optionally substituted by and is 0 The compound according to any one of claims 35 to wherein represents group wherein represents an unsaturated heterocyclic group one or two nitrogen atoms and optionally substituted by alkyl and is 0 and p is The compound according to 39 or wherein represents optionally substituted A pharmaceutical composition comprising as active ingredient the compound according to any one of claims 5 to 7 or a pharmaceut cally acceptable salt or solvate Use of the compound according to any one of claims 5 to 7 or a pharmaceutically acceptable salt or solvate for the manufacture of a therapeutic agent for use in the treatment of a disease selected from the group consisting of diabetic chronic and A pharmaceutical composition comprising as active ingredient the compound according to any one of claims 8 to 41 a pharmaceutically acceptable salt or solvate Use of the compound according to any one of claims 8 to 41 or a pharmaceutically acceptable salt or solvate for the manufacture of a therapeutic agent for use in the treatment of a disease selected from the group consisting of diabetic chronic and sarcoma LUZZATTO insufficientOCRQuality